<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13560897
    </Internal_Number>
    <TrialID>NCT06127771
    </TrialID>
    <Last_Refreshed_on>27 November 2023
    </Last_Refreshed_on>
    <Public_title>Effects of Unblocking the Full Potential of Percept PC IPG
    </Public_title>
    <Scientific_title>Examining the Effects of Unblocking the Full Potential of Medtronic PerceptTM PC IPG on Symptoms of Individuals With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231106
    </Date_registration3>
    <Date_registration>06/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06127771
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 29, 2023
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email>alfonso.fasano@uhn.ca
    </Contact_Email>
    <Contact_Tel>(416) 603-5800
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with idiopathic Parkinson's disease who previously underwent DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who had IPG replacement from Activa PC to Medtronic PerceptTM PC&#x0D;&lt;br&gt;             Neurostimulator as standard-of-care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals should be able to provide their informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognition impairment (MoCA &lt; 20/30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe PD symptoms who are unable to come to the clinic three times&#x0D;&lt;br&gt;             within three months (e.g. bedridden patients)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Programming DBS using Percept PC neurostimulator's full potential
    </Intervention>
    <Primary_outcome>Patients' Global Impression of Change (PGIC) scale
    </Primary_outcome>
    <Secondary_outcome>MDS-UPDRS-III;MDS-UPDRS-IV;The Parkinson's Disease Questionnaire (PDQ-39)
    </Secondary_outcome>
    <Secondary_ID>23-5697
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13528369
    </Internal_Number>
    <TrialID>NCT06122675
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Cerebellar Deep Brain Stimulation for Movement Disorders in Cerebral Palsy in Children and Young Adults
    </Public_title>
    <Scientific_title>Cerebellar Deep Brain Stimulation for Severe Combined Movement Disorders and Spasticity in Children and Young Adults With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231102
    </Date_registration3>
    <Date_registration>02/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06122675
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>25 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2024
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Marta San Luciano Palenzuela, MD, MS;Marta San Luciano Palenzuela, MD, MS
    </Contact_Lastname>
    <Contact_Email>;Marta.SanLucianoPalenzuela@ucsf.edu
    </Contact_Email>
    <Contact_Tel>;4153532311
    </Contact_Tel>
    <Contact_Affiliation>University of California, San Francisco;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of DCP (dystonic and/or choreoathetotic cerebral palsy) with or without&#x0D;&lt;br&gt;             comorbid spasticity, with a clear history of hypoxic ischemic brain injury preceding&#x0D;&lt;br&gt;             motor symptoms made by a pediatric neurologist, with supporting MRI findings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 7-25 at the time of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gross Motor Function Classification System (GMFCS) Levels II-V.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of appropriate therapy with oral medications with inadequate relief as&#x0D;&lt;br&gt;             determined by a movement disorders or pediatric neurologist. Prior history of&#x0D;&lt;br&gt;             selective dorsal rhizotomy is allowed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient and family have requested surgical intervention with DBS for their movement&#x0D;&lt;br&gt;             disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No gross cerebellar abnormalities observed and reported on structural MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent and written/verbal assent for those younger than 18 years of&#x0D;&lt;br&gt;             age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to comply with study follow-up visits for brain recordings, neuroimaging and&#x0D;&lt;br&gt;             testing of sham and effective stimulation and clinical assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Coagulopathy, uncontrolled epilepsy, severe cardiopulmonary or gastrointestinal&#x0D;&lt;br&gt;             conditions, or other medical conditions considered to place the patient at elevated&#x0D;&lt;br&gt;             risk for surgical complications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy: all women of child-bearing potential will be required to have a negative&#x0D;&lt;br&gt;             urine pregnancy test prior to undergoing their surgical procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion of genetic mimics of cerebral palsy: exclusion of conditions that manifest&#x0D;&lt;br&gt;             with a clinical syndrome similar to CP, in the absence of documented risk factors or&#x0D;&lt;br&gt;             neuroimaging findings consistent with a history of brain injury or congenital cerebral&#x0D;&lt;br&gt;             malformation. Work up may include comparative genomic hybridization (CGH) microarray&#x0D;&lt;br&gt;             and multi-gene panel and/or whole genome or whole exome sequencing.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe fixed contractions and skeletal deformities that would preclude determination&#x0D;&lt;br&gt;             of improvement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Traumatic brain injury (i.e., non-accidental trauma) or history of infectious or&#x0D;&lt;br&gt;             autoimmune encephalitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requirement of diathermy, electroconvulsive therapy or transcranial magnetic&#x0D;&lt;br&gt;             stimulation.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dyskinetic Cerebral Palsy;Dystonic Cerebral Palsy
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Average total (global index) MD-CRS 4-18-R scores;Average total standardized CPCHILD scores
    </Primary_outcome>
    <Secondary_ID>22-37182
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13503452
    </Internal_Number>
    <TrialID>NCT06090682
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment
    </Public_title>
    <Scientific_title>Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tianjin Huanhu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231014
    </Date_registration3>
    <Date_registration>14/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06090682
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2023
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Zhao Guangrui, doctor;Yin Shaoya, doctor
    </Contact_Lastname>
    <Contact_Email>Guangrui-Zhao@hotmail.com;yinsya@hotmail.com
    </Contact_Email>
    <Contact_Tel>+86 18956405513;+86 18622139285
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease&#x0D;&lt;br&gt;        Society Brain Bank criteria, with disease duration over 5 years, acute levodopa motor&#x0D;&lt;br&gt;        response =30%, and indication for STN-DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria included patients with severe cognitive impairment, severe psychiatric&#x0D;&lt;br&gt;        disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and&#x0D;&lt;br&gt;        contraindications to surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognitive Impairment
    </Condition>
    <Intervention>Device: Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
    </Intervention>
    <Primary_outcome>Montreal Cognitive Rating Scale(MoCA);verbal fluency test (VF)
    </Primary_outcome>
    <Secondary_outcome>the third part of the Unified Parkinson's Disease Rating Scale (UPDRS III)
    </Secondary_outcome>
    <Secondary_ID>TianjinHH-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13503471
    </Internal_Number>
    <TrialID>NCT06090929
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>STN-DBS and the Risk of Sialorrhea
    </Public_title>
    <Scientific_title>STN-DBS is a Risk Factor of Sialorrhea in Patients With Advanced Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Qilu Hospital of Shandong University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231007
    </Date_registration3>
    <Date_registration>07/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06090929
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>234
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Single (Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of Alzheimer's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 20 and 80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  without drooling&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  swallowing function &lt;5 on the Drooling Rate Scale (DRS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medications affecting drooling had to have stopped medications at least 4 weeks before&#x0D;&lt;br&gt;             study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not he typical PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects on warfarin,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  with significant medical illnesses or neuromuscular transmission disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  past use of BoNT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  -cognitive impairment (&lt;23/30 on Mini Mental Status Exam) were excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN-DBS
    </Intervention>
    <Primary_outcome>DRS score 36 months postoperatively
    </Primary_outcome>
    <Secondary_outcome>DSFS score 36 months postoperatively;BOTOX injection ratio 36 months postoperatively
    </Secondary_outcome>
    <Secondary_ID>DBS &amp; drooling in PD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13306436
    </Internal_Number>
    <TrialID>NCT05997667
    </TrialID>
    <Last_Refreshed_on>28 August 2023
    </Last_Refreshed_on>
    <Public_title>Study on the Efficacy and Safety of Rechargeable Implantable DBS System in the Treatment of Parkinson's Disease
    </Public_title>
    <Scientific_title>A Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Rechargeable Implantable Deep Brain Stimulation System for the Treatment of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Lepu Medical Technology (Beijing) Co., Ltd.
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230807
    </Date_registration3>
    <Date_registration>07/08/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05997667
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 20, 2023
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ting Zhang
    </Contact_Lastname>
    <Contact_Email>ting_zhang@lepumedical.com
    </Contact_Email>
    <Contact_Tel>+86-010-80120666
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. 18-75 years old, male or female;.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary PD (according to the UK Parkinson's Disease Society Brain Bank clinical&#x0D;&lt;br&gt;             diagnostic criteria for primary PD or Chinese diagnostic criteria for primary PD),&#x0D;&lt;br&gt;             with a duration of PD = 4 years, and the improvement rate after an acute levodopa&#x0D;&lt;br&gt;             challenge test = 30%; or primary PD, mainly characterized by tremor, the improvement&#x0D;&lt;br&gt;             of tremor by standardized drug treatment is not satisfactory and tremor is severe,&#x0D;&lt;br&gt;             which affects the patients' quality of life, after evaluation, duration can be relaxed&#x0D;&lt;br&gt;             to 3 years, the improvement rate of acute levodopa challenge test can be&lt;30%.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The use of levodopa once had good effects, but currently cannot satisfactorily control&#x0D;&lt;br&gt;             symptoms (significant decrease in efficacy or occurrence of fluctuations in motor&#x0D;&lt;br&gt;             function or motor dysfunction), which affects quality of life.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Good compliance, patients and their families have the willingness to participate in&#x0D;&lt;br&gt;             the clinical trial of "bilateral implantation surgery of nervous stimulation system",&#x0D;&lt;br&gt;             voluntarily participate in this trial and sign informed consent form, patients can&#x0D;&lt;br&gt;             follow up regularly, and can accurately complete of assessment items, or the family&#x0D;&lt;br&gt;             members, guardians, or caregivers may assist the patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Severe cognitive impairment (MMSE score: illiterate&lt;17, elementary school&lt;20, junior&#x0D;&lt;br&gt;             high school or above&lt;24), poor compliance due to dementia, and/or inability to sign&#x0D;&lt;br&gt;             informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with a history of severe mental illness and a Hamilton Depression Scale&#x0D;&lt;br&gt;             (HAMD) score&gt;24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Seizure history in the last 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with severe heart, liver and kidney diseases, severe hypertension and severe&#x0D;&lt;br&gt;             orthostatic hypotension that affect their health status.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe diabetes or serious cardiovascular and cerebrovascular diseases&#x0D;&lt;br&gt;             that affect their health status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Confirmed malignant tumor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients with surgical contraindications (e.g., the presence of active implants&#x0D;&lt;br&gt;             (whether turned on or not), or the presence of non-active implants that may affect the&#x0D;&lt;br&gt;             deep brain stimulation system, stereotactic nucleus lesioning, etc.), or other&#x0D;&lt;br&gt;             surgical procedures within six months that the researchers believe have an impact on&#x0D;&lt;br&gt;             this trial, or other neurosurgery contraindications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients who have suffered a previous cranial neurological injury&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Women who are pregnant or preparing for pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patients with severe alcohol dependence and drug abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patients who received electric shock therapy within 30 days before surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Patients who are abnormally sensitive to temperature or who are allergic to heat&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subjects who are currently participating in other clinical trials or have participated&#x0D;&lt;br&gt;             in other clinical studies that have not reached the primary endpoint within three&#x0D;&lt;br&gt;             months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patients who are not suitable to participate in this clinical study in the opinion of&#x0D;&lt;br&gt;             the investigator.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Rechargeable implantable deep brain stimulation system;Device: Rechargeable implantable deep brain stimulation system
    </Intervention>
    <Primary_outcome>Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? in "med off" state relative to baseline
    </Primary_outcome>
    <Secondary_outcome>Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? in "med on" state relative to baseline;Change in motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in non-motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in motor complications score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in "ON" time and "OFF" time relative to the baseline;Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? with stimulation in "med on" and "med off" states relative to baseline;Change in daily levodopa equivalent dose relative to baseline;Change in the Parkinson's Disease Questionnaire (PDQ-39) score relative to baseline;Evaluation of equipment operational performance;Incidence of adverse events
    </Secondary_outcome>
    <Secondary_ID>LPDBS-2023
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13204299
    </Internal_Number>
    <TrialID>NCT05959161
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's (A Retrospective Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tianjin Huanhu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230717
    </Date_registration3>
    <Date_registration>17/07/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05959161
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2023
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:The clinical diagnosis of PD is consistent with the United Kingdom&#x0D;&lt;br&gt;        Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, age&#x0D;&lt;br&gt;        under 75, acute levodopa motor response =30%, and indication for STN-DBS. -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria: patients with severe cognitive impairment, severe psychiatric&#x0D;&lt;br&gt;        disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and&#x0D;&lt;br&gt;        contraindications to surgery -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation;Non-motor Symptoms
    </Condition>
    <Intervention>Procedure: DBS
    </Intervention>
    <Primary_outcome>motor symptom
    </Primary_outcome>
    <Secondary_ID>TianjinHH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13341977
    </Internal_Number>
    <TrialID>NCT06012461
    </TrialID>
    <Last_Refreshed_on>11 September 2023
    </Last_Refreshed_on>
    <Public_title>Closed-loop DBS in Parkinson's Disease
    </Public_title>
    <Scientific_title>Safety and Effectiveness of Closed-loop DBS in Parkinson's Disease: A Long-term Follow-up Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tsinghua University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230618
    </Date_registration3>
    <Date_registration>18/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06012461
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 30, 2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Weizhi Pan, B.S.;Huiling Yu, M.D.
    </Contact_Lastname>
    <Contact_Email>neln@mail.tsinghua.edu.cn;hellokittylene@163.com
    </Contact_Email>
    <Contact_Tel>+86-010-62796172;86-010-62794952
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of primary Parkinson's disease: Diagnosis of primary Parkinson's disease&#x0D;&lt;br&gt;             should meet the diagnostic criteria outlined in the "Diagnosis Standards for&#x0D;&lt;br&gt;             Parkinson's Disease in China" published in 2016 or the diagnostic criteria for primary&#x0D;&lt;br&gt;             Parkinson's disease by the International Parkinson and Movement Disorder Society (MDS)&#x0D;&lt;br&gt;             published in 2015.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Good response to levodopa combination therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Significant reduction in drug efficacy or significant impact on the patient's quality&#x0D;&lt;br&gt;             of life due to prominent motor complications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Intolerable adverse reactions to medication affecting its efficacy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of uncontrollable tremors despite medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who have undergone pallidotomy or other brain surgeries.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with secondary Parkinson syndromes or Parkinson plus syndromes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with concurrent central nervous system and peripheral nervous system&#x0D;&lt;br&gt;             diseases.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with severe systemic diseases, unstable vital signs, or those who cannot&#x0D;&lt;br&gt;             tolerate clinical assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe psychiatric disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients who are unable to provide informed consent due to cognitive or communication&#x0D;&lt;br&gt;             impairments or those who refuse to sign the informed consent form.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Closed-loop DBS stimulation for 24 hours;Other: Open-loop DBS stimulation for 24 hours;Other: Closed-loop DBS stimulation for 72 hours;Other: Open-loop DBS stimulation for 72 hours
    </Intervention>
    <Primary_outcome>Movement disorders evaluation;Sleep Structure Evaluation;Diary Outcomes in Parkinson's Disease
    </Primary_outcome>
    <Secondary_outcome>Safety (Stimulation-related AEs) and Subjective Satisfactory;Total Electrical Energy Delivered to patients
    </Secondary_outcome>
    <Secondary_ID>CDBS_PD_2023
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Engineering Research Center of Neuromodulation, Tsinghua University;Beijing Tiantan Hospital;Peking Union Medical College Hospital;Beijing Pins Medical Co., Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13526721
    </Internal_Number>
    <TrialID>NCT05893186
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
    </Public_title>
    <Scientific_title>Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
    </Scientific_title>
    <Acronym>MOPSO PIGD
    </Acronym>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230512
    </Date_registration3>
    <Date_registration>12/05/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05893186
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>89 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 25, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>Early Phase 1
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Scott Cooper, MD, PhD;Zuzanna Pasek;Zuzanna Pasek
    </Contact_Lastname>
    <Contact_Email>;pasek013@umn.edu;pasek013@umn.edu
    </Contact_Email>
    <Contact_Tel>;612-624-0018;612-624-0018
    </Contact_Tel>
    <Contact_Affiliation>University of Minnesota;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilateral DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Directional DBS electrode system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI, at least 7 Tesla, with diffusion tensor imaging, prior to DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Head CT, at least 1mm cuts, following DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 3 months since initial activation of the neurostimulator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological or musculoskeletal disorder that significantly affects gait, balance, or&#x0D;&lt;br&gt;             limb movements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior stereotactic neurosurgery other than DBS for movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Deep Brain Stimulation, STN;Other: GP Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Gait test
    </Primary_outcome>
    <Secondary_outcome>Balance Test;Bradykinesia test;Rigidity Test
    </Secondary_outcome>
    <Secondary_ID>NEUR-2019-28436
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13039712
    </Internal_Number>
    <TrialID>NCT05843084
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>STEREO-DBS
    </Acronym>
    <Primary_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230411
    </Date_registration3>
    <Date_registration>11/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05843084
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 11, 2023
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Maarten Bot, MD, PhD
    </Contact_Lastname>
    <Contact_Email>m.bot@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>0031621514048
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        1.2 Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In order to be eligible to participate in this study, a subject must meet all of the&#x0D;&lt;br&gt;        following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD who underwent STN DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1.3 Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        A potential subject who meets any of the following criteria will be excluded from&#x0D;&lt;br&gt;        participation in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legally incompetent adults;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No written informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Diffusion Magnetic Resonance Imaging;Brain;Subthalamic Nucleus;Deep Brain Stimulation;Human;Treatment Outcome
    </Condition>
    <Intervention>Procedure: 7T MRI network analysis for deep brain stimulation in Parkinson's disease
    </Intervention>
    <Primary_outcome>Unified Parkinson's Disease Rating Scale (UPDRS-III)
    </Primary_outcome>
    <Secondary_outcome>The Amsterdam Linear Disability Score for functional health status;Parkinson's disease questionnaire-39;Starkstein apathy scale
    </Secondary_outcome>
    <Secondary_ID>W20_540 # 20.599
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13039076
    </Internal_Number>
    <TrialID>NCT05822388
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>Cognitive Decline Following Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Neural Basis for Cognitive Decline Following Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medical University of South Carolina
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230410
    </Date_registration3>
    <Date_registration>10/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05822388
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2023
    </Date_enrollement>
    <Target_size>55
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Daniel H Lench, PhD;Daniel H Lench, PhD;Daniel H Lench, PhD
    </Contact_Lastname>
    <Contact_Email>;lenchd@musc.edu;lenchd@musc.edu
    </Contact_Email>
    <Contact_Tel>;843-792-9115;843-792-9115
    </Contact_Tel>
    <Contact_Affiliation>Medical University of South Carolina;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects above 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who will undergo DBS surgery as part of their clinical care for PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncorrected visual or hearing impairments, as indicated by self-report&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who are pregnant or expect to become pregnant during the course of the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with claustrophobia, or the inability to lie supine position in the MRI&#x0D;&lt;br&gt;             scanner&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  COPD with oxygen dependence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Movement Disorders
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care
    </Intervention>
    <Primary_outcome>Change in Cognition;Brain Microstructure (DKI)
    </Primary_outcome>
    <Secondary_outcome>Brain Functional Connectivity;Brain Microstructure (DTI)
    </Secondary_outcome>
    <Secondary_ID>Pro00125181
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13649253
    </Internal_Number>
    <TrialID>DRKS00030841
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Temporal Interference Stimulation of Deep Brain Regions in Parkinson's disease and health Controls
    </Public_title>
    <Scientific_title>Transcranial Temporal Interference Stimulation of Deep Brain Regions in Parkinson's disease and health Controls - TETRIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universität Oldenburg/Evang. Krankenhaus Oldenburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230301
    </Date_registration3>
    <Date_registration>01/03/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00030841
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/03/2023
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active//No treatment / Standard of care; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Karsten 
    </Contact_Firstname>
    <Contact_Lastname>Witt
    </Contact_Lastname>
    <Contact_Address>Marienstraße 11
    </Contact_Address>
    <Contact_Email>karsten.witt@uni-oldenburg.de
    </Contact_Email>
    <Contact_Tel>+49 (0)441 236 649
    </Contact_Tel>
    <Contact_Affiliation>Universität Oldenburg/Evang. Krankenhaus Oldenburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - German as mother tongue&#x0D;&lt;br&gt;- Normale or corrected vision&#x0D;&lt;br&gt;- Dexterity&#x0D;&lt;br&gt;(- Diagnosis of idiopathic Parkinson's disease)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Neurological or psychiatric diagnosis other than PD&#x0D;&lt;br&gt;Medication with effects on the central nervous system (besides PD medication)&#x0D;&lt;br&gt;Non-removable metallic parts in/at the body&#x0D;&lt;br&gt;Implanted neurostimulation&#x0D;&lt;br&gt;Contraindications for mri &#x0D;&lt;br&gt;Diagnosis of epilepsy (in the family)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Parkinson's disease patients, deep brain regions will be targeted using trans cranial temporal interference stimulation while the patients execute different tasks to measure motor learning, motor performance and effort behaviour&lt;br&gt;&lt;br&gt;Group 2: Healthy controls , deep brain regions will be targeted using trans cranial temporal interference stimulation hile the participants execute different tasks to measure motor learning, motor performance and effort behaviour
    </Intervention>
    <Primary_outcome>Motor performance by a finger tapping task&lt;br&gt;Motor learning by a sequential finger tapping task&lt;br&gt;Motivational behaviour by an effort/reward task&lt;br&gt;Probabilistic learning by an effort/reward task
    </Primary_outcome>
    <Secondary_outcome>Explorative evaluation of side effects
    </Secondary_outcome>
    <Source_Support>Universität Oldenburg, Abt. Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/02/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Geschäftsstelle der medizinischen Ethikkommission, Fakultät VI Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Gebäude V04 (Raum 1-137)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-441-7983109
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00030841#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12890656
    </Internal_Number>
    <TrialID>NCT05753449
    </TrialID>
    <Last_Refreshed_on>13 March 2023
    </Last_Refreshed_on>
    <Public_title>Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Public_title>
    <Scientific_title>Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Pilot Study of Tolerability and Efficacy
    </Scientific_title>
    <Acronym>BURST
    </Acronym>
    <Primary_sponsor>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230207
    </Date_registration3>
    <Date_registration>07/02/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05753449
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 24, 2022
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Nestor Tomycz, MD;Clinical Trials Contact
    </Contact_Lastname>
    <Contact_Email>Nestor.Tomycz@ahn.org;clinicaltrials@ahn.org
    </Contact_Email>
    <Contact_Tel>412-359-6200;412-330-6151
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilateral DBS-STN (subthalamic nucleus) target for idiopathic Parkinson's disease&#x0D;&lt;br&gt;             implanted minimum 6 months prior to the day of study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable DBS programming settings and Parkinson's disease medications defined as no&#x0D;&lt;br&gt;             changes to either within past 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Comfortable using DBS controller to turn off device prior to study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent and complete follow-up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS technology other than Boston scientific Genus/Gevia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to complete follow-up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS brain targets other than STN (subthalamic nucleus)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of progressive cognitive decline&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: Burst-type DBS electrical stimulation programming;Device: Standard of care DBS programming
    </Intervention>
    <Primary_outcome>Change in Unified Parkinson's Disease Rating Scale (UPDRS) v-III Motor Examination Score
    </Primary_outcome>
    <Secondary_ID>2022-234
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13156886
    </Internal_Number>
    <TrialID>NCT05713721
    </TrialID>
    <Last_Refreshed_on>3 July 2023
    </Last_Refreshed_on>
    <Public_title>Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Public_title>
    <Scientific_title>SensoMo-PD: Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Scientific_title>
    <Acronym>SensoMo-PD
    </Acronym>
    <Primary_sponsor>University Hospital Schleswig-Holstein
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230127
    </Date_registration3>
    <Date_registration>27/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05713721
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Anne Weissbach, MD;Anne Weissbach, MD;Anne Weissbach, MD
    </Contact_Lastname>
    <Contact_Email>;anne.weissbach@neuro.uni-luebeck.de;anne.weissbach@neuro.uni-luebeck.de
    </Contact_Email>
    <Contact_Tel>;+49 451 3101 8219;+49 451 3101 8219
    </Contact_Tel>
    <Contact_Affiliation>Institute of Systems Motor Science;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria for mutation carriers:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for healthy control participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No medication with influences on the central nervous system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &lt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication that reduces the seizure threshold&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson;Dystonia;DYT3;DYT5;PINK1 Gene Deletion;Dystonia, Familial
    </Condition>
    <Intervention>Device: Transcranial magnetic stimulation (TMS);Other: Video-based clinical examination;Other: 24 hours drug withdrawal of dopaminergic medication;Other: Evaluation of deep brain stimulation
    </Intervention>
    <Primary_outcome>Contrast sensorimotor integration in patients with three different monogenic Parkinson-dystonia syndromes.;Define whether asymptomatic mutation carriers show abnormalities in sensorimotor integration and clinical signs of Parkinson and dystonia upon video examination.;Correlate clinical symptom severity with changes in sensorimotor integration.;Evaluate treatment effects on sensorimotor integration, e.g., for PARK-Parkin/PARK-PINK1 and DYT/PARK-GCH1 chronic dopaminergic medication and for DYT/PARK-TAF1 deep brain stimulation effects.
    </Primary_outcome>
    <Secondary_ID>MJFF-022062
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12891268
    </Internal_Number>
    <TrialID>NCT05765110
    </TrialID>
    <Last_Refreshed_on>13 March 2023
    </Last_Refreshed_on>
    <Public_title>SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
    </Public_title>
    <Scientific_title>SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
    </Scientific_title>
    <Acronym>EMO-SPEECH-PD
    </Acronym>
    <Primary_sponsor>University Hospital Inselspital, Berne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230111
    </Date_registration3>
    <Date_registration>11/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05765110
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 3, 2023
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Czechia;Switzerland;Czechia;Switzerland
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Paul Krack, Prof.;Paul Krack, Prof.;Paul Krack, Prof.
    </Contact_Lastname>
    <Contact_Email>;paul.krack@insel.ch;paul.krack@insel.ch
    </Contact_Email>
    <Contact_Tel>;31 66 4 03 71;31 66 4 03 71
    </Contact_Tel>
    <Contact_Affiliation>University Hospital Inselspital, Berne;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Patients with Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD according to the Movement Disorders Society Criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age of participants &gt; 30 and = 75 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in German or French&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of aphasia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's&#x0D;&lt;br&gt;             disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury,&#x0D;&lt;br&gt;             epilepsy, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Montreal Cognitive Assessment (MoCa) &lt; 24/30 points);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Depression with acute suicidal ideation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Healthy Controls&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults from 50-70 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in German or French&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson's disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Montreal Cognitive Assessment (MoCa) &lt; 24/30 points);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease,&#x0D;&lt;br&gt;             vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy,&#x0D;&lt;br&gt;             etc.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of aphasia, dysarthria, and stuttering;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Dopaminergic OFF drug state;Other: DBS OFF state;Other: Dopaminergic ON drug state;Other: DBS ON state
    </Intervention>
    <Primary_outcome>Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients;Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients;Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients;Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients
    </Primary_outcome>
    <Secondary_outcome>Dyskinesia severity;Momentary mood state;Momentary anxiety state;Bradyphrenia assessment
    </Secondary_outcome>
    <Secondary_ID>2022-01304
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Czech Technical University in Prague
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13630548
    </Internal_Number>
    <TrialID>NCT06008717
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
    </Public_title>
    <Scientific_title>A Prospective, Randomized Feasibility Clinical Trial Evaluating Bilateral Stimulation of the Dorsolateral Region of the Subthalamic Nucleus Receiving Hyperdirect (M1/SMA) Input in Subjects With Early-Stage Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mallory Hacker
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20221223
    </Date_registration3>
    <Date_registration>23/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06008717
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2025
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. A clinical diagnosis of idiopathic Parkinson's disease (PD). The diagnosis will be&#x0D;&lt;br&gt;             based upon the presence of at least two of the three cardinal motor signs of this&#x0D;&lt;br&gt;             disorder (akinesia/bradykinesia, rest tremor, and rigidity) with at least one of the&#x0D;&lt;br&gt;             signs being rest tremor or bradykinesia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clear and dramatic beneficial response to dopaminergic therapy, defined as =30% in&#x0D;&lt;br&gt;             UPDRS III with administration of the patient's medication during the screening&#x0D;&lt;br&gt;             neurological examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Hoehn and Yahr (H&amp;Y) stage II when OFF medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. No contraindications to surgery (i.e., subject does not have uncontrollable medical or&#x0D;&lt;br&gt;             psychiatric illness; Exclusion Criteria).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Age between 50 and 75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Dopaminergic therapy for greater than one year and less than four years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Available for follow-up for the entire duration of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Informed Consent (Appendix C): The subject is willing and able to provide written&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. MRI within normal range (Exclusion Criteria).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects receiving antidepressant medication used specifically for the treatment of&#x0D;&lt;br&gt;             depression must be on stable doses for at least eight weeks prior to enrolling in the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Subjects must agree to maintain a stable regimen, if deemed medically appropriate by&#x0D;&lt;br&gt;             the treating physician, of any psychotropic medications throughout the blinded&#x0D;&lt;br&gt;             treatment phase.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Features unusual early in the clinical course (e.g., prominent postural&#x0D;&lt;br&gt;                  instability, freezing phenomena, or hallucinations unrelated to medications in&#x0D;&lt;br&gt;                  the first 3 years after symptom onset)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Dementia preceding motor symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Neurologic signs of upper motor neuron or cerebellar involvement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Significant orthostatic hypotension unrelated to medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unequivocal cortical sensory loss (i.e., graphesthesia, sterognosis with intact&#x0D;&lt;br&gt;                  primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Vertical supranuclear gaze palsy, or selective slowing of vertical saccades&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unequivocal cerebellar abnormalities on examination, such as cerebellar gait,&#x0D;&lt;br&gt;                  limb ataxia, or cerebellar oculomotor abnormalities (e.g., sustained gaze-evoked&#x0D;&lt;br&gt;                  nystagmus, macro square wave jerks, hypermetric saccades)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Documentation of a condition known to produce parkinsonism and plausibly&#x0D;&lt;br&gt;                  connected to the subject's symptoms (e.g., MRI scan with evidence of significant&#x0D;&lt;br&gt;                  brain atrophy, lacunar infarcts, or iron deposits in the putamen; history of&#x0D;&lt;br&gt;                  stroke, exposure to toxins, or encephalitis; or neuroleptic use within the past 6&#x0D;&lt;br&gt;                  months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The expert evaluating physician, based on the full diagnostic assessment,&#x0D;&lt;br&gt;                  believes that an alternative syndrome is more likely than PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Uncontrolled medical condition or clinically significant medical disease that would&#x0D;&lt;br&gt;             increase the risk of developing pre- or postoperative complications (e.g., significant&#x0D;&lt;br&gt;             cardiac or pulmonary disease, uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Dementia as evidenced by a Dementia Rating Score of less than 123.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Diagnosis of probable behavioral variant frontotemporal dementia or primary&#x0D;&lt;br&gt;             progressive aphasia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Currently active diagnosis of a major psychiatric disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Previous brain operation or injury.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Active participation in another clinical trial for the treatment of PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subjects with cardiac pacemakers or medical conditions that require repeat MRI scans.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Evidence of existing dyskinesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any current substance use disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Any history of recurrent or unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any prior movement disorder treatments that involved intracranial surgery or device&#x0D;&lt;br&gt;             implantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Any other active implanted intracranial device (e.g., cochlear implant) or implanted&#x0D;&lt;br&gt;             device to treat movement disorders (e.g., duodopa pump) whether turned on or off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. A condition requiring or likely to require the use of magnetic resonance imaging (MRI)&#x0D;&lt;br&gt;             or diathermy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. History of suicide attempt.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. A female who is breastfeeding or of child-bearing potential with a positive urine&#x0D;&lt;br&gt;             pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Inability or unwillingness of subject to give written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Parkinsonian features restricted to the lower limbs for more than three years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and&#x0D;&lt;br&gt;             time course consistent with drug-induced parkinsonism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Normal functional neuroimaging of the presynaptic dopaminergic system, as measured by&#x0D;&lt;br&gt;             DaTSCAN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Rapid progression of gait impairment requiring regular use of a wheelchair.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Early bulbar dysfunction, defined as one of severe dysphonia, dysarthria (speech&#x0D;&lt;br&gt;             unintelligible most of the time), or dysphagia (requiring soft food, nasogastric (NG)&#x0D;&lt;br&gt;             tube, or gastrostomy feeding).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Inspiratory respiratory dysfunction defined as either diurnal or nocturnal inspiratory&#x0D;&lt;br&gt;             stridor or frequent inspiratory sighs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. Recurrent (&gt;1/year) falls because of impaired balance within 3 years of onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         25. Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness or clear&#x0D;&lt;br&gt;             pathologic hyperreflexia (excluding mild reflex asymmetry in the more affected limb&#x0D;&lt;br&gt;             and isolated extensor plantar response).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         26. Bilateral symmetric parkinsonism throughout the disease course. The patient or&#x0D;&lt;br&gt;             caregiver reports bilateral symptom onset with no side predominance, and no side&#x0D;&lt;br&gt;             predominance is observed on objective examination.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: active subthalamic nucleus deep brain stimulation plus optimal drug therapy;Device: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
    </Intervention>
    <Primary_outcome>frequency and severity of adverse events;frequency and severity of adverse cognitive outcome
    </Primary_outcome>
    <Secondary_outcome>Stopped or Reversed Motor Progression
    </Secondary_outcome>
    <Secondary_ID>G220314
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13648400
    </Internal_Number>
    <TrialID>DRKS00029222
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Potsdam Dream Research Parkinson
    </Public_title>
    <Scientific_title>Potsdam Dream Research Parkinson - PotsDReam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Ernst von Bergmann Klinikum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220620
    </Date_registration3>
    <Date_registration>20/06/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00029222
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/06/2022
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Holger
    </Contact_Firstname>
    <Contact_Lastname>Joswig
    </Contact_Lastname>
    <Contact_Address>Charlottenstr. 72
    </Contact_Address>
    <Contact_Email>holger.joswig@klinikumevb.de
    </Contact_Email>
    <Contact_Tel>+4933124137902
    </Contact_Tel>
    <Contact_Affiliation>Ernst von Bergmann Klinikum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All consentable patients &gt; 18 years old with diagnosed Parkinson's disease, who either receive DBS or a Levodopa- / Apomorphin-pump and who are physically and psychologically able to document their dreams.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Excluded are all minors and non-consentable patients and those unable to document their dreams.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation (DBS) or Levodopa-/Apomorphin-pump-implantation
    </Intervention>
    <Primary_outcome>Dream content according to the Calvin S. Hall and Robert Van de Castle system
    </Primary_outcome>
    <Secondary_outcome>L-Dopa equivalent dose, disease burden using Hoehn and Yahr (H &amp; Y) scale, Unified Parkinson's Disease Rating Scale-I, II, III, IV (UPDRS) during on and off, Life quality using Short-Form 36 (SF-36), Parkinson’s Disease Questionnaire (PDQ-39), Self-efficacy, psychological well being using the Ardouin Scale of Behavior in Parkinson's Disease (ASBPD), Impulse control disorders using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP-RS), Cognition using the Mattis Dementia Rating Scale (MDRS), Questions regarding Religiosity / Spirituality in addition to the Daily Spiritual Experience Scale (DSES).
    </Secondary_outcome>
    <Source_Support>Ernst von Bergmann Klinikum
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/05/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik@laekb.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Landesärztekammer Brandenburg Ethikkommission
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-355-7801053
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik@laekb.de
    </Ethics_review_contact_email>
    <results_date_completed>27/10/2023
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00029222#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13648302
    </Internal_Number>
    <TrialID>DRKS00029073
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Electrophysiological characterization of neuronal networks in tic patients with deep brain stimulation
    </Public_title>
    <Scientific_title>Electrophysiological characterization of neuronal networks in tic patients with deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Klinik für Stereotaxie und Funktionelle Neurochirurgie, Klinikum der Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220527
    </Date_registration3>
    <Date_registration>27/05/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00029073
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>25/05/2022
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Open (masking not used); Control: No treatment / Standard of care; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thomas
    </Contact_Firstname>
    <Contact_Lastname>Schüller
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>thomas.schueller@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 98844
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität zu Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Fluent in the German language&lt;br&gt;- Age 18 to 65 years&lt;br&gt;- Chronic motor tic disorder (F95.1) or chronic motor and vocal tic disorder (F95.2) as main diagnosis according to the International Classification of Diseases 10 (ICD 10)&lt;br&gt;- Deep brain stimulation (Percept PC Neurostimulator)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Active suicidal ideation &lt;br&gt;- Current psychotic symptomatology&lt;br&gt;- Active or recent substance abuse (except intake of cannabis-based substances, if consumed for treatment of tics)&lt;br&gt;- Serious systemic medical disease &lt;br&gt;- Severe neurological disorder of the central nervous system such as stroke, epilepsy, neoplasia&lt;br&gt;- Mental retardation&lt;br&gt;- Withdrawal of consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.1 &lt;br&gt;F95.2;Chronic motor or vocal tic disorder;Combined vocal and multiple motor tic disorder [de la Tourette];F95.1;F95.2
    </Condition>
    <Intervention>Group 1: Arm 1: Patients with tic disorder will be interviewed once and asked to perform computerized tasks with Deep Brain Stimulation turned on.&lt;br&gt;&lt;br&gt;The following assessments will be performed:&lt;br&gt;1) Carious questionnaires to assess the severity of Tourette's disorder and other psychological symptoms.&lt;br&gt;2) Application of the electroencephalographic (EEG) cap. During the computerized tasks EEG is used to measure brain activity.&lt;br&gt;3) Infrared 3-D scanner is used to localize the exact position of the EEG electrodes.&lt;br&gt;4) Patients are asked to indicate the urge before the tic. This will take place in six blocks of five minutes each, during which the tics will be freely performed or the tics will be suppressed as best as possible. Video will be recorded during this task. In addition, adhesive electrodes will be attached to the muscles of the most common tics.&lt;br&gt;5) Finger-tapping task: This is a computerized task with two different conditions. In one condition, patients are asked to press in the direction of a presented arrow with the corresponding left or right finger. In a second condition, patients are asked to decide for themselves whether to press with the left or right finger within a period of four to eight seconds.&lt;br&gt;Group 2: Arm 2: Patients with tic disorder will be interviewed once and asked to perform computerized tasks with Deep Brain Stimulation turned off.&lt;br&gt;&lt;br&gt;The following assessments will be performed:&lt;br&gt;1) Carious questionnaires to assess the severity of Tourette's disorder and other psychological symptoms.&lt;br&gt;2) Application of the electroencephalographic (EEG) cap. During the computerized tasks EEG is used to measure brain activity.&lt;br&gt;3) Infrared 3-D scanner is used to localize the exact position of the EEG electrodes.&lt;br&gt;4) Patients are asked to indicate the urge before the tic. Th
    </Intervention>
    <Primary_outcome>1) Urge correlated connectivity between cortical areas (SMA, PFC, ACC) and the DBS target in the theta (4-8 Hz) and beta (15-30 Hz) frequency bands.
    </Primary_outcome>
    <Secondary_outcome>2) Movement planning and movement execution-correlated connectivity between cortical areas (SMA, PFC) and DBS target in the delta (1-4 Hz) and theta (4-8 Hz) frequency band.&lt;br&gt;3) Connectivity between cortical areas (SMA, PFC, ACC) and DBS target in the delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), and beta (15-30 Hz) frequency bands at rest.&lt;br&gt;4) Modulation of connectivity profiles in 1., 2., &amp; 3. by THS.
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>13/12/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00029073#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12784015
    </Internal_Number>
    <TrialID>NCT05397340
    </TrialID>
    <Last_Refreshed_on>30 January 2023
    </Last_Refreshed_on>
    <Public_title>Asymmetric Targeted DBS for PD With PIGD
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of Asymmetric Targets Versus Bilateral Subthalamic Nucleus (STN) for Parkinson's Disease With Postural Instability/Gait Difficulty: a Prospective, Randomized, Double-blinded Trial
    </Scientific_title>
    <Acronym>ATS-PIGD
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220518
    </Date_registration3>
    <Date_registration>18/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05397340
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2022
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD;Dianyou Li, MD, PhD;Dianyou Li, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;ldy11483@rjh.com.cn;ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>;+0086-021-64370045;
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  postural instability/gait difficulty (PIGD) phenotypes in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history that would increase pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change from Baseline in the Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 12 months;Change from Baseline in balance ability on the Burg Balance Scale (BBS) at 12 months;Change from Baseline in the number of freezing episodes on the Timed Up and Go test at 12 months
    </Primary_outcome>
    <Secondary_outcome>Change from Baseline in completion time on the Timed Up and Go test at 12 months;Change from Baseline in completion time on the Timed Up and Go test at 6 months;Change from Baseline in the number of steps on the Timed Up and Go test at 12 months;Change from Baseline in the number of steps on the Timed Up and Go test at 6 months;Change from Baseline in the Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 6 months;Change from Baseline in balance confidence on the Activities-Specific Balance Confidence Scale (ABC) at 12 months;Change from Baseline in balance confidence on the Activities-Specific Balance Confidence Scale (ABC) at 6 months;Change from Baseline in freezing of gait on the New Freezing of Gait Questionnaire (NFOG-Q) at 12 months;Change from Baseline in freezing of gait on the New Freezing of Gait Questionnaire (NFOG-Q) at 6 months;Change from Baseline in dysphagia severity on the Swallowing Disturbance Questionnaire (SDQ) at 12 months;Change from Baseline in dysphagia severity on the Swallowing Disturbance Questionnaire (SDQ) at 6 months;Change from Baseline in gait impairment on the Gait and Fall Questionnaire (GFQ) at 12 months;Change from Baseline in gait impairment on the Gait and Fall Questionnaire (GFQ) at 6 months;Change from Baseline in medication usage on the Levodopa Equivalent Daily Dose at 12 months;Change from Baseline in medication usage on the Levodopa Equivalent Daily Dose at 6 months;Change from Baseline in maximal phonatory time at 12 months;Change from Baseline in maximal phonatory time at 6 months;Change from Baseline in dysphonia severity index (DSI) at 12 months;Change from Baseline in dysphonia severity index (DSI) at 6 months;Change from Baseline in cognition on the Montreal Cognitive Assessment at 12 months;Change from Baseline in cognition on the Montreal Cognitive Assessment at 6 months;Adverse events;Change from Baseline in balance ability on the Burg Balance Scale (BBS) at 6 months;Change from Baseline in the number of freezing episodes on the Timed Up and Go test at 6 months
    </Secondary_outcome>
    <Secondary_ID>Asym Stim-PIGD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12835117
    </Internal_Number>
    <TrialID>NCT05382858
    </TrialID>
    <Last_Refreshed_on>20 February 2023
    </Last_Refreshed_on>
    <Public_title>PSA Versus STN DBS for TD-PD
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial
    </Scientific_title>
    <Acronym>PSA-STN
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220501
    </Date_registration3>
    <Date_registration>01/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05382858
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD;Dianyou Li, MD, PhD;Dianyou Li, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;ldy11483@rjh.com.cn;ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>;+0086-021-64370045;
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  tremor-dominant subtype in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  modified Hoehn-Yahr scale of 2 to 4 in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  receiving regular anti-parkinsonian drugs for more than 6 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  good compliance and written informed consent provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with the intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history that would increase pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 4 months;Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 6 months
    </Primary_outcome>
    <Secondary_outcome>Change from baseline Berg balance scale to 4 months;Change from baseline Berg balance scale to 6 months;Change from baseline 39-item Parkinsons disease questionnaire to 4 months;Change from baseline 39-item Parkinsons disease questionnaire to 6 months;Change from baseline Levodopa equivalent daily dose to 4 months;Change from baseline Levodopa equivalent daily dose to 6 months;Change from baseline maximal phonatory time to 4 months;Change from baseline maximal phonatory time to 6 months;Change from baseline dysphonia severity index to 4 months;Change from baseline dysphonia severity index to 6 months;Change from baseline Mini-Mental Status Exam to 4 months;Change from baseline Mini-Mental Status Exam to 6 months;Change from baseline Beck depression inventory to 4 months;Change from baseline Beck depression inventory to 6 months;Adverse events;Change from baseline Timed up and go test to 6 months;Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 4 months;Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 6 months;Change from baseline Timed up and go test to 4 months
    </Secondary_outcome>
    <Secondary_ID>TDPSA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Suzhou Sceneray Medical Co. , Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13648056
    </Internal_Number>
    <TrialID>DRKS00028703
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Extending the Data-Driven Characterization of Neural Markers During Deep Brain Stimulation for Patients with Parkinson’s Disease
    </Public_title>
    <Scientific_title>Extending the Data-Driven Characterization of Neural Markers During Deep Brain Stimulation for Patients with Parkinson’s Disease - PD-Interaktiv I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220425
    </Date_registration3>
    <Date_registration>25/04/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00028703
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>12/01/2023
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Volker
    </Contact_Firstname>
    <Contact_Lastname>Coenen
    </Contact_Lastname>
    <Contact_Address>Breisacher Straße 64
    </Contact_Address>
    <Contact_Email>volker.coenen@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>0761 270-50630
    </Contact_Tel>
    <Contact_Affiliation>Klinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.Patients diagnosed with PD according to UK PDS Brain Bank Criteria.&#x0D;&lt;br&gt;2. Written informed consent.&#x0D;&lt;br&gt;3. Patients who are eligible for STN DBS surgery according to the guidelines of the DGN
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Contraindication for stereotactic neurosurgery or other surgery.&#x0D;&lt;br&gt;2. Dementia (Mattis Dementia Rating Score = 130).&#x0D;&lt;br&gt;3. Acute psychosis assessed by a psychiatric physician.&#x0D;&lt;br&gt;4. Inability to give written informed consent.&#x0D;&lt;br&gt;5. Medications that are likely to cause interactions in the opinion of the investigator.&#x0D;&lt;br&gt;6. Fertile women not using adequate contraceptive methods.&#x0D;&lt;br&gt;7. Current or planned pregnancy, nursing period.&#x0D;&lt;br&gt;8. Contraindication for undergoing MRI.&#x0D;&lt;br&gt;9. Contraindication for undergoing Diathermy (either shortwave, microwave, and/or&#x0D;&lt;br&gt;ultrasound diathermy).&#x0D;&lt;br&gt;10. Patient incapable to follow and perform the task instructions
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Step 1: Implantation of DBS and ECoG electodes. 2nd step: Experimental measurements over 5 days. 3rd step: implantation of cables and generator for conventional continuous stimulation. Follow-up up to one year.
    </Intervention>
    <Primary_outcome>O1: Understanding the influence of previously applied stimulation patterns onto the&lt;br&gt;current motor performance.&lt;br&gt;O2: Detection and characterization of novel, potentially multivariate, neural markers.&lt;br&gt;O3: Investigation of neural markers derived from electrocorticogram signals.&lt;br&gt;O4: Characterization of alternative stimulation strategies.
    </Primary_outcome>
    <Secondary_outcome>O2: Detection and characterization of novel, potentially multivariate, neural markers for decoding of motor peformance. End-point: average performance difference (in r-values) between the subject-specific decoding models that incorporate EEG features and the STN LFPs model
    </Secondary_outcome>
    <Source_Support>Klinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/03/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00028703#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13398449
    </Internal_Number>
    <TrialID>NCT05348837
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
    </Public_title>
    <Scientific_title>Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220421
    </Date_registration3>
    <Date_registration>21/04/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05348837
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2022
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Alexander Baumgartner, MD;Lisa Hirt;Pamela Gerecht, PhD
    </Contact_Lastname>
    <Contact_Email>;lisa.hirt@cuanschutz.edu;pamela.davidgerecht@cuanschutz.edu
    </Contact_Email>
    <Contact_Tel>;720-848-2080;303-724-4134
    </Contact_Tel>
    <Contact_Affiliation>University of Colorado - Anschutz Medical Campus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Research subjects must be willing and able to do the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be able to learn to use and maintain a wristband-style sleep monitor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Wear a wristband-style sleep monitor for two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be able to learn to use and maintain a headband sleep monitor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Wear a headband sleep monitor for two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Log daily routine events, such sleeping, eating, and medication regimens for the&#x0D;&lt;br&gt;             two-week study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Withhold dopaminergic medications after 5:00pm for three consecutive nights&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects will be excluded if they:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Carry a diagnosis of dementia (e.g., Parkinson's Disease Dementia or Dementia with&#x0D;&lt;br&gt;             Lewy Bodies)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently use or recently (within past 30 days) used a sedative-hypnotic agent for&#x0D;&lt;br&gt;             sleep (e.g., Zolpidem, Suvorexant, Eszopiclone)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fulfill criteria or carry a diagnosis of a circadian sleep-wake rhythm disorder, as&#x0D;&lt;br&gt;             defined by the International Classification of Sleep Disorders, Third Edition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change in total sleep time (TST) as measured by polysomnogram-capable headband
    </Primary_outcome>
    <Secondary_outcome>Change in sleep efficiency (SE) as measured by polysomnogram-capable headband;Change in sleep onset latency (SOL) as measured by polysomnogram-capable headband;Change in wake after sleep onset (WASO) as measured by polysomnogram-capable headband;Change in total sleep time (TST) as measured by actigraphy;Change in sleep efficiency (SE) as measured by actigraphy;Change in sleep onset latency (SOL) as measured by actigraphy;Change in wake after sleep onset (WASO) as measured by actigraphy
    </Secondary_outcome>
    <Secondary_ID>22-0393
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12652905
    </Internal_Number>
    <TrialID>NCT05402163
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>CANadian Adaptive DBS TriAl
    </Public_title>
    <Scientific_title>Adaptive/Closed Loop vs. Continuous/Open Loop Deep Brain Stimulation of Subthalamic Nucleus: a Two-Phase, Cross-Over, Double-Blind Trial in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>CANADA
    </Acronym>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220404
    </Date_registration3>
    <Date_registration>04/04/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05402163
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD treated with bilateral STN DBS using Medtronic lead&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent and comply with study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Need to replace the implantable pulse generator (IPG) due to battery end of life&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of disabling gait and/or balance and/or speech issues, as clinically judged&#x0D;&lt;br&gt;             by the PI and the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence that these disabling gait and/or balance and/or speech issues are worsened by&#x0D;&lt;br&gt;             DBS, i.e. they improve after turning DBS off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of contact 1 and/or 2 on one hemisphere and/or 9 and/or 10 on the other one&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good LFP signal (assessable only after IPG replacement with Percept) in at least one&#x0D;&lt;br&gt;             hemisphere&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS surgery without Medtronic products&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Potential use of any therapeutic stimulation configuration (such as bipolar) during&#x0D;&lt;br&gt;             the study which will prevent the use of aDBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any other disorders potentially impacting the outcome measures (e.g.&#x0D;&lt;br&gt;             orthopaedic issues)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically unstable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe non-motor problems, such as depression, dementia, etc.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS;Device: Continuous DBS
    </Intervention>
    <Primary_outcome>Change in Activities of Daily Living using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II;Change in Quality of Life (QoL) using Parkinson's Disease Questionnaire (PDQ39);Change in Gait using the Zeno Walkway by Protokinetics;Change in Speech Quality using the Praat software (Phonetic Sciences)
    </Primary_outcome>
    <Secondary_outcome>Change in Motor Outcomes (adaptive DBS vs continuous DBS arms) using Unified Parkinson's Disease Rating Scale part III (motor examination)
    </Secondary_outcome>
    <Secondary_ID>17-5527
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12110509
    </Internal_Number>
    <TrialID>IRCT20220227054136N1
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>The effect of deep brain stimulation on cognitive disorders in Parkinson's disease patients
    </Public_title>
    <Scientific_title>Visual-spatial attention and risk decision making of  Parkinson's disease Patients in Comparison with healthy individuals and the effect of deep brain stimulation on it                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Kordestan university
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220321
    </Date_registration3>
    <Date_registration>2022-03-21
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/62205
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 years
    </Inclusion_agemin>
    <Inclusion_agemax>no limit
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2022-03-11
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Iran (Islamic Republic of)
    </Countries>
    <Contact_Firstname>Mahshad Sohrabi Jahromi
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Tavakoli4 , N Edalat Blvd , Shiraz
    </Contact_Address>
    <Contact_Email>m.sohrabi1374@gmail.com
    </Contact_Email>
    <Contact_Tel>+98 71 5444 9616
    </Contact_Tel>
    <Contact_Affiliation>The University of Kordestan
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: all Parkinson's disease patients&lt;br&gt;Persons with a minimum age of 15 years&lt;br&gt;Minimum literacy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People with neurodegenerative diseases except for Parkinson's patients&lt;br&gt;Inability to perform tests for any reason&lt;br&gt;Dissatisfaction with participation in research
    </Exclusion_Criteria>
    <Condition>parkinson,s disease. &lt;br&gt;Parkinson's disease
    </Condition>
    <Intervention>Intervention 1: Control group 1 : This group includes Parkinson's patients without the need for deep brain stimulation surgery and no therapeutic interventions are performed on them. Intervention 2: Control group 2 : This group includes healthy people without Parkinson's disease and no therapeutic intervention is performed on them. Intervention 3: Intervention group: Parkinson's patients are candidates for deep brain stimulation surgery performed by a surgical intervention surgeon.
    </Intervention>
    <Primary_outcome>Spatial visual attention scores in the Simon task. Timepoint: First pre-test about 20 to 10 days before surgery, second pre-test about 3 to 1 day before surgery, first post-test 1 to 7 days after surgery, second post-test about 40 days after surgery, third post-test about 3 Month after surgery. Method of measurement: simon task.;Risk ratings in the Cambridge Risk Task have been modified. Timepoint: First pre-test about 20 to 10 days before surgery, second pre-test about 3 to 1 day before surgery, first post-test 1 to 7 days after surgery, second post-test about 40 days after surgery, third post-test about 3 Month after surgery. Method of measurement: Modified Cambridge Risk Task.
    </Primary_outcome>
    <Source_Support>cognitive sciences and technologies council
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/02/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics committee of Shiraz University of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12188228
    </Internal_Number>
    <TrialID>NCT05314322
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation on Dual-task Gait Performance in PD
    </Public_title>
    <Scientific_title>The Impacts of Deep Brain Stimulation on Dual-task Gait Performance in Parkinson's Disease: Focusing on Long-term Outcome and the Effects of Stimulation Modes
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Yang Ming University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220316
    </Date_registration3>
    <Date_registration>16/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05314322
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2022
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Taiwan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Yea-Ru Yang, PhD
    </Contact_Lastname>
    <Contact_Email>yryang@nycu.edu.tw
    </Contact_Email>
    <Contact_Tel>+886-2-2876-7279
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: 50~80 yrs old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage = IV after DBS operation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted DBS system for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MMSE =24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other neurological disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any major systemic, psychiatric, visual, and musculoskeletal disturbances or other&#x0D;&lt;br&gt;             causes of walking inability&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation with high frequency;Procedure: Deep brain stimulation with low frequency
    </Intervention>
    <Primary_outcome>Dual-task gait performance: Stride length;Dual-task gait performance: Double limb support time;Executive function - Inhibition control;Executive function - Shifting attention;Executive function - Working memory;Cognitive function;Non-motor symptoms
    </Primary_outcome>
    <Secondary_outcome>Usual gait performance: Stride length;Usual gait performance: Double limb support time;Brain activity: Prefrontal Cortex;Brain activity: Supplementary Motor Cortex;Brain activity: Premotor Cortex;Functional activity: Gait and balance performance;Functional activity: Lower limb function;Balance performance;Motor symptoms;Parkinson's Disease patients' Quality of life
    </Secondary_outcome>
    <Secondary_ID>2022-02-016A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13116006
    </Internal_Number>
    <TrialID>NCT05307055
    </TrialID>
    <Last_Refreshed_on>13 June 2023
    </Last_Refreshed_on>
    <Public_title>Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation
    </Public_title>
    <Scientific_title>Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation of Bilateral Subthalamic Nucleus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Southern California
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220314
    </Date_registration3>
    <Date_registration>14/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05307055
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 11, 2022
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Darrin Lee, MD PhD;Darrin Lee, MD PhD;Darrin Lee
    </Contact_Lastname>
    <Contact_Email>;darrin.lee@med.usc.edu;Darrin.Lee@med.usc.edu
    </Contact_Email>
    <Contact_Tel>;9495220866;949-522-0866
    </Contact_Tel>
    <Contact_Affiliation>University of Southern California, Keck School of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients who had previously undergone bilateral STN deep brain&#x0D;&lt;br&gt;             stimulation implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age &gt;18 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Stable medication regimen for at least 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient informed and able to give written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Able to comply with all testing, follow-ups and study appointments and protocols&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of epilepsy or seizure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of major substance abuse&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN DBS - Theta Burst;Device: STN DBS - Gamma
    </Intervention>
    <Primary_outcome>Evaluation of motor symptoms;Evaluation of executive functioning;Neuroimaging
    </Primary_outcome>
    <Secondary_ID>HS-20-00676
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12188702
    </Internal_Number>
    <TrialID>NCT05320523
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment
    </Public_title>
    <Scientific_title>Simultaneous Deep Brain Stimulation of the Globus Pallidus Internus and the Nucleus Basalis of Meynert in Patients With Parkinson's Disease and Mild Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220314
    </Date_registration3>
    <Date_registration>14/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05320523
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 20, 2021
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD, PhD
    </Contact_Lastname>
    <Contact_Email>rubens_cury@usp.br
    </Contact_Email>
    <Contact_Tel>+551126617877
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age at the time of enrollment: 50 - 75 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD according to Movement Disorders Society (MDS) criteria&#x0D;&lt;br&gt;             (Albanese et al., 2017).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mild cognitive impairment (MCI) related to Parkinson's disease according to MDS&#x0D;&lt;br&gt;             criteria. (Livtan et al. 2012).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of bilateral idiopathic PD: = 5 years of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Modified Hoehn and Yahr stage = 2 on off medication state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  UPDRS subset III (motor) = 30 points on off medication state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa must improve PD symptoms by = 30% in a levodopa challenge test, as measured&#x0D;&lt;br&gt;             by UPDRS subset III score.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of motor complications related to Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to comply with all visits and study related procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study requirements and the treatment procedures and to provide&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol or drug abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including acute confusional state (delirium),&#x0D;&lt;br&gt;             ongoing psychosis, or clinically significant depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for deep brain stimulation (DBS) surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Heart failure, heart disease or any condition that contraindicates surgical&#x0D;&lt;br&gt;             procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker or other active implanted stimulators.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clearly established Parkinson's disease dementia according to Movement Disorders&#x0D;&lt;br&gt;             Criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another drug, device, or biologics trial concurrently.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Mild Cognitive Impairment
    </Condition>
    <Intervention>Device: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.;Device: GPi stimulation;Device: NBM stimulation;Device: Sham stimulation
    </Intervention>
    <Primary_outcome>Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events.
    </Primary_outcome>
    <Secondary_outcome>Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS).;Change in Mattis Dementia Rating Scale.;Change in Verbal Fluency Battery.;Change in Trail Making Task.;Change in Stroop Test.;Change in Symbol Digit Modalities Test.;Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39).;Change in Questionnaire of the EuroQol-group (EQ-5D-5L).;Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I).;Change in Unified Parkinson's Disease Rating Scale section II (UPDRS II).;Change in Unified Parkinson's Disease Rating Scale section III (UPDRS III).;Change in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV).;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess balance.;Change in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M).;Change in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M).;Change in objective assessment of gait measured by freezing of gait score (FOG score).;Change in New Freezing of Gait Questionnaire (N-FOG).;Change in Falls Efficacy Scale International (FES-I).;Change in Activities-Specific Balance Confidence Scale (ABC scale).;Change in Beck Depression Inventory (BDI).;Change in Beck Anxiety Inventory (BAI).;Change in Starkstein Apathy Scale.;Change in Neuropsychiatric Inventory (NPI).;Change in Ardouin Scale of Behavior in Parkinson's Disease.
    </Secondary_outcome>
    <Secondary_ID>38865720.1.0000.0068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>11986636
    </Internal_Number>
    <TrialID>NCT05262348
    </TrialID>
    <Last_Refreshed_on>7 March 2022
    </Last_Refreshed_on>
    <Public_title>An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Prospective, Multi-center, Open-label, Pivotal Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Advanced Levodopa-Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation
    </Scientific_title>
    <Acronym>ADVENT
    </Acronym>
    <Primary_sponsor>Newronika
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220221
    </Date_registration3>
    <Date_registration>21/02/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05262348
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>95 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2022
    </Date_enrollement>
    <Target_size>51
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jason Jones
    </Contact_Lastname>
    <Contact_Email>jason.jones@newronika.com
    </Contact_Email>
    <Contact_Tel>901-451-4792
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient is =55 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for&#x0D;&lt;br&gt;             =5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The disease stage is II, III or IV according to the Hoehn and Yahr scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has history of improvement of Parkinson's symptoms as a direct result of&#x0D;&lt;br&gt;             administering levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. PD-related symptoms are not adequately controlled with medication, including motor&#x0D;&lt;br&gt;             complications of recent onset (&gt;4 months duration)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient experiences persistent disabling PD-related symptoms or drug side effects&#x0D;&lt;br&gt;             (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal&#x0D;&lt;br&gt;             medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient has been selected for bilateral STN or Gpi DBS, independently from this study,&#x0D;&lt;br&gt;             in accordance with local standard of care DBS screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patient has been selected to receive Medtronic leads model 3389 or 37086,&#x0D;&lt;br&gt;             independently from this study, in accordance with local standard of care DBS screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patient has DBS circuit integrity assessed and confirmed by impedance testing, before&#x0D;&lt;br&gt;             IPG implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. =6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time&#x0D;&lt;br&gt;             "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Montreal Cognitive Assessment (MoCA) &gt;26 in MedON condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Beck Depression Inventory II (BDI-II) score &lt;17 in MedON condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. UPDRS-III improvement by =33% following intake of anti-parkinsonian medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patient is able to understand the study requirements and the treatment procedures and&#x0D;&lt;br&gt;             has provided written informed consent to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patient is willing and capable of completing a 3-day diary and reaches a sufficient&#x0D;&lt;br&gt;             level of agreement (&gt; 75%) with study personnel responses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Patient has a responsible caregiver who will help completing the 3-day diary, provide&#x0D;&lt;br&gt;             feedback on activities of daily living (ADL), and ensure the patient complies with&#x0D;&lt;br&gt;             visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Patient is willing to maintain a constant anti-PD medication treatment (best medical&#x0D;&lt;br&gt;             management) for at least one month prior to study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Patient is willing and able to attend all study-required visits, complete the study&#x0D;&lt;br&gt;             procedures and attend appropriate follow up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient has contraindications for DBS surgery, including any intracranial abnormality&#x0D;&lt;br&gt;             (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous&#x0D;&lt;br&gt;             or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant&#x0D;&lt;br&gt;             (e.g., aneurysm clip, cochlear implant, etc.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient has a history of suicide attempt or current active suicidal ideation as&#x0D;&lt;br&gt;             determined by a positive response to Item 2-5 of suicide ideation sub-scale of the&#x0D;&lt;br&gt;             Columbia Suicide Severity Rating Scale (CSSR-S)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has dementia, major depression, seizures, congestive heart failure,&#x0D;&lt;br&gt;             uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any&#x0D;&lt;br&gt;             other severe medical condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has any medical condition that could interfere with study procedures, confound&#x0D;&lt;br&gt;             the assessment of study endpoints, or prevent a proper data collection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient had confirmation of diagnosis of a terminal illness associated with survival&#x0D;&lt;br&gt;             &lt;12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient needs repeated MRI scans&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient requires diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis,&#x0D;&lt;br&gt;             pacemaker, neurostimulator, etc.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patient has, or plans to obtain, an implanted electrical stimulation medical device&#x0D;&lt;br&gt;             and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated&#x0D;&lt;br&gt;             with a portable infusion pump&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patient is on anticoagulant therapy which cannot be paused for &gt;5 days before IPG&#x0D;&lt;br&gt;             implant surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient with a history of cranial surgery including ablation procedure or any other&#x0D;&lt;br&gt;             previous neurosurgical procedure for the treatment of PD symptoms on either side of&#x0D;&lt;br&gt;             the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Patient is currently participating in another clinical study (excluding any sub-study&#x0D;&lt;br&gt;             of the present study)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Patient is a female who is breastfeeding or of child-bearing potential with a positive&#x0D;&lt;br&gt;             urine pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: adaptive DBS delivered through AlphaDBS IPG System;Device: conventional DBS delivered through AlphaDBS IPG System
    </Intervention>
    <Primary_outcome>To assess safety;To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
    </Primary_outcome>
    <Secondary_outcome>Success rate, number of patients with at least 2 hours improvement in each treatment mode;Patient fluctuations;UPDRS III;UdysRS;Percentage of time in which the system is used in aDBS mode
    </Secondary_outcome>
    <Secondary_ID>NWK_AlphaDBS_PIV_2022
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13201771
    </Internal_Number>
    <TrialID>NCT05269862
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>ROAM-DBS
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220117
    </Date_registration3>
    <Date_registration>17/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05269862
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 24, 2022
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Germany;Spain;United Kingdom;Germany;Spain;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Bradley White;Devyani Nanduri
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Abbott;Abbott Medical Devices Neuromodulation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is a participant in the ADROIT study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject is over 21 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is able to read and write.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is indicated for implant with an Infinity IPG for Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has not previously been implanted with a DBS system.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The treating physician believes Virtual Clinic is appropriate as a component in the&#x0D;&lt;br&gt;             treatment regime for this subject.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject will have access to the Abbott Virtual Clinic system through a participating&#x0D;&lt;br&gt;             site.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject will have internet access on their Patient Controller in a location suitable&#x0D;&lt;br&gt;             for a Virtual Clinic session.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject, or a legally acceptable representative, must provide written informed consent&#x0D;&lt;br&gt;             prior to any study-related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is currently enrolled or plans to enroll in an investigational study that may&#x0D;&lt;br&gt;             confound the results of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the study or to comply with follow-up&#x0D;&lt;br&gt;             requirements, or impact the scientific soundness of the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. As assessed by the treating physician, lead misplacement would prevent the DBS therapy&#x0D;&lt;br&gt;             from providing clinically meaningful benefit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is unable to use the Virtual Clinic feature.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject will not be able, in the investigator's opinion, to demonstrate or articulate&#x0D;&lt;br&gt;             symptoms during a Virtual Clinic visit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature;Device: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)
    </Intervention>
    <Primary_outcome>Primary Efficacy Endpoint: The time to achieve a 1 point improvement Patient's Global Impression of change (PGIC) relative to the subject's status at the end of the initial programming visit;Primary Safety Endpoint: Rate of programming related adverse events for the Virtual Clinic cohort
    </Primary_outcome>
    <Secondary_outcome>Patient Global Impression (PGI);Patient Global Impression (PGI);Clinical Global Impression (CGI);Clinical Global Impression (CGI);Parkinson's Disease Questionnaire (PDQ-39);Parkinson's Disease Questionnaire (PDQ-39);Levodopa Equivalent Dose (LED);Levodopa Equivalent Dose (LED);Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS);Home Monitoring (Tremor);Home Monitoring (Dyskinesia);"On Time" (time each day without troublesome symptoms or side effects) (derived from Home Monitoring);Health care resource utilization: Number of hospitalizations and ER visits;Time to resolve programming related adverse events
    </Secondary_outcome>
    <Secondary_ID>ABT-CIP-10413
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13646769
    </Internal_Number>
    <TrialID>DRKS00026085
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Evaluation of conscious Signal interpretation TheRapy Improvement for DEep brain stimulation (DBS) in chronically implanted patients
    </Public_title>
    <Scientific_title>Evaluation of conscious Signal interpretation TheRapy Improvement for DEep brain stimulation (DBS) in chronically implanted patients - STRIDE CHRONIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210920
    </Date_registration3>
    <Date_registration>20/09/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00026085
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>20/09/2021
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. male or female patients aged at least 20 and no older than 85 years; &#x0D;&lt;br&gt;2. patients with any of the following diagnoses: &#x0D;&lt;br&gt;a. Essential tremor, DBS implanted in the subthalamic region, &#x0D;&lt;br&gt;b. Tremor-dominant PD, DBS implanted in the thalamic target, &#x0D;&lt;br&gt;c. Drug-refractory PD with fluctuations, DBS target in the subthalamic nucleus (STN), &#x0D;&lt;br&gt;d. Neuropathic pain, DBS implanted in the thalamic target; &#x0D;&lt;br&gt;3. Patients implanted with a DBS system at least 3 months ago - either as part of STRIDE (preceding study to this protocol), or as part of routine clinical routine; &#x0D;&lt;br&gt;4. Written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. patients with dementia symptoms, 2. pregnant or breastfeeding women
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;G25.0 &lt;br&gt;M79.20 &lt;br&gt;G11.2 &lt;br&gt;G11.1;Parkinson disease;Essential tremor;Late-onset cerebellar ataxia;Early-onset cerebellar ataxia;G25.0;M79.20;G11.2;G11.1
    </Condition>
    <Intervention>Group 1: Patients with DBS systems present to the clinic at regular intervals as part of routine clinical practice for fine-tuning of their settings. On one such visit, two additional examinations are to be performed: first, the conventional DBS will be switched off for a short time, and single-blinded testing of sensoric stimulations will be performed (patient will be asked, "When I adjust this, do you feel anything?"), followed by testing (a random sequence of on/off is run with the sensoric stimulations; it is recorded whether the patient correctly identifies sensations).&lt;br&gt;&lt;br&gt;Second, after this brief calibration session, the patient will perform study-specific gait tests. Three gait tests are performed, one in each of the conditions "No stimulation," "Conventional DBS," and "Sensory DBS".&lt;br&gt;&lt;br&gt;All stimulation settings are safe and are performed within the intended purpose of the implanted DBS system and under the supervision of a study physician. Gait testing is performed in order to check whether perceiving the applied stimulation signals can improve the gait pattern.
    </Intervention>
    <Primary_outcome>Correct interpretation and assignment of signals by the patient. Unchanged or improved arrhythmicity of the gait pattern.
    </Primary_outcome>
    <Secondary_outcome>- Qualitatively characterize patients' perceptions when exposed to sensory stimulation signals that are useful for the patient &#x0D;&lt;br&gt;- Quantify improvements in the patient's gait pattern achieved through the additional sensory stimulation signals.
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie;CereGate GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/09/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00026085#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13524759
    </Internal_Number>
    <TrialID>NCT05089682
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
    </Public_title>
    <Scientific_title>Morpheus - Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210816
    </Date_registration3>
    <Date_registration>16/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05089682
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 22, 2021
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gregory Worrell, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS in one of the defined nuclei of interest during the period of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to give written and oral informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to complete all required study procedures including travelling to Mayo Clinic&#x0D;&lt;br&gt;             and staying overnight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All women of childbearing potential and women who have been amenorrheic for less than&#x0D;&lt;br&gt;             1 year must practice effective contraception during the study. This includes a barrier&#x0D;&lt;br&gt;             method such as condom or diaphragm with spermicide; barrier intrauterine device (IUD)&#x0D;&lt;br&gt;             or abstinence.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This is including&#x0D;&lt;br&gt;             anyone who, in the opinion of the clinician taking consent is unlikely to retain&#x0D;&lt;br&gt;             sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any other medical condition that would interfere with study conduct or&#x0D;&lt;br&gt;             make it unsafe for them to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy test positive.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Neurological Disease;Parkinson Disease;Epilepsy
    </Condition>
    <Intervention>Device: DBS Stimulation during sleep
    </Intervention>
    <Primary_outcome>Participants to Complete Study
    </Primary_outcome>
    <Secondary_outcome>Total Sleep Time;Psychomotor Vigilance Test;Karolinska Sleepiness Scale;Latency to Sleep Onset;Latency to Rapid Eye Movement (REM) Sleep;Number of Sleep Cycles;Number of Awakenings Per Night
    </Secondary_outcome>
    <Secondary_ID>19-001216
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>01/11/2023
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT05089682
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12651412
    </Internal_Number>
    <TrialID>NCT05011773
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
    </Public_title>
    <Scientific_title>Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
    </Scientific_title>
    <Acronym>MORPHEUS
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210804
    </Date_registration3>
    <Date_registration>04/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05011773
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 3, 2021
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alexander L Green, FRCS(SN)
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Oxford University Hospitals NHS Trust
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Either already implanted with DBS electrodes or undergoing DBS implantation in one of&#x0D;&lt;br&gt;             the defined nuclei of interest (for Surrey or Rochester: STN, PPN, Hypothalamus,&#x0D;&lt;br&gt;             PAG/PVG - for the Mayo clinic, may use hippocampus or ANT) for standard clinical care&#x0D;&lt;br&gt;             during the period of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged 18 to 85&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to give written and oral informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to complete all required study procedures including travelling to the Sleep&#x0D;&lt;br&gt;             Centre and staying overnight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  By the time of the first visit to Surrey, participants should have already had their&#x0D;&lt;br&gt;             stimulation settings programmed by the Functional Neurosurgery team and have been&#x0D;&lt;br&gt;             stable on the settings for at least two weeks, as per their routine clinical care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For patients with chronic pain, they should be stable on their current medication and&#x0D;&lt;br&gt;             settings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This is including&#x0D;&lt;br&gt;             anyone who, in the opinion of the clinician taking consent is unlikely to retain&#x0D;&lt;br&gt;             sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any other medical condition that would interfere with study conduct or&#x0D;&lt;br&gt;             make it unsafe for them to participate. Such conditions may be poorly controlled&#x0D;&lt;br&gt;             diabetes, poorly controlled/end stage heart disease, renal failure as well as&#x0D;&lt;br&gt;             recurrent, uncontrolled seizures or epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who have started new medication or changed doses 3 weeks prior to a study&#x0D;&lt;br&gt;             visit may not be eligible as deemed by the PI of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients on medication that can affect the study results (such as hypnotics -&#x0D;&lt;br&gt;             benzodiazepines and analogues), at the discretion of the PI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients currently taking ketamine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol intake exceeding 28 units per week.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;MSA - Multiple System Atrophy;Chronic Pain;Epilepsy
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Sleep stages;Sleep inertia
    </Primary_outcome>
    <Secondary_outcome>Control of sleep
    </Secondary_outcome>
    <Secondary_ID>20/PR/0409
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Surrey Sleep Research Centre, Surrey, UK;Mayo Clinic;University of California, San Francisco
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13644068
    </Internal_Number>
    <TrialID>DRKS00021799
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Organization of cortical and subcortical neural networks in psychiatric patients treated with deep brain stimulation
    </Public_title>
    <Scientific_title>Organization of cortical and subcortical neural networks in psychiatric patients treated with deep brain stimulation - None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Klinik für Stereotaxie und Funktionelle NeurochirurgieUniversitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210621
    </Date_registration3>
    <Date_registration>21/06/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00021799
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/08/2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thibaut
    </Contact_Firstname>
    <Contact_Lastname>Sesia
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>thibaut.sesia@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0049(0)22147882772
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Stereotaxie und Funktionelle Neurochirurgie Universitätsklinikum Köln (AöR)
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Selected for deep brain stimulation therapy independently of this study&lt;br&gt;- Good general condition&lt;br&gt;- be able to consent&lt;br&gt;- be able to sign the declaration of consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Unable to give consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F42.9 &lt;br&gt;F95.2;Obsessive-compulsive disorder, unspecified;Combined vocal and multiple motor tic disorder [de la Tourette];F42.9;F95.2
    </Condition>
    <Intervention>Group 1: Change in cortical network communication following DBS treatment (deep brain stimulation)
    </Intervention>
    <Primary_outcome>Change in cerebral band frequency post treatment (e.g. theta, gamma bands).
    </Primary_outcome>
    <Secondary_outcome>Change in cross frequency coherence post treatment (e.g. theta-gamma bands).
    </Secondary_outcome>
    <Source_Support>Klinik Fuer Stereotaxie und Funktionelle NeurochirurgieUniklinikum Koeln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00021799#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13104773
    </Internal_Number>
    <TrialID>NCT04976569
    </TrialID>
    <Last_Refreshed_on>5 June 2023
    </Last_Refreshed_on>
    <Public_title>Neuromodulation of Sleep Architecture by STN-DBS in Parkinsonian Patients
    </Public_title>
    <Scientific_title>Neuromodulation of Sleep Architecture by STN-DBS in Parkinsonian Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tsinghua University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210616
    </Date_registration3>
    <Date_registration>16/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04976569
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 10, 2021
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Huiling Yu, MD
    </Contact_Lastname>
    <Contact_Email>yuhuiling@mail.tsinghua.edu.cn
    </Contact_Email>
    <Contact_Tel/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are&#x0D;&lt;br&gt;             the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic&#x0D;&lt;br&gt;             Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's&#x0D;&lt;br&gt;             disease were made by three neurologists who were experienced in the field of movement&#x0D;&lt;br&gt;             disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Bilateral STN-DBS has been implanted for more than 1 year, and stable drug therapy&#x0D;&lt;br&gt;             regimen and parameter program control regimen have been maintained for 6 weeks or&#x0D;&lt;br&gt;             more;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with onset age of 50 years and above;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Do not use phenobarbital, chloral hydrate, benzodiazepines and non-benzodiazepines as&#x0D;&lt;br&gt;             sedatives and hypnotics at night.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who underwent pallidotomy and other brain surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with other central nervous system and peripheral nervous system diseases;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients complicated with severe medical system diseases, patients with unstable vital&#x0D;&lt;br&gt;             signs and unable to tolerate clinical evaluation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe mental illness;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Use phenobarbital, chloral hydrate, benzodiazepines and non-benzodiazepines as&#x0D;&lt;br&gt;             sedatives and hypnotics at night;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients who cannot complete informed consent due to cognitive and communication&#x0D;&lt;br&gt;             barriers, or refuse to sign informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Sleep Disorder
    </Condition>
    <Intervention>Device: STN-DBS stimulation pattern change
    </Intervention>
    <Primary_outcome>ratio of slow wave sleep;ratio of rem sleep;Sleep Efficiency
    </Primary_outcome>
    <Secondary_outcome>Motor Function Evaluation
    </Secondary_outcome>
    <Secondary_ID>STN_DBS_Sleep_TsinghuaU
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Beijing Tsinghua Changgeng Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13646375
    </Internal_Number>
    <TrialID>DRKS00025490
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Imaging-based registry for quality of life and symptom control after deep brain stimulation in movement disorders
    </Public_title>
    <Scientific_title>Imaging-based registry for quality of life and symptom control after deep brain stimulation in movement disorders - DBS-Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung Stereotaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210615
    </Date_registration3>
    <Date_registration>15/06/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025490
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/10/2021
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz at uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1.) All patients who are admitted to the Medical Center - University of Freiburg, Dept. of Stereotactic and Functional Neurosurgery, and receive or have received a new DBS implantation since 01 Jan 2013.&#x0D;&lt;br&gt;(2.) Written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;G24 &lt;br&gt;G25.0;Parkinson disease;Dystonia;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1:  Clinical outcomes (especially bleeding complications) and long-term effects of DBS will be assessed. For this purpose, parts of the routinely collected data of the control visits will be data of the control visits will be documented in the registry.
    </Intervention>
    <Primary_outcome>Baseline/descriptive data (all patients): &lt;br&gt;&lt;br&gt;(1) Baseline data (demographics, duration of movement disorder, handedness)&lt;br&gt;(2) Pre-existing conditions and preoperative medication&lt;br&gt;(3) Surgery-related haemorrhage in routine postoperative imaging&lt;br&gt;(4) Acquisition of data from intraoperative procedure: Type of anesthesia, number and type of temporary test electrodes used, results of intraoperative test measurements, implanted stimulation system (type, manufacturer) and date of implantation (electrodes and stimulator), and any follow-up operations on the stimulation system and their indication &lt;br&gt;(5) High-resolution magnetic resonance imaging of the skull (3T) including structural anatomical data as well as diffusion-tensor magnetic resonance imaging (DTI) and subsequent fiber tracking to visualize the respective target structure (depending on implantation site and indication)&lt;br&gt;(6) Stimulation settings during routine controls &lt;br&gt;(7) Calculation/simulation of the electric fields around the stimulation electrode and their position with respect to the target structure (EFS = electric field simulation), distance between field and target structure as a measure of field simulations&lt;br&gt;(8) Acquisition of functional disease-specific diagnostic data collected as part of routine clinical practice (e.g., neuropsychological testing, PET examinations, and gait laboratory testing)&lt;br&gt;(9) Quality of life (EQ-5D-5L)&lt;br&gt;&lt;br&gt;Outcome measures (PD): &lt;br&gt;- Mattis Dementia Rating Scale (DRS-2)&lt;br&gt;- Quality of life disease-specific (PDQ-39)&lt;br&gt;- Unified Parkinson's Disease Rating Scale (UPDRS) IIII&lt;br&gt;- Non-motor Symptoms Scale (NMSS)&lt;br&gt;- Barratt Impulsiveness Scale (BIS-11)&lt;br&gt;- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)&lt;br&gt;- Beck's Depression Inventory Revision (BDI II)&lt;br&gt;- Self-Report Manic Inventory&lt;br&gt;- L-DOPA Equivalent of Parkinson's Disease Medication (LED)&lt;br&gt;&lt;br&gt;Target variables (tremor): &lt;br&gt;- Essential Tremor Rating Assessment Scale (TETRAS)&lt;br&gt;- Examination of tremor intensity and tremor frequency preoperatively and at postoperative appointments with on and off stimulation&lt;br&gt;- Mattis Dementia Rating Scale (DRS-2)&lt;br&gt;- Scale for the assessment and rating of ataxia (SARA)&lt;br&gt;- Beck's Depression Inventory Revision (BDI II)&lt;br&gt;- Quality of life disease-specific (QUEST)&lt;br&gt;&lt;br&gt;Target variables (dystonia): &lt;br&gt;- For cervical dystonia, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)&lt;br&gt;- For cervical dystonia Quality of life disease-specific: Craniocervical dystonia questionnaire (CDQ-24)&lt;br&gt;- For all other dystonias: Unified Dystonia Rating Scale (UDRS) 
    </Primary_outcome>
    <Secondary_outcome>A distinction between primary and secondary endpoints will not be made in this registry. Rather, a list of equivalent outcome parameters is defined.
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025490#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>11052125
    </Internal_Number>
    <TrialID>NCT04928079
    </TrialID>
    <Last_Refreshed_on>21 June 2021
    </Last_Refreshed_on>
    <Public_title>6-year Follow-up of Dysphagia in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>6-year Follow-up of Dysphagia in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Second Affiliated Hospital, School of Medicine, Zhejiang University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210609
    </Date_registration3>
    <Date_registration>09/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04928079
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2014
    </Date_enrollement>
    <Target_size>116
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Wei Luo, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  idiopathic PD according to the United Kingdom PD Society Brain Bank Clinical&#x0D;&lt;br&gt;             Diagnostic Criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (1) Parkinsonian syndromes;(2) with severe lung disease, severe liver insufficiency&#x0D;&lt;br&gt;             and cardiac insufficiency; (3) Kubota water drinking test grade =3; (4) have had or&#x0D;&lt;br&gt;             combined other diseases that affect swallowing function; (5) Nasal feeding, gastric&#x0D;&lt;br&gt;             reflux or gastrostomy; (6) Mental disorders Or patients with low intelligence and&#x0D;&lt;br&gt;             cognitive function, unable to understand and cooperate with the examination.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dysphagia
    </Condition>
    <Intervention>Procedure: deep brain stimulation;Drug: Anti-Parkinsonian Drugs
    </Intervention>
    <Primary_outcome>penetration - aspiration score;residue score
    </Primary_outcome>
    <Secondary_outcome>water swallow test;SDQ-C
    </Secondary_outcome>
    <Secondary_ID>(2020)LunShenYan( 191 )
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12908156
    </Internal_Number>
    <TrialID>NCT04922411
    </TrialID>
    <Last_Refreshed_on>27 March 2023
    </Last_Refreshed_on>
    <Public_title>Cortical Network Modulation by Subthalamic Nucleus DBS
    </Public_title>
    <Scientific_title>Cortical Network Modulation by Subthalamic Nucleus Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Washington University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210604
    </Date_registration3>
    <Date_registration>04/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04922411
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 23, 2021
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Tamara G Hershey;Samantha Ranck, MSW, MA, LPC;Samantha Ranck, MSW, MA, LPC
    </Contact_Lastname>
    <Contact_Email>;blankens@wustl.edu;blankens@wustl.edu
    </Contact_Email>
    <Contact_Tel>;314-362-6514;314-362-6514
    </Contact_Tel>
    <Contact_Affiliation>Washington University Medical School;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pilot Group: Participants who enroll as part of the Pilot Group of up to10, will&#x0D;&lt;br&gt;             follow the same inclusion criteria as the Control group with the exception of matching&#x0D;&lt;br&gt;             the age and sex distribution of the DBS group. Pilot participants will be males or&#x0D;&lt;br&gt;             females between 20 and 75 years of age who do not meet criteria for clinically&#x0D;&lt;br&gt;             definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Control Group: Participants who enroll as part of the Control Group will match the age&#x0D;&lt;br&gt;             and sex distributions of the DBS groups. Control participants will be males or females&#x0D;&lt;br&gt;             between 50 and 75 years of age who do not meet criteria for clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-Surgical DBS Group: Participants with PD who have been clinically consented for&#x0D;&lt;br&gt;             bilateral STN DBS surgery will be recruited from the DBS program within the Movement&#x0D;&lt;br&gt;             Disorders Clinic at WUSM. Pre-surgical STN DBS patients will be males or females&#x0D;&lt;br&gt;             between 50 and 75 years of age who meet criteria for clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-Surgical DBS Group: Participants with PD who have had bilateral STN DBS surgery&#x0D;&lt;br&gt;             will be males or females between 50 and 75 years of age who meet criteria for&#x0D;&lt;br&gt;             clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pilot Group: Exclusions include any significant past or current neurologic or&#x0D;&lt;br&gt;             psychiatric diagnosis or any other condition which could interfere with testing (e.g.&#x0D;&lt;br&gt;             severe visual loss, non-English speaking, and illiteracy) and contraindications for&#x0D;&lt;br&gt;             MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Control Group: Exclusions include any significant past or current neurologic or&#x0D;&lt;br&gt;             psychiatric diagnosis or any other condition which could interfere with testing (e.g.&#x0D;&lt;br&gt;             severe visual loss, non-English speaking, and illiteracy) and contraindications for&#x0D;&lt;br&gt;             MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-Surgical DBS Group: Patients will have already passed clinical screening for&#x0D;&lt;br&gt;             neurological and psychiatric comorbidities, including dementia. From this group of&#x0D;&lt;br&gt;             potential subjects, we will also exclude those with contraindications for MRI&#x0D;&lt;br&gt;             pre-surgically, inability to tolerate off medication or off DBS states, or any other&#x0D;&lt;br&gt;             condition which could interfere with testing (e.g. severe visual loss, non-English&#x0D;&lt;br&gt;             speaking, illiteracy).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-Surgical DBS Group: Patients will have already passed clinical screening for&#x0D;&lt;br&gt;             neurological and psychiatric comorbidities, including dementia. From this group of&#x0D;&lt;br&gt;             potential subjects, we will also exclude those with contraindications for MRI&#x0D;&lt;br&gt;             pre-surgically, clinically determined dementia manifesting after surgery, significant&#x0D;&lt;br&gt;             complications of surgery (e.g. stroke), inability to tolerate off medication or off&#x0D;&lt;br&gt;             DBS states, or any other condition which could interfere with testing (e.g. severe&#x0D;&lt;br&gt;             visual loss, non-English speaking, illiteracy).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: STN DBS
    </Intervention>
    <Primary_outcome>Functional Connectivity measures
    </Primary_outcome>
    <Secondary_ID>1R01NS109487-01A1;201908154
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13646227
    </Internal_Number>
    <TrialID>DRKS00025287
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Connectivity based study for risk behaviour for Patients with idiopathic Parkinson´s Syndrome after Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Connectivity based study for risk behaviour for Patients with idiopathic Parkinson´s Syndrome after Deep Brain Stimulation - KORINTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210531
    </Date_registration3>
    <Date_registration>31/05/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025287
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>25/05/2021
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Juan Carlos
    </Contact_Firstname>
    <Contact_Lastname>Baldermann
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>juan.baldermann@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147897602
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis: Idiopathic Parkinsons Syndrome&lt;br&gt;Therapy with Deep Brain Stimulation in the Nucleus subtalamicus on both sides&lt;br&gt;Minimum age: 18 Years&lt;br&gt;Fluent in German
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Dementia&lt;br&gt;Instable psychiatric disorder in need of treatment
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation of the STN in ventral, dorsal, and regular clinical stimulation setting&lt;br&gt;Group 2: Switched-off deep brain stimulation
    </Intervention>
    <Primary_outcome>Impulsivity measured with the CGT (30 minutes after stimulation setting)
    </Primary_outcome>
    <Secondary_outcome>Motor status&lt;br&gt;Dyskinesia&lt;br&gt;Futher Impulsivity scores
    </Secondary_outcome>
    <Source_Support>Universität zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>04/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025287#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>11356867
    </Internal_Number>
    <TrialID>NCT04811807
    </TrialID>
    <Last_Refreshed_on>13 September 2021
    </Last_Refreshed_on>
    <Public_title>Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Multicentre Observational Study of Impulsive Behaviours Following Deep Brain Stimulation in Parkinson's Disease
    </Scientific_title>
    <Acronym>CRIPS
    </Acronym>
    <Primary_sponsor>King's College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210319
    </Date_registration3>
    <Date_registration>19/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04811807
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2021
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Selected for DBS to treat motor symptoms of Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  English language fluency&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  nil&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Impulsive Behavior;Impulse Disorders;Gambling, Pathological;Eating, Binge;Hoarding Disorder;Hypersexuality;Compulsive Shopping;Dopamine Dysregulation Syndrome;Caregiver Burnout;Parkinson Disease
    </Condition>
    <Intervention>Device: Subthalamic Nucleaus Deep brain stimulation
    </Intervention>
    <Primary_outcome>change in severity of ICBs and development of new ICBs;Descriptive analysis of recurrence of ICBs in those with history of ICBs using scores on QUIP-RS/PICs;Descriptive analysis of de novo cases of Impulsive control disorders ICD/ICBs
    </Primary_outcome>
    <Secondary_outcome>predictive factors for de novo, recurrence and change in severity of ICD/ICBs;change in ICB relate to quality of life in patients and carers;change in ICD relates to changes in mood;change in ICD relates to change in personality traits
    </Secondary_outcome>
    <Secondary_ID>285162
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>South London and Maudsley NHS Foundation Trust;NHS Greater Glasgow and Clyde;King's College Hospital NHS Trust;Walton Centre NHS Foundation Trust;Newcastle-upon-Tyne Hospitals NHS Trust;Oxford University Hospitals NHS Trust;Barking, Havering and Redbridge University Hospitals NHS Trust;Salford Royal NHS Foundation Trust
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13524150
    </Internal_Number>
    <TrialID>NCT04735458
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Investigating Inhibitory Control Networks in Parkinson's Disease
    </Public_title>
    <Scientific_title>Investigating Inhibitory Control Networks in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210128
    </Date_registration3>
    <Date_registration>28/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04735458
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>90
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Nicole Bentley, MD;Nicole Bentley, MD;Nicole Bentley, MD
    </Contact_Lastname>
    <Contact_Email>;jbentley@uabmc.edu;jbentley@uabmc.edu
    </Contact_Email>
    <Contact_Tel>;205-975-0011;205-975-0011
    </Contact_Tel>
    <Contact_Affiliation>University of Alabama at Birmingham;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Eligible for DBS surgery based on multi-disciplinary consensus review&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of Parkinson's disease or Essential Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A minimum of 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to participate in the paradigms described in the protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to provide full and informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are not surgical candidates due to co-morbid conditions or pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have not undergone an adequate trial of conservative medical management&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a clinical presentation for which DBS surgery is not indicated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are not able to participate in study-related activities&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
    </Intervention>
    <Primary_outcome>Accuracy via Simon Task (% correct);Response times via Simon Task (sec);Simon Effect on Response times (sec);Simon Effect on Accuracy (% correct);United Parkinson's disease Rating Scale part 3: Motor Examination Score 0-108 (Higher score represents worse symptoms);Dementia Rating Scale Score 0-144 points (Higher score represents better symptoms)
    </Primary_outcome>
    <Secondary_ID>1K23NS117735-01A1;IRB300003605
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13124567
    </Internal_Number>
    <TrialID>NCT04712552
    </TrialID>
    <Last_Refreshed_on>20 June 2023
    </Last_Refreshed_on>
    <Public_title>In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
    </Public_title>
    <Scientific_title>In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
    </Scientific_title>
    <Acronym>NEUROLOCATE
    </Acronym>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210114
    </Date_registration3>
    <Date_registration>14/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04712552
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 26, 2021
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Denys FONTAINE
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Centre Hospitalier Universitaire de Nice
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients aged 18 to 70 years old requiring a stereotactic robot-guided deep brain&#x0D;&lt;br&gt;             stimulation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signature of the Informed Consent Form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Affiliation to the French social security system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindication to MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hypersensitivity to gadoteric acid, meglumine or any product containing gadolinium.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anterior and posterior commissure anatomy modifying brain anatomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient unable to complete the Comfort Questionnaire due to cognitive or speech&#x0D;&lt;br&gt;             impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dystonia;Tremor
    </Condition>
    <Intervention>Procedure: deep brain stimulation
    </Intervention>
    <Primary_outcome>Euclidean distance between the point theoretically aimed at by the robot and the point actually reached
    </Primary_outcome>
    <Secondary_outcome>Occupancy time of the operating room;comfort of the patient
    </Secondary_outcome>
    <Secondary_ID>19-PP-22
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13217582
    </Internal_Number>
    <TrialID>NCT04725773
    </TrialID>
    <Last_Refreshed_on>21 August 2023
    </Last_Refreshed_on>
    <Public_title>Apraxia in Parkinson's Disease Patients With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Apraxia in Parkinson's Disease Patients With Deep Brain Stimulation
    </Scientific_title>
    <Acronym>Apraxia DBS
    </Acronym>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210113
    </Date_registration3>
    <Date_registration>13/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04725773
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Bhavana Patel, DO;Bhavana Patel, DO;Bhavana Patel, DO
    </Contact_Lastname>
    <Contact_Email>;Bhavana.Patel@neurology.ufl.edu;Bhavana.Patel@neurology.ufl.edu
    </Contact_Email>
    <Contact_Tel>;(352) 294-5400;352-294-5400
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with PD as defined by the UK Brain Bank Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male or female, ages 18 to 80 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Chronically implanted DBS of either the STN or GPi for a minimum of 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other neurological diagnoses (e.g. Alzheimer's disease, atypical parkinsonism, stroke)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of previous neurosurgical intervention that was not DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with DBS of targets other than the STN or GPi, or leads in both targets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients in whom there is poor manual dexterity for a reason other than PD (e.g.&#x0D;&lt;br&gt;             orthopedic injury, amputation)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with a diagnosis of PD dementia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Deep Brain Stimulation;Parkinson Disease;Apraxia, Motor
    </Condition>
    <Intervention>Device: Deep brain stimulation effect on apraxia
    </Intervention>
    <Primary_outcome>Evaluate for the presence or absence of ideomotor apraxia in PD patients;Evaluate for the presence or absence of ideational apraxia in PD patients;Evaluate for the presence or absence of limb-kinetic apraxia in PD patients;Evaluate for the presence or absence of limb-kinetic apraxia in PD patients
    </Primary_outcome>
    <Secondary_ID>IRB202001999
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13124506
    </Internal_Number>
    <TrialID>NCT04677621
    </TrialID>
    <Last_Refreshed_on>20 June 2023
    </Last_Refreshed_on>
    <Public_title>TEND Study:Telemedicine Nurse DBS for Parkinson's Disease
    </Public_title>
    <Scientific_title>Telemedicine Nurse DBS for Parkinson's Disease: The TEND Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201217
    </Date_registration3>
    <Date_registration>17/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04677621
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2023
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-operative Inclusion Criteria: A good response to levodopa is required in order to&#x0D;&lt;br&gt;             exclude patients with Parkinson's plus syndromes, and will be defined as a 30%&#x0D;&lt;br&gt;             improvement in parkinsonian motor signs based upon the Unified PD Rating Scale (UPDRS)&#x0D;&lt;br&gt;             motor examination subscore, following the administration of 1.5 times the typical&#x0D;&lt;br&gt;             dopaminergic dose during the screening neurological examination. Patients must also&#x0D;&lt;br&gt;             have PD for a minimum of 5 years duration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Additional inclusion criteria consist of: 1) Hoehn &amp; Yahr stage II or worse when off;&#x0D;&lt;br&gt;             2) Intractable, disabling motor fluctuations and/or tremor; 3) Age between 30-75&#x0D;&lt;br&gt;             years; 4) Unsatisfactory clinical response to maximal medical management (with trials&#x0D;&lt;br&gt;             of both higher and lower doses of antiparkinsonian drugs). 5) A stable/optimal medical&#x0D;&lt;br&gt;             regimen of antiparkinsonian drug therapy for at least one month prior to surgery; 6)&#x0D;&lt;br&gt;             access to high-speed internet in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase the risk of developing pre-&#x0D;&lt;br&gt;             or postoperative complications (e.g. significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major untreated psychiatric disorder.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Nurse Telehealth;Other: STANDARD DBS
    </Intervention>
    <Primary_outcome>The number of participant clinic visits
    </Primary_outcome>
    <Secondary_outcome>PDQ-39 Scores
    </Secondary_outcome>
    <Secondary_ID>OCR39945;PRO00042966;IRB202002994-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13347259
    </Internal_Number>
    <TrialID>NCT04703556
    </TrialID>
    <Last_Refreshed_on>18 September 2023
    </Last_Refreshed_on>
    <Public_title>Recording and Modulation of Brain Activity Through Chronically Implanted Stimulation Electrodes
    </Public_title>
    <Scientific_title>Recording and Modulation of Brain Activity Through Chronically Implanted Stimulation Electrodes in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>PDNeuroGAIT
    </Acronym>
    <Primary_sponsor>Jocelyne Bloch
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201201
    </Date_registration3>
    <Date_registration>01/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04703556
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 4, 2021
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: 18 years old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed Consent as documented by signature&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with Parkinson's disease, and being treated with deep brain stimulation&#x0D;&lt;br&gt;             therapies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exhibiting severe locomotor deficits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to comply in good faith with all conditions of the recordings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to follow the procedures of the study, e.g. due to language problems,&#x0D;&lt;br&gt;             psychological disorders, dementia, etc. of the participant,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another investigational study in the preceding 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous enrolment into the current study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Devices for deep brain stimulation
    </Intervention>
    <Primary_outcome>Changes in gait performance induced by DBS parameters;Changes in gait performance induced by DBS parameters;Changes in gait performance induced by DBS parameters;Changes in gait quality induced by DBS parameters;Changes in global motor scores induced by DBS parameters;Changes in brain dynamics induced by DBS parameters;Changes in brain dynamics induced by DBS parameters
    </Primary_outcome>
    <Secondary_ID>DBSgait2020
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Hôpital du Valais
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12728319
    </Internal_Number>
    <TrialID>NCT04650932
    </TrialID>
    <Last_Refreshed_on>9 January 2023
    </Last_Refreshed_on>
    <Public_title>Dual Frequency Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Davis
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201116
    </Date_registration3>
    <Date_registration>16/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04650932
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 22, 2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kiarash Shahlaie, MD, PhD;Kiarash Shahlaie, MD, PhD;Jessica Beatty, MS
    </Contact_Lastname>
    <Contact_Email>;krshahlaie@ucdavis.edu;jabeatty@ucdavis.edu
    </Contact_Email>
    <Contact_Tel>;916-703-5505;916-734-0901
    </Contact_Tel>
    <Contact_Affiliation>University of California, Davis;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who are 18 years and older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with idiopathic Parkinson's Disease who previously underwent implantation&#x0D;&lt;br&gt;             with the Boston Scientific VerciseTM DBS system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have been implanted with the Boston Scientific VerciseTM DBS system&#x0D;&lt;br&gt;             for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals diagnosed with advanced PD who had bilateral dorsal subthalamic nucleus&#x0D;&lt;br&gt;             DBS surgery, as standard of care for motor improvement, with distal contacts of the&#x0D;&lt;br&gt;             electrodes implanted into the ventral STN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals unable to provide consent and/or lack capacity to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals diagnosed with any cognitive or physical impairments that would limit&#x0D;&lt;br&gt;             their ability to participate in the cognitive testing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who score below 15 on the Montreal Cognitive Assessment Test-Blind&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who score above 20 on the Center for Epidemiologic Studies Depression&#x0D;&lt;br&gt;             Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women (note: pregnant women are not candidates for DBS surgery), and&#x0D;&lt;br&gt;             prisoners&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-English speaking individuals. Cognitive tasks will only be conducted in English.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Mean Change from Baseline in Depression Scores on the Center for Epidemiologic Studies Depression Scale (CES-D);Mean Change from Baseline in Impulsiveness Scores on the Barratt Impulsiveness Scale (BIS-11);Mean Change from Baseline in Neuropsychiatric Inventory (NPI);Mean Change from Baseline in Movement Scores on Part III of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS);Mean Change from Baseline in Cognitive Performance Scores on the Montreal Cognitive Assessment - Blind (MoCA);Mean Change from Baseline in Depression Scores on the CES-D Short Version (CES-D-R10);Mean Change from Baseline in Motor and Non-Motor Aspects of Daily Living Scores on Parts I and II of the MDS-UPDRS
    </Primary_outcome>
    <Secondary_outcome>Mean Change from Baseline in Decision-Making Scores on Probabilistic Gambling Task;Mean Change from Baseline in Inter-Temporal Choice Scores on a Temporal Discounting Task;Mean Change from Baseline in Verbal Fluency Scores on Word Generation Task
    </Secondary_outcome>
    <Secondary_ID>1633883
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10382482
    </Internal_Number>
    <TrialID>NCT04618887
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
    </Public_title>
    <Scientific_title>A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Peking University People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201101
    </Date_registration3>
    <Date_registration>01/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04618887
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2020
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients confirmed Meige sydrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who cannot finish the neurosurgery or the postoperative evaluation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Meige Syndrome;Meigs Syndrome;Meige Disease;Meig Syndrome;Blepharospasm;Blepharospasm of Left Eyelid;Blepharospasm of Right Eyelid;Blepharospasm of Both Eyelids;Blepharospasm Oromandibular Dystonia
    </Condition>
    <Intervention>Procedure: pallidotomy;Procedure: deep brain stimulation
    </Intervention>
    <Primary_outcome>Symptom;complications
    </Primary_outcome>
    <Secondary_outcome>quality of life;depression scale
    </Secondary_outcome>
    <Secondary_ID>MeigeSyndrome
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10382300
    </Internal_Number>
    <TrialID>NCT04616521
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>ADP Study: A Multicenter, Prospective, Single Arm, Open Label Study
    </Public_title>
    <Scientific_title>Asymmetric Deep Brain Stimulation for Parkinson's Disease: A Multicenter, Prospective, Single Arm, Open Label Study
    </Scientific_title>
    <Acronym>ADP
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04616521
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD
    </Contact_Lastname>
    <Contact_Email>ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>13817864569
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with idiopathic Parkinson's disease based on the MDS clinical diagnostic&#x0D;&lt;br&gt;             criteria for Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged more than 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa challenge test indicating a preoperative levodopa responsiveness over 24%&#x0D;&lt;br&gt;             based on MDS UPDRS-III&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the modified Hoehn-Yahr Scale between 2 and 4 under on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Compliance with written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonian syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with the intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history or that increases pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale - Part III (MDS UPDRS-III)
    </Primary_outcome>
    <Secondary_outcome>Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale - Part I, II, IV;Time-Up-Go (TUG) task;Berg Balance Scale, BBS;Gait and Falls Questionnaire, GFQ;Montreal Cognitive Assessment (MoCA);Beck Depression Inventory, BDI;Beck Anxiety Inventory, BAI;Apathy Estimation Scale, AES;Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Current Full, QUIP-CF;Epworth Sleepiness Scale, ESS;Non-Motor Symptoms Scale, NMSS;Scales for Outcomes in PArkinson's disease - Autonomic, SCOPA-AUT;8-item Parkinson's Disease Questionnaire (PDQ-8);5-Level EuroQol Five Dimensions Questionnaire, EQ-5D-5L;Levodopa Equivalent Daily Dose, LEDD;Adverse Events, Severe Adverse Events
    </Secondary_outcome>
    <Secondary_ID>Ruijin_ADP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Huashan Hospital;Shanghai Tongji Hospital, Tongji University School of Medicine;The First Affiliated Hospital with Nanjing Medical University;First Affiliated Hospital, Sun Yat-Sen University;The First Affiliated Hospital of Guangzhou Medical University;West China Hospital;Second Affiliated Hospital of Soochow University;Tianjin Huanhu Hospital;Guangzhou General Hospital of Guangzhou Military Command;The Affiliated Hospital of Xuzhou Medical University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10518829
    </Internal_Number>
    <TrialID>NCT04617873
    </TrialID>
    <Last_Refreshed_on>25 January 2021
    </Last_Refreshed_on>
    <Public_title>DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism
    </Public_title>
    <Scientific_title>Deep Brain Stimulation and Spinal Cord Stimulation Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism: a Multi-center, Prospective, Open Label Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>zhangyuqing
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04617873
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 5, 2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Yuqing Zhang, MD;Jiping Li, MD;Jiping Li, MD
    </Contact_Lastname>
    <Contact_Email>;yhljp89@163.com;yhljp89@163.com
    </Contact_Email>
    <Contact_Tel>;8610-83198899-8630;8610-83198899-8630
    </Contact_Tel>
    <Contact_Affiliation>Capital Medical University- Xuanwu Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. meet the clinical diagnostic criteria of possible MSA-P;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. with moderate to severe parkinsonism motor symptoms;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. accept levodopa treatment for at least 6 months, and stable medication dose for at&#x0D;&lt;br&gt;             least 4 weeks;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. severe orthostatic hypotension;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. score of Hamilton Depression Scale is more than 24.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. score of Mini-mental State Examination is less than 24;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. elevated risks for bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. with evident lesions on MRI structural images at T8-12 spinal cord segment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Multiple System Atrophy, Parkinson Variant (Disorder)
    </Condition>
    <Intervention>Procedure: Bilateral STN-DBS and T10-T12 SCS
    </Intervention>
    <Primary_outcome>change in motor examination( Movement Disorders Society's revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III) at 3 months postoperatively;change in motor examination( Movement Disorders Society's revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III) at 12 months postoperatively;change in PD-related quality of life(PDQ-39)
    </Primary_outcome>
    <Secondary_outcome>change in the score of Gait and Fall Questionnaire (GFQ) at 3 months postoperatively;change in the score of Gait and Fall Questionnaire (GFQ) at 12 months postoperatively;change in severity of freezing of gait (New Freezing of Gait Questionnaire,NFOGQ) at 3 months postoperatively;change in severity of freezing of gait (New Freezing of Gait Questionnaire,NFOGQ) at 12 months postoperatively;Clinical Global Impression-Global Improvement (CGI-GI) at 3 months postoperatively;Clinical Global Impression-Global Improvement (CGI-GI) at 12 months postoperatively;change in the score of Berg Balance Scale(BBS) at 3 months postoperatively;change in the score of Berg Balance Scale(BBS) at 12 months postoperatively
    </Secondary_outcome>
    <Secondary_ID>2020005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13665820
    </Internal_Number>
    <TrialID>NCT04577651
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Cartesia eXTend 3D Study
    </Public_title>
    <Scientific_title>Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)
    </Scientific_title>
    <Acronym>eXTend 3D
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200926
    </Date_registration3>
    <Date_registration>26/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04577651
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2, 2020
    </Date_enrollement>
    <Target_size>58
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany;Netherlands;United Kingdom;Germany;Netherlands;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Candidate for DBS implant in the treatment of Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be on stable anti-parkinsonian medications for 28 days prior to Informed Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persistent disabling Parkinson's disease symptoms such as dyskinesias, motor&#x0D;&lt;br&gt;             fluctuations, or disabling "off" periods despite optimal medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to comply with all visits and study related procedures (e.g.,&#x0D;&lt;br&gt;             using the remote control, charging system, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any intracranial abnormality or medical condition that would contraindicate DBS&#x0D;&lt;br&gt;             surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have any significant psychiatric or cognitive condition likely to compromise the&#x0D;&lt;br&gt;             subject's ability to comply with requirements of the study protocol (e.g. bipolar,&#x0D;&lt;br&gt;             schizophrenia, mood disorder with psychotic features, cluster B personality disorders)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any current drug or alcohol abuse, as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of recurrent or unprovoked seizures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: 16-contact Directional Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in motor function
    </Primary_outcome>
    <Secondary_outcome>Change in motor function;Change in Quality of Life
    </Secondary_outcome>
    <Secondary_ID>A4092
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13565462
    </Internal_Number>
    <TrialID>NCT04605263
    </TrialID>
    <Last_Refreshed_on>4 December 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN)
    </Public_title>
    <Scientific_title>Effects of Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN) on Gait, Postural Stability, Freezing of Gait (FOG), and Falls
    </Scientific_title>
    <Acronym>PPNGB01
    </Acronym>
    <Primary_sponsor>St. Joseph's Hospital and Medical Center, Phoenix
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200831
    </Date_registration3>
    <Date_registration>31/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04605263
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2021
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Guillermo Moguel-Cobos, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Muhammad Ali Movement Disorders Clinic Physician
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Informed consent signed by the subject.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Diagnosed with Parkinson's disease per UK Parkinson's Disease Society Brain Bank&#x0D;&lt;br&gt;                  (Queens Square) criteria for at least 4 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Demonstrates levodopa responsiveness of at least 30%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Experiences tremor or motor complications including wearing off and/or dyskinesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. DBS candidate per FDA guidelines as outlined in criteria 2-4&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Candidate for STN targeting per the consensus committee&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Subject exhibits gait instability, or a history of at least one fall within the&#x0D;&lt;br&gt;                  last year, or a history of falls on tests of Static or Dynamic Stability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               8. PD Stage 2-3 with predominant axial symptoms or FOG refractory to Levodopa &gt; 600&#x0D;&lt;br&gt;                  mg and UPDRS Part III Subscore of &gt;6.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               9. Subject is ambulatory and able to walk for limited periods of time without using&#x0D;&lt;br&gt;                  an assistive device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              10. 18-75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              11. Primary English speaking&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              12. Physically and cognitively capable of completing evaluations and consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              13. Medically cleared for surgery and anesthesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              14. Female subjects with child-bearing potential have a negative serum pregnancy test&#x0D;&lt;br&gt;                  prior to DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Dementia per DSM-V criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Condition precluding MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of supraspinal CNS disease other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of schizophrenia, delusions, or currently uncontrolled visual hallucinations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subjects who require rTMS, ECT, diathermy, or repeat MRI procedures to treat a medical&#x0D;&lt;br&gt;             condition.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subjects with a history of seizure disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subjects who have made a suicide attempt within the prior year,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subjects with any medical contraindications to undergoing DBS surgery (eg, infection,&#x0D;&lt;br&gt;             coagulopathy, or significant cardiac or other medical risk factors for surgery)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator,&#x0D;&lt;br&gt;             neurostimulator and cochlear implant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects who are pregnant or nursing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient that is unwilling or unable to comply with the requirements of this protocol,&#x0D;&lt;br&gt;             including the presence of any condition (physical, mental, or social) that is likely&#x0D;&lt;br&gt;             to affect the subject's ability to comply with the protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any other reasons that, in the opinion of the investigator, the candidate is&#x0D;&lt;br&gt;             determined to be unsuitable for entry into the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN-PPN DBS Surgery;Procedure: Deep Brain Stimulation Surgery (DBS)
    </Intervention>
    <Primary_outcome>STN-PPN Stimulation Effect on Fall Risk
    </Primary_outcome>
    <Secondary_outcome>STN-PPN on Linear and Nonlinear Measures of Gait;STN-PPN on Linear and Nonlinear Measures of Balance;STN-PPN on Attention;STN-PPN on Subjective Measures of Alertness;STN-PPN on Subjective Measures of Sleep;STN-PPN on Subjective Measures of Non-Motor Symptoms;STN-PPN on Subjective Measures of Balance in Daily Life
    </Secondary_outcome>
    <Secondary_ID>PHX-19-500-412-30-04
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Arizona State University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13619758
    </Internal_Number>
    <TrialID>NCT04547712
    </TrialID>
    <Last_Refreshed_on>15 January 2024
    </Last_Refreshed_on>
    <Public_title>Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
    </Public_title>
    <Scientific_title>Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
    </Scientific_title>
    <Acronym>ADAPT-PD
    </Acronym>
    <Primary_sponsor>MedtronicNeuro
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200820
    </Date_registration3>
    <Date_registration>20/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04547712
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 14, 2020
    </Date_enrollement>
    <Target_size>85
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Canada;France;Netherlands;Canada;France;Netherlands;United States;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Helen Bronte-Stewart, MD, MSE
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Stanford University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        General&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject is implanted with Percept PC (Model B35200) and Medtronic DBS leads (Model&#x0D;&lt;br&gt;             3387, 3389, B33005 or B33015) and extensions (Model 37085, 37086, or B34000)&#x0D;&lt;br&gt;             bilaterally in the same target (physician confirmed), STN or GPi&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. In the opinion of the investigator, the subject responds to DBS Therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Based on the opinion of the investigator, the subject's cDBS parameters and PD&#x0D;&lt;br&gt;             medications are stable and expected to remain stable from enrollment through the end&#x0D;&lt;br&gt;             of the aDBS Evaluation phase&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. (Primary Cohort) Subject is configured to ring mode monopolar or dual monopolar&#x0D;&lt;br&gt;             stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. (Directional Stimulation Cohort) Subject is configured to directional monopolar or dual&#x0D;&lt;br&gt;        monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) 6. Subject is willing and&#x0D;&lt;br&gt;        able to attend all study-required visits and complete the study procedures (e.g. 1-month&#x0D;&lt;br&gt;        recall questionnaires, MDS-UPDRS III) 7. Subject has the ability to understand and provide&#x0D;&lt;br&gt;        written informed consent for participation in the study prior to the study-related&#x0D;&lt;br&gt;        procedures being conducted 8. Subject is a male or non-pregnant female. If female of&#x0D;&lt;br&gt;        child-bearing potential, and if sexually active, must be using, or agree to use, a&#x0D;&lt;br&gt;        medically-acceptable method of birth control as confirmed by the investigator 9. For&#x0D;&lt;br&gt;        subjects with the SenSight system: Subject is configured to the following stimulation&#x0D;&lt;br&gt;        rates: 55, 85, 110, 125, 145, 164 or 180 Hz (as required for sensing/aDBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        LFP Screening Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Subject has required Beta band (8-30 Hz) amplitude detected on either left and/or right&#x0D;&lt;br&gt;        DBS leads&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject and/or caregiver is unable to utilize the patient programmer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has more than one lead in each hemisphere of the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject has cortical leads or additional unapproved hardware implanted in the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject has more than one INS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. At enrollment, the subject's INS has a predicted battery life of &lt;1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subject has Beck Depression Inventory II (BDI-II) &gt; 25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject has a metallic implant in the head, (eg, aneurysm clip, cochlear implant)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject has, or plans to obtain, an implanted electrical stimulation medical device&#x0D;&lt;br&gt;             anywhere in the body (eg, cardiac pacemaker, defibrillator, spinal cord stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject has, or plans to obtain, an implanted medication pump for the treatment of&#x0D;&lt;br&gt;             Parkinson's disease (eg, DUOPATM infusion pump) and/or portable infusion pump&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Based on the opinion of the investigator, the subject has an abnormal neurological&#x0D;&lt;br&gt;             examination that would preclude them from study participation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Subject is breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subject is under the age of 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or&#x0D;&lt;br&gt;             device study that may confound the results of this study as determined by the&#x0D;&lt;br&gt;             Medtronic study team&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Subject is unable to use or tolerate wearable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads)&#x0D;&lt;br&gt;             which preclude the clinician from setting thresholds&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS
    </Intervention>
    <Primary_outcome>On time without troublesome dyskinesia
    </Primary_outcome>
    <Secondary_outcome>Stimulation energy use
    </Secondary_outcome>
    <Secondary_ID>MDT19001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10375222
    </Internal_Number>
    <TrialID>NCT04524377
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease
    </Public_title>
    <Scientific_title>Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Charite University, Berlin, Germany
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200814
    </Date_registration3>
    <Date_registration>14/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04524377
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 25, 2019
    </Date_enrollement>
    <Target_size>47
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Philipp Spindler;Philipp Spindler;Philipp Spindler
    </Contact_Lastname>
    <Contact_Email>;philipp.spindler@charite.de;philipp.spindler@charite.de
    </Contact_Email>
    <Contact_Tel>;+49(0)30450660778;+49(0)30450660778
    </Contact_Tel>
    <Contact_Affiliation>Charite University, Berlin, Germany;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  women and men, over 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medical indication for deep brain Stimulation for Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed declaration of consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  withdrawal of consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  non-Parkinson's-associated diseases of the spine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Spine Degeneration;Spine Deformity;Spinal Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Sagittal Imbalance
    </Primary_outcome>
    <Secondary_outcome>Spine Mobility;Oswestry Disability Index (ODI);Visual Analoge Scale (VAS);Unified Parkinsons Disease Rating Scala (Part III Motor Examination) (UPDRS-Part III);Parkinsons Disease Questionaire 39 (PDQ-39);Pelvic incidence (PI);Pelvit tilt (PT);Sacral slope (SS);Lumbar Lordisis (LL);Mismatch of Pelvic incidence and LL (PI - LL);Scoliosis
    </Secondary_outcome>
    <Secondary_ID>40000256
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13642678
    </Internal_Number>
    <TrialID>DRKS00017721
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Prospective study to define clinical markers which predict 36 months outcome in the early disease phase (part I) and treatment response to deep brain stimulation (part II) in late stages of Parkinson’s disease.
    </Public_title>
    <Scientific_title>Prospective study to define clinical markers which predict 36 months outcome in the early disease phase (part I) and treatment response to deep brain stimulation (part II) in late stages of Parkinson’s disease. - LOC-PD: Part I, LOC-EARLY; Part II, LOC-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Tübingen, Abteilung Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200709
    </Date_registration3>
    <Date_registration>09/07/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00017721
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>05/05/2020
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Ina
    </Contact_Firstname>
    <Contact_Lastname>Wolfstädter
    </Contact_Lastname>
    <Contact_Address>Hoppe-Seyler-Str. 3
    </Contact_Address>
    <Contact_Email>Ina.Wolfstaedter@med.uni-tuebingen.de
    </Contact_Email>
    <Contact_Tel>07071 2980472
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Tübingen,Abteilung Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Part I, LOC-EARLY: age = 18 years; PD diagnosis according to the MDS Task Force Criteria; disease duration = 3 years; ability to give consent and communicate well with the investigator, to understand and comply with the requirements of the study; written informed consent prior to undertaking any study-related procedures.&lt;br&gt;&lt;br&gt;Part II LOC-DBS: Age between 18 and 80 years; eligible for DBS surgery according to best-practice strategies (DGN S3-Leitlinie Parkinson), response to levodopa &gt; 30% verified by scores of the MDS-UPDRS-III assessed twice or medication-resistant disabling PD tremor; no signs of PDD; no neurosurgical contraindications; no relevant psychiatric (active depression, psychosis, suicidal ideation), or somatic competing disease; eligibility for DBS confirmed during an inpatient DBS screening procedure by an interdisciplinary board of neurologists, neurosurgeons, and psychiatrists; patients written informed consent for DBS surgery; ability to give consent and communicate well with the investigator, to understand and comply with the requirements of the study and good German language skills (primary or secondary language); having given written informed consent prior to undertaking any study-related procedures.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Part I, LOC-EARLY:&lt;br&gt;Under any administrative or legal supervision or unable to give informed consent; participation in any clinical investigation of a new investigational compound or therapy within 4 weeks prior to baseline visit, and for any other limitation of participation based on local regulations; patients with conditions/concomitant diseases making them non-evaluable for the defined outcomes (e.g. pre-existing neurological disease, brain disease other than PD, e.g. head trauma, stroke, encephalitis);&lt;br&gt;alcohol, medication, or drug dependency or abuse (except for nicotine); inability to meet specific protocol requirements (e.g., need for hospitalization, not able to read and understand the protocol); patient is directly involved in the conduct of the protocol: the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof; patient is uncooperative or has any condition that could make the patient potentially non-compliant to the study procedures; patients with presence of postural instability (MDS-UPDRS-III Item 3.12 = 1) at time of study inclusion;&lt;br&gt;- For the prediction of the dichotomous outcome referring to cognitive worsening:&lt;br&gt;Patients with diagnosis of dementia or cognitive impairment (MoCA=26) at time of study inclusion will not be included into the analysis&lt;br&gt;&lt;br&gt;Part II, LOC-DBS:&lt;br&gt;Under any administrative or legal supervision or unable to give informed consent; participation in any clinical investigation of a new investigational compound or therapy within 4 weeks prior to baseline visit, and for any other limitation of participation based on local regulations;&lt;br&gt;diagnosis of dementia at time of study inclusion; surgical contraindication for implantation surgery; patients with conditions/concomitant diseases making them non-evaluable for the defined outcomes; alcohol, medication, or drug dependency or abuse (except for nicotine); inability to meet specific protocol requirements (e.g., need for hospitalization, not able to read and understand the protocol); patient is directly involved in the conduct of the protocol: the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof; patient is uncooperative or has any condition that could make the patient potentially non-compliant to the study procedures.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: LOC-EARLY:&lt;br&gt;Mandatory assessments:&lt;br&gt;Visit 0, 1, 2, 3: Demographics, medical history, medication, neurological exam, MDS-UPDRS-III/IV, Hoehn &amp;Yahr score, MoCA, PD-NMSQ, Schellong-Test (UMSARS-III), BDI-II, GDS, blood sampling.&lt;br&gt;&lt;br&gt;Optional assessments:&lt;br&gt;Visit 0, 1, 2, 3: MRI, PDQ-39, Sniffing Sticks, RBDSQ, ADS, Parkinson Psychosis Questionnaire, Restless Leg Questionnaire, ESS, Starkstein Apathy Scale, PSP Rating Scale, Verbal fluency, Luria Sequence, Munich Dysphagia Test, UMSARS, lumbar puncture, tear fluid, stool and urin sampling.&lt;br&gt;Group 2: LOC-DBS: &lt;br&gt;Mandatory assessments:&lt;br&gt;Visit 0, 2, 3, 4: Demographics, body weight and size, medical history, medication, neurological exam, MDS-UPDRS-I/II/III/IV, Hoehn &amp;Yahr Score, MoCA, Schellong-Test (UMSARS-III), PDQ-39, BDI-II, blood sampling (only at Visit 0), MRT (only at Visit 0).&lt;br&gt;&lt;br&gt;Visit 1: CT, Dokumentation der Sicherheitsmaße. &lt;br&gt;&lt;br&gt;Optional assessments:&lt;br&gt;Visit 0, 1, 2, 3, 4: PD-NMSQ, lumbar puncture, tear fluid, stool and urin sampling.
    </Intervention>
    <Primary_outcome>The main objective in part I (LOC-EARLY) is to evaluate the predictive value of a single or a combination of markers (demographics, scale scores, environmental, imaging, biomarker data) commonly assessed within the clinical daily routine to predict each of three independent disease specific outcomes after 36 months in early PD. Presence of the following outcomes at months 36 is recorded:&lt;br&gt;Postural instability (Item 3.12 = 1, MDS-UPDRS-III) (primary outcome). &lt;br&gt;&lt;br&gt;The primary objective in part II (LOC-DBS) is to evaluate the predictive value of a single or a combination of markers predicting a beneficial outcome of DBS surgeryaccording to the following criteria: Preserved or less reduced cognitive function at 36 months (MoCA score continuously scaled) (primary outcome).
    </Primary_outcome>
    <Secondary_outcome>Part I, LOC-EARLY: Cognitive worsening: diagnosis of cognitive impairment (PD-MCI) or PDD according to Level I cognitive testing, (MoCA = 26) (secondary outcome); differential atypical PD diagnosis: appearance of “red flags” indicating an atypical Parkinsonian syndrome (secondary outcome); diagnosis of atypical PD according to consensus guidelines (secondary outcome). &lt;br&gt;&lt;br&gt;Part II, LOC-DBS: Improvement of MDS-UPDRS-III scores of at least 30% when comparing preoperative MDS-UPDRS-III scores without intake of dopaminergic medication (MedOff) and postoperative MDS-UPDRS-III scores in MedOff condition and with brain stimulator active (StimOn) at 36-month visit (secondary outcome).
    </Secondary_outcome>
    <Source_Support>Bundesministerium für Bildung und Forschung
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link>http://drks.de/search/en/trial/DRKS00017721#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12182885
    </Internal_Number>
    <TrialID>NCT04461730
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Role of Basal Ganglia and Thalamus in Perceptual Consciousness and Metacognition
    </Public_title>
    <Scientific_title>Role of Basal Ganglia and Thalamus in Perceptual Consciousness and Metacognition
    </Scientific_title>
    <Acronym>METACTION
    </Acronym>
    <Primary_sponsor>University Hospital, Grenoble
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200626
    </Date_registration3>
    <Date_registration>26/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04461730
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2021
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>ELENA MORO
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital, Grenoble
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major patient in need of brain stimulation therapy for motor disorders (Parkinson's&#x0D;&lt;br&gt;             disease, tremor, dystonia) or psychiatric disorders (OCD).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Outpatient or inpatient follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in French and able to understand the study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient affiliated to social security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written agreement to participate in the patient's study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intellectual abilities compatible with the performance of cognitive or motor tasks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP (pregnant women,&#x0D;&lt;br&gt;             parturient women, mothers, etc.) who is breastfeeding, person deprived of liberty by&#x0D;&lt;br&gt;             judicial or administrative decision, person subject to a legal protection measure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients in whom transient cessation of stimulation is not tolerated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject in period of exclusion from another study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject cannot be contacted in case of emergency&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject under administrative or judicial supervision&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;OCD;Dystonia
    </Condition>
    <Intervention>Device: deep brain stimulation
    </Intervention>
    <Primary_outcome>Behavioral effect of DBS on confidence
    </Primary_outcome>
    <Secondary_outcome>Effect of DBS on EEG markers of confidence
    </Secondary_outcome>
    <Secondary_ID>2019-A02328-49;38RC19.271
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13665649
    </Internal_Number>
    <TrialID>NCT04449068
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Observational Database on Deep Brain Stimulation in Tourette Syndrome
    </Public_title>
    <Scientific_title>Pre et Post-operative Evaluation of Patients With Tourette Syndrome Treated With High Frequency Bilateral Stimulation of the Anterior Part of the Internal Pallid Globus
    </Scientific_title>
    <Acronym>POSTSTIC
    </Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200623
    </Date_registration3>
    <Date_registration>23/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04449068
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 12, 2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Andreas HARTMANN, MD;Andres Hartmann, MD
    </Contact_Lastname>
    <Contact_Email>andreas.hartmann@aphp.fr;andreas.hartmann@aphp.fr
    </Contact_Email>
    <Contact_Tel>1 42 16 13 16;01 42 16 13 16
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tourette syndrome severe and drug-resistant eligible for bilateral deep brain&#x0D;&lt;br&gt;             stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who voluntarily and knowledgeably agreed to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non affiliation to a French social security system (recipient or assign) excluding AME&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Other: Neurological and neuropsychological Follow-up after deep brain stimulation
    </Intervention>
    <Primary_outcome>Measure the severity of tics
    </Primary_outcome>
    <Secondary_ID>APHP190808
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10366324
    </Internal_Number>
    <TrialID>NCT04408573
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cycling Deep Brain Stimulation on Parkinson's Disease Gait
    </Public_title>
    <Scientific_title>Effects of Cycling Deep Brain Stimulation on Parkinson's Disease Gait
    </Scientific_title>
    <Acronym>DBS
    </Acronym>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200525
    </Date_registration3>
    <Date_registration>25/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04408573
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 19, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD, PhD;Rubens G Cury, MD, PhD;Rubens G Cury, MD PhD
    </Contact_Lastname>
    <Contact_Email>;rubens_cury@usp.br;rubens_cury@usp.br
    </Contact_Email>
    <Contact_Tel>;55 11 26617877;55 11 26617877
    </Contact_Tel>
    <Contact_Affiliation>University of Sao Paulo General Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently receiving Deep Brain Stimulation as a Parkinson's disease treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn &amp; Yahr stage between 2-4 during off-medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying gait disorders despite optimal medical and stimulation treatment: score&#x0D;&lt;br&gt;             over or equal to 1 in the subitem 2.12 of the MDS-UPDRS scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to comply with all study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active moderate/severe psychiatric condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active infection or other uncontrolled moderate/grave comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with experimental drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breast-feeding&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Cycling deep brain stimulation
    </Intervention>
    <Primary_outcome>Change in the part II of the Unified Parkinson's disease rating scale;Change in the New Freezing of Gait Questionnaire
    </Primary_outcome>
    <Secondary_outcome>Change in Falls Efficacy Scale;Change in The Parkinson's Disease Questionnaire (PDQ-39);Change in Activities-Specific Balance Confidence Scale (ABC scale);Number of falls
    </Secondary_outcome>
    <Secondary_ID>67914017.6.0000.0068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>9245716
    </Internal_Number>
    <TrialID>ChiCTR2000032852
    </TrialID>
    <Last_Refreshed_on>18 May 2020
    </Last_Refreshed_on>
    <Public_title>Clinical study of deep brain stimulation in the treatment of Meige syndrome
    </Public_title>
    <Scientific_title>Clinical study of deep brain stimulation in the treatment of Meige syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200513
    </Date_registration3>
    <Date_registration>2020-05-13
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=53568
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2020-05-25
    </Date_enrollement>
    <Target_size>STN DBS group:18;GPi DBS group:18;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Wei Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China
    </Contact_Address>
    <Contact_Email>wcnsww@163.com
    </Contact_Email>
    <Contact_Tel>+86 18980601521
    </Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed as primary Meige syndrome;&#x0D;&lt;br&gt;2. Patients who fail to control the symptoms and seriously affect the quality of life after the treatment of oral drugs and botulinum toxin;&#x0D;&lt;br&gt;3. Patients in good health except for dystonia;&#x0D;&lt;br&gt;4. Patients with normal screening results by MMSE;&#x0D;&lt;br&gt;5. The subjects or their families can fully understand the treatment and sign the informed consent;&#x0D;&lt;br&gt;6. The patients with good compliance can cooperate with the patients who complete the postoperative follow-up requirements.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with abnormal changes of basal ganglia on imaging;&#x0D;&lt;br&gt;2. Patients with serious progressive nervous system, cardiovascular system, respiratory system or digestive system diseases; patients with unstable mental state;&#x0D;&lt;br&gt;3. Patients with contraindications to surgery or anesthesia, such as taking anticoagulant and antiplatelet drugs for a long time;&#x0D;&lt;br&gt;4. Women who plan to be pregnant, or are in pregnancy and lactation;&#x0D;&lt;br&gt;5. Patients who have or need other implantable devices, such as pacemakers, defibrillators, cochlear implants and chiropractic root stimulators;&#x0D;&lt;br&gt;6. Patients who need 3.0T MRI for many times in the future clinical trials due to their own reasons;&#x0D;&lt;br&gt;7. Patients who have participated in other clinical trials.
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>STN DBS group:Accept bilateral STN DBS;GPi DBS group:Accept bilateral GPi DBS;
    </Intervention>
    <Primary_outcome>Burke- fahn-marsden Dystonia Rating scale (BFMDRS);
    </Primary_outcome>
    <Secondary_outcome>Mini-Mental State Examination, MMSE;Montreal Cognitive Assessment, MoCA;Hamilton Dpression Scale, HAMD;Hamilton Anxiety Scale, HAMA;Health-related quality of life (QOL), SF-36;
    </Secondary_outcome>
    <Source_Support>Beijing pinchi medical equipment co., LTD
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Shaolin Deng
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10364411
    </Internal_Number>
    <TrialID>NCT04383665
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Low Frequency Subthalamic Nucleus Deep Brain Stimulation to Improve Verbal Fluency
    </Public_title>
    <Scientific_title>Evaluation of Neurocognitive Changes in Parkinson's Disease Patients Following Acute Low Frequency Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Southern California
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200507
    </Date_registration3>
    <Date_registration>07/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04383665
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 31, 2020
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Darrin J Lee, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Southern California
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients who had previously undergone bilateral STN deep brain&#x0D;&lt;br&gt;             stimulation implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age &gt;18 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Stable medication regimen for at least 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient informed and able to give written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Able to comply with all testing, follow-ups and study appointments and protocols&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of epilepsy or seizure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of major substance abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with baseline settings at less than 1.5 V will be excluded from the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN DBS 10Hz;Device: STN DBS 130Hz;Device: STN DBS off
    </Intervention>
    <Primary_outcome>Delis-Kaplan Executive Function System Verbal fluency;Delis-Kaplan Executive Function System Color Word Interference Task;Random number generation
    </Primary_outcome>
    <Secondary_ID>HS-19-00518
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13396658
    </Internal_Number>
    <TrialID>NCT04563143
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Novel Paradigms of Deep Brain Stimulation for Movement Disorders
    </Public_title>
    <Scientific_title>Novel Paradigms of Deep Brain Stimulation for Movement Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The Cleveland Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200422
    </Date_registration3>
    <Date_registration>22/04/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04563143
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 17, 2020
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Kenneth Baker, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Cleveland Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease for greater than 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  determined appropriate for deep brain stimulation surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to give consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary Parkinson's disease, stroke, progressive central nervous system disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia that disallows the subject ability to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current alcohol or substance abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hearing or visual impairment precluding cognitive or sensory testing&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Novel DBS Stimulation
    </Intervention>
    <Primary_outcome>Upper extremity motor speed;Verbal Fluency
    </Primary_outcome>
    <Secondary_outcome>Cognitive Reaction Time;EEG - sensorimotor evoked potentials;EEG - Oscillatory activity;EMG;fMRI - Bold response;MEG;Movement Disorders Society Unified Parkinson Disease Rating Scale - III
    </Secondary_outcome>
    <Secondary_ID>19-1637
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Farmer Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12360310
    </Internal_Number>
    <TrialID>NCT04342754
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation in Forel's H Field in Tourette's Syndrome
    </Public_title>
    <Scientific_title>Bilateral Deep Brain Stimulation of Forel's H Field in Tourette's Syndrome: Prospective, Randomized, Crossover, Double-blind Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200401
    </Date_registration3>
    <Date_registration>01/04/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04342754
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 27, 2019
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Sao Paulo General Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Tourette's Syndrome diagnosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age equal to or above 14 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe impairment of motor tics (Yale Global Tic Severity Scale = 35/50).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who are refractory to drug treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients intellectually able to understand and sign the consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Possibility to adhere to research and periodic medical visits after surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent to your participation in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with non-stabilized psychiatric comorbidities, such as anxiety and&#x0D;&lt;br&gt;             depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Concomitant treatment with other experimental drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are pregnant or breastfeeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing previous neurosurgical procedures for the treatment of Tourette's&#x0D;&lt;br&gt;             Syndrome.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS);Device: Sham Stimulation
    </Intervention>
    <Primary_outcome>Percent of change in the score of Yale Global Tic Severity Scale (YGTSS) pré and pós stimulation, comparing device On(active) and device OFF (sham) conditions.
    </Primary_outcome>
    <Secondary_outcome>Change in psychiatric symptoms - Anxiety;Change in Quality of Life;Change in psychiatric symptom - Depression;Change in psychiatric symptom - obsessive-compulsive disorder;Change in psychiatric symptom - attention deficit hyperactivity disorder;assessment of structural connectivity patterns
    </Secondary_outcome>
    <Secondary_ID>3.158.435
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13544631
    </Internal_Number>
    <TrialID>NCT04329676
    </TrialID>
    <Last_Refreshed_on>20 November 2023
    </Last_Refreshed_on>
    <Public_title>directSTIM Deep Brain Stimulation System Study
    </Public_title>
    <Scientific_title>A Prospective, Multi-center, Post-market Clinical Follow-up Study of the directSTIM Deep Brain Stimulation (DBS) System
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Aleva Neurotherapeutics SA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200313
    </Date_registration3>
    <Date_registration>13/03/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04329676
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 9, 2021
    </Date_enrollement>
    <Target_size>62
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alain Dransart;Alain Dransart
    </Contact_Lastname>
    <Contact_Email>;clinical@aleva-neuro.com
    </Contact_Email>
    <Contact_Tel>;+4121 353 8764
    </Contact_Tel>
    <Contact_Affiliation>Aleva Neurotherapeutics SA;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's Disease for 4 years or more according&#x0D;&lt;br&gt;             to the United Kingdom Parkinson's disease Brain Bank criteria, with disabling motor&#x0D;&lt;br&gt;             complications despite optimal medical treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is eligible for bilateral DBS for STN therapy according to center's routine&#x0D;&lt;br&gt;             criteria and according to the directSTIM DBS system Indications for Use statement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient who is willing to provide a written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient complies with the study follow-up, in particular the follow-up visits, and&#x0D;&lt;br&gt;             other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is not eligible for DBS per center criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a cognitive impairment, or exhibits any characteristic, that would limit&#x0D;&lt;br&gt;             study candidate's ability to complete study assessments, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Active major psychiatric disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Dementia (MoCa Dementia Rating Scale score &lt;26 or otherwise not capable of&#x0D;&lt;br&gt;                  discernment).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presence of an electrical or electromagnetic implant (e.g. cochlear implant,&#x0D;&lt;br&gt;                  pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Previous surgery for the treatment of Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Previous brain ablation procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Coagulopathies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Abuse of drugs or alcohol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is participating in another clinical study that would confound data analysis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is pregnant or nursing. As for other DBS systems, the effects of the device on&#x0D;&lt;br&gt;             an unborn child are not established.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in UPDRS III score without medication;Materiovigilance
    </Primary_outcome>
    <Secondary_outcome>Therapeutic Window (TW);UPDRS
    </Secondary_outcome>
    <Secondary_ID>CLI-12011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10728107
    </Internal_Number>
    <TrialID>NCT04255719
    </TrialID>
    <Last_Refreshed_on>16 March 2021
    </Last_Refreshed_on>
    <Public_title>Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD
    </Public_title>
    <Scientific_title>Unilateral Pallidal vs Unilateral Subthalamic Nucleus Deep Brain Stimulation in the Same Patient With Parkinson Disease: A Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200202
    </Date_registration3>
    <Date_registration>02/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04255719
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2020
    </Date_enrollement>
    <Target_size>9
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged between 55 and 75 years, both male and female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have undergone combined unilateral STN and contralateral GPi DBS for more&#x0D;&lt;br&gt;             than 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A Hoehn-Yahr (H-Y) stage of less than 4 in the off-medication state&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A left-extremity to right-extremity ratio of less than 0.15 on the Unified Parkinson's&#x0D;&lt;br&gt;             Disease Rating Scale part ? (UPDRS-?) in the both off-medication and on-medication&#x0D;&lt;br&gt;             states&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of serious psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intractable epilepsy (i.e., seizures)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed by the investigators that patients with severe cardiac, liver and kidney&#x0D;&lt;br&gt;             diseases, or other serious health conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (A Mini-Mental State Examination (MMSE) score of &lt; 24), inability to&#x0D;&lt;br&gt;             comprehend the experimental protocol or voluntarily provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of cooperation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Additional reasons for exclusion at the discretion of the clinical investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poorly controlled depression or anxiety&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Past history of suicidal attempt&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation;Globus Pallidus Interna;Subthalamic Nucleus
    </Condition>
    <Intervention>Procedure: DBS
    </Intervention>
    <Primary_outcome>Difference in Timed Up-and-Go (TUG) task scores between treatment conditions in the on- and off- medication states
    </Primary_outcome>
    <Secondary_outcome>Differences in total Uni?ed Parkinson's Disease Rating Scale Part ? (UPDRS ?) scores between two treatment conditions in the on- and off- medication states;Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.;Differences in postural angles between two treatment conditions in the on- and off- medication states.;Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.;Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.;Differences in voice parameters between treatment conditions in the on- and off- medication states.;Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states.
    </Secondary_outcome>
    <Secondary_ID>2020 UPS study
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>9178999
    </Internal_Number>
    <TrialID>ISRCTN51601294
    </TrialID>
    <Last_Refreshed_on>27 April 2020
    </Last_Refreshed_on>
    <Public_title>Finding brain signals that might guide the delivery of deep brain stimulation
    </Public_title>
    <Scientific_title>An investigation into the chronic neurophysiological biomarkers of Parkinson's disease (PD) and their application to closed loop deep brain stimulation (DBS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200131
    </Date_registration3>
    <Date_registration>31/01/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN51601294
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/01/2020
    </Date_enrollement>
    <Target_size>38
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Non-randomised; Interventional; Design type: Treatment, Device, Physical, Surgery (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Participant is willing and able to give informed consent for participation in the study&lt;br&gt;                2. Male or female, aged 18 to 80 years old&lt;br&gt;                3. Diagnosed with Parkinson’s disease, essential tremor or dystonia&lt;br&gt;                4. Has completed stage 1 of a two-stage surgery for deep brain stimulation as therapy for their movement disorder&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Cognitive impairment (judged by the clinician taking consent as not having sufficient mental capacity to understand the study and its requirements). This is including anyone who, in the opinion of the clinician taking consent, is unlikely to retain sufficient mental capacity for the duration of their involvement in the study&lt;br&gt;                2. Intracranial bleeding, cerebrospinal fluid leak or any other complication after the first stage of surgery&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Parkinson's disease &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson disease
    </Condition>
    <Intervention>&lt;br&gt;                The study will take place either in the Neurosciences Ward or the Charles Wolfson clinical research facility (one floor below the ward) in the John Radcliffe University Hospital according to the patient's preference. The above represents only one study site.&lt;br&gt;&lt;br&gt;                Patients will be enrolled who are undergoing surgery for deep brain stimulation as therapy for a movement disorder. Surgery will be performed purely on clinical grounds. Some of such patients have a staged surgery with stage 1 consisting of electrode implantation and stage 2 consisting of the connection of the electrodes to a subcutaneous stimulator and battery unit. This staging is performed for clinical reasons (such as testing of stimulation effects prior to committing to implantation of an expensive stimulator and battery unit) or service reasons (such as maximising the efficiency of surgical operating time). It is these patients who the researchers hope to study. Patients will be studied over up to two days between stage 1 and stage 2, which are usually separated by 4-7 days. On each study day, the patient will undergo recording and testing that may last up to 4 hours. Thus the patient is only asked to volunteer for one or two days study and no other visits are required. Whether the study takes one or two days depends on the patients’ preference.&lt;br&gt;&lt;br&gt;                Study day 1 will consist of:&lt;br&gt;                1. Further explanation and consent&lt;br&gt;                Suitable patients to approach will be identified by the surgical team. The study will be described to them and a PIL left with them so that they can read it over at least 24 hours. On the day of the proposed study, the researchers will go over the PIL and answer any questions the participant may have. If they would like to 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured before and after feedback-controlled stimulation:&lt;br&gt;                1. Kinematic recordings (accelerometer and BRAIN test in all patients) related to movement speed, spasms and the presence of tremor&lt;br&gt;                2. Scores on standard, disease-specific clinical rating scales (UPDRS and UDysRS in Parkinson’s disease, TETRAS in essential tremor and BFMRS and UDysRS in dystonia) and on Speech Intelligibility Test (all patients)&lt;br&gt;                3. Scalp EEG (brain waves), depth EEG and EMG (muscle) recordings (all patients)&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CPMS 42210, IRAS 271953
    </Secondary_ID>
    <Source_Support>Medical Research Council, National Institute for Health Research (NIHR) (UK)
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 03/05/2011, South Central - Oxford C Research Ethics Committee (Level 3, Block B, Whitefriars Building, Lewins Mead,  Bristol, BS1 2NT, UK; Tel: +44 (0)207 104 8241, 0207 104 8041; Email: nrescommittee.southcentral-oxfordc@nhs.net), ref: 11/SC/0100
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>09/07/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10352110
    </Internal_Number>
    <TrialID>NCT04223427
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients
    </Public_title>
    <Scientific_title>Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients - MApping Gait and Balance Issues With Current Shaping
    </Scientific_title>
    <Acronym>MAGIC
    </Acronym>
    <Primary_sponsor>University Hospital, Rouen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191210
    </Date_registration3>
    <Date_registration>10/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04223427
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 14, 2020
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marie-Laure Welter
    </Contact_Lastname>
    <Contact_Email>Marie-Laure.Welter@chu-rouen.fr
    </Contact_Email>
    <Contact_Tel>02 32 88 86 98
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age between 18 and 70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosis of Parkinson's Disease; as defined by the United Kingdom Parkinson's Disease&#x0D;&lt;br&gt;             Society Brain Bank (UKPDSBB) criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients eligible for subthalamic bilateral deep brain stimulation (STN-DBS) according&#x0D;&lt;br&gt;             to local inclusion criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Freezing of gait in the OFF-dopa condition with item 2.13 of the MDS-UPDRS &gt; 0 in&#x0D;&lt;br&gt;             usual life;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient having read and understood the information letter and signed the Informed&#x0D;&lt;br&gt;             Consent Form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient affiliated with, or beneficiary of a social security category&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Stability of others medical disorders or that do not interfere with the research&#x0D;&lt;br&gt;             protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Woman of childbearing potential with effective contraception according to WHO&#x0D;&lt;br&gt;             definition (estrogen-progestin or intra-uterine device or tubal ligation) since at&#x0D;&lt;br&gt;             least 3 months (negative urinary pregnancy test at inclusion)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Actual and severe psychiatric pathology or other neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Dementia (MMS &lt;24/30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Contraindication to research MRI (without contrast product) such as claustrophobia,&#x0D;&lt;br&gt;             metallic splinters in the eyes, ferromagnetic foreign bodies close to nerve&#x0D;&lt;br&gt;             structures, cardiac, ORL and neurological devices not MRI compatible, wearing of&#x0D;&lt;br&gt;             osteosynthseis equipment prior to 1980, metal prostheses, bypass valves&#x0D;&lt;br&gt;             ventriculoperitoneal neurosurgery, tattoos containing iron particles…&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Contraindication to surgery: hemostasis trouble, anticoagulants or antiagregants&#x0D;&lt;br&gt;             treatment, ongoing infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Hypersensitivity to contrasts agents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Persons under guardianship, tutorship or any other administrative or judicial measure&#x0D;&lt;br&gt;             of deprivation of rights and liberty&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject at the time of exclusion from other biomedical research or participating in&#x0D;&lt;br&gt;             any other biomedical research or therapeutic trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pregnant or parturient or lactating woman or lack of proven and effective&#x0D;&lt;br&gt;             contraception according to WHO definition (estrogen-progestin or intra-uterine device&#x0D;&lt;br&gt;             or tubal ligation) (for women of childbearing age)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Directional and single ring STN-DBS on gait
    </Intervention>
    <Primary_outcome>Changes in the principal components analysis (PCA) of the gait initiation kinetics during gait initiation with cognitive interference
    </Primary_outcome>
    <Secondary_ID>2018/0427/HP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13605407
    </Internal_Number>
    <TrialID>NCT04218526
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-resistant Freezing of Gait in Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-resistant Freezing of Gait in Parkinson's Disease
    </Scientific_title>
    <Acronym>DBS + FOG
    </Acronym>
    <Primary_sponsor>Jonathan Jagid
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191202
    </Date_registration3>
    <Date_registration>02/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04218526
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 27, 2020
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jonathan R Jagid, MD;Letitia Fisher, BLA;Letitia Fisher, BLA
    </Contact_Lastname>
    <Contact_Email>;lfisher@miami.edu;lfisher@miami.edu
    </Contact_Email>
    <Contact_Tel>;305-243-3056;305-243-7108
    </Contact_Tel>
    <Contact_Affiliation>University of Miami;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Confirmed Parkinson's Disease according to movement disorder neurologist with&#x0D;&lt;br&gt;             documented exclusion of other disorders such as fronto-temporal dementia (FTD)/&#x0D;&lt;br&gt;             frontal gait disorder/normal pressure hydrocephalus (NPH)/progressive supranuclear&#x0D;&lt;br&gt;             palsy (PSP)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. PD stage3 ON medication, with severe gait dysfunction and predominant axial symptoms:&#x0D;&lt;br&gt;             Movement Disorder Society-Unified Parkinson's Disease Rating Scale Tremor Dominant&#x0D;&lt;br&gt;             (MDS-UPDRS TD), Postural Instability Gait Difficulty (PIGD) ratio = 0.90 and Freezing&#x0D;&lt;br&gt;             Of Gait Questionnaire (FOGQ) score &gt; 12.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age 40-75 with good response to Levodopa (defined as greater than 20% improvement in&#x0D;&lt;br&gt;             UPDRS score)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. FOG refractory to LEVODOPA&gt;600 mg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. 6. Minimal tremor, bradykinesia, and rigidity symptoms, or well controlled with&#x0D;&lt;br&gt;             Levodopa and/or with already implanted STN/GPi DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. a) Poor candidate for STN or GPi DBS due to good control of tremor, bradykinesia, and&#x0D;&lt;br&gt;             rigidity symptoms with Levodopa b) or Post-operative STN/GPi DBS PD patients with&#x0D;&lt;br&gt;             significant residual non-levodopa responsive postural and gait instability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Must agree to full 6-month participation in study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Individuals with major executive dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Individuals with dementia, as defined by the Mattis Dementia Rating Scale-2 (DRS-2)&#x0D;&lt;br&gt;             score = 130&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Individuals with other neurocognitive impairments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Individuals who have depression, as defined for example by the Beck Depression&#x0D;&lt;br&gt;             Inventory II (BDI-II) &gt; 25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of major medical co-morbidities and other surgical contra-indications such as&#x0D;&lt;br&gt;             coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Individuals who require diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Individuals with a history of prior intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Individuals with a metallic implant in their head that is not MRI compatible (e.g.,&#x0D;&lt;br&gt;             aneurysm clip, cochlear implant)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Individuals with active implantable devices anywhere in the body (e.g. cardiac&#x0D;&lt;br&gt;             pacemaker, defibrillator, spinal cord stimulator, implanted medication pump)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Individuals who are pregnancy or desire to become pregnant during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Individuals who are breastfeeding12.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Individuals who are on investigational drugs and any other intervention (not part of&#x0D;&lt;br&gt;             the guidelines for management of Parkinson's Disease) known to have a potential impact&#x0D;&lt;br&gt;             on outcome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subjects utilizing recreational drugs at the time of screening will be excluded from&#x0D;&lt;br&gt;             the study with the exception of medicinal marijuana&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Vercise DBS System
    </Intervention>
    <Primary_outcome>Percent Change in Gait Velocity;Percent change in UPDRS Part III on/off stimulation
    </Primary_outcome>
    <Secondary_outcome>Percent Change in FOG Questionnaire;Percent Change in PDQ 39;Percent Change in PDQ-L;Percent Change in Muscle Amplitude;Percent Change in number of Falls
    </Secondary_outcome>
    <Secondary_ID>20190702
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13302048
    </Internal_Number>
    <TrialID>NCT04184791
    </TrialID>
    <Last_Refreshed_on>28 August 2023
    </Last_Refreshed_on>
    <Public_title>Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
    </Public_title>
    <Scientific_title>Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Northwell Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191122
    </Date_registration3>
    <Date_registration>22/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04184791
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 15, 2020
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ritesh Ramdhani, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Northwell Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female, aged 21-80&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients diagnosed with Parkinson's disease (PD)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. PD subjects who have bilateral STN-DBS (greater than 3 months) or in the preoperative&#x0D;&lt;br&gt;             stage of being implanted with bilateral STN-DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Have underlying gait disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Currently treated with oral levodopa therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Willingness to comply with all study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Cognitive deficits based on historical record that limit participant compliance with&#x0D;&lt;br&gt;             study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Vestibular disorder or musculoskeletal problems affecting gait or balance&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in Gait and Balance using Wearable Sensors;Accuracy of Predicting Gait Response to 60hz with Machine Learning;Accuracy of Predicting Best Stimulation Frequency (60hz vs. High Frequency) with Machine Learning
    </Primary_outcome>
    <Secondary_outcome>Change in Hand Tremor Severity;Change in Speed of Limb Movements
    </Secondary_outcome>
    <Secondary_ID>R21NS111301;19-0217
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS);The University of Tennessee, Knoxville
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13642554
    </Internal_Number>
    <TrialID>DRKS00017528
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Short pulses in neurostimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Short pulses in neurostimulation for Parkinson's Disease - SPIN-PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Klinik und Poliklinik für Neurologie der Universitätskliniken zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191106
    </Date_registration3>
    <Date_registration>06/11/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00017528
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/08/2019
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: Other; Assignment: crossover; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Jan Niklas
    </Contact_Firstname>
    <Contact_Lastname>Petry-Schmelzer
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>jan.petry-schmelzer@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-84791
    </Contact_Tel>
    <Contact_Affiliation>Universitätskliniken Köln Klinik und Poliklinik für Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Bilateral Implantation of electrodes for deep brain stimulation of the subthalamic nucleus for the treatment of idiopathic Parkinson's disease:&#x0D;&lt;br&gt;a. at least 3 months prior to study participation&#x0D;&lt;br&gt;b. the implanted pulse generator enables a pulse width of 30µs per clinical routine (Boston Scientific Vercise, Vercise PC and Gevia; Abbott Medical Infinity DBS System&#x0D;&lt;br&gt;2. The patient is not allowed to participate at another studies during which an adjustment of medication or stimulation parameters is needed at the same time&#x0D;&lt;br&gt;3. Patients need to agree with video and voice recordings and sign a patient consent form
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Inclusion criteria not completed.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation with a pulse width of 30µs for 4 weeks, followed by a deep brain stimulation with 60µs for 4 weeks.&lt;br&gt;Group 2: Deep brain stimulation with a pulse width of 60µs for 4 weeks, followed by a deep brain stimulation with 30µs for 4 weeks.
    </Intervention>
    <Primary_outcome>- Motor Diary during the last three days before the next follow-up visit after 4 weeks of deep brain stimulation with one of the two pulse widths (30µs or 60µs)&lt;br&gt;- co-primary endpoint: Unified Parkinson's disease rating scale in MedOFF/StimON at follow-up visit
    </Primary_outcome>
    <Secondary_outcome>After four weeks of deep brain stimulation with one of the two pulse widths respectively (30µs or 60µs):&#x0D;&lt;br&gt;- energy consumption&#x0D;&lt;br&gt;- Parkinson's disease Questionnaire 39&#x0D;&lt;br&gt;- Non-motor symptom scale, Non-motor symptoms questionnaire&#x0D;&lt;br&gt;- reading of a German standard text&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;additionally:&#x0D;&lt;br&gt;- preferred setting after finishing the study
    </Secondary_outcome>
    <Source_Support>Klinik und Poliklinik für Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/08/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>26/01/2023
    </results_date_posted>
    <results_date_completed>03/12/2020
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00017528#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12844754
    </Internal_Number>
    <TrialID>NCT04116996
    </TrialID>
    <Last_Refreshed_on>27 February 2023
    </Last_Refreshed_on>
    <Public_title>Globus Pallidus Stimulation to Treat Insomnia
    </Public_title>
    <Scientific_title>Stimulation of the External Pallidal Segment for Insomnia in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>GPS-I
    </Acronym>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191002
    </Date_registration3>
    <Date_registration>02/10/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04116996
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Pablo Castillo, MD;Pablo R Castillo, MD
    </Contact_Lastname>
    <Contact_Email>;castillo.pablo@mayo.edu
    </Contact_Email>
    <Contact_Tel>;904-953-2000
    </Contact_Tel>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  40-80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptomatic with Parkinsonism for 7-20 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe insomnia based on ISI score&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant dementia (MMSE &lt;23)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn &amp; Yahr [Hoehn, 1967 #1839] stage I or V disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other significant neurological or psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous pallidotomy or thalamotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous placement of other implantable devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Secondary parkinsonism (non-idiopathic parkinsonism)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to travel to Jacksonville for post-operative study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe sleep apnea&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insomnia due to pain or untreated mood disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications to 3T MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Circadian rhythm sleep disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of hypnotics&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DEEP BRAIN STIMULATION
    </Intervention>
    <Primary_outcome>Change in Insomnia Severity Index
    </Primary_outcome>
    <Secondary_outcome>Change in Parkinson's Sleep Scale (PDSS)
    </Secondary_outcome>
    <Secondary_ID>17-010112
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13642866
    </Internal_Number>
    <TrialID>DRKS00018838
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation induced Cortical Modulation in Tourette syndrome
    </Public_title>
    <Scientific_title>Deep Brain Stimulation induced Cortical Modulation in Tourette syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Klinik für Psychiatrie und Psychotherapie, Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191002
    </Date_registration3>
    <Date_registration>02/10/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00018838
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>27/05/2020
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thomas
    </Contact_Firstname>
    <Contact_Lastname>Schüller
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>thomas.schueller@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147898844
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Psychiatrie und Psychotherapie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Suficient German language skills&lt;br&gt;- Age between 18 and 65 Jahren&lt;br&gt;- Ability to give informed consent&lt;br&gt;- Diagnosis Tourette syndrome (ICD 10)&lt;br&gt;- Thalamic deep brain stimulation&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Suicidal tendencies&lt;br&gt;- Psychotic symptoms&lt;br&gt;- Drug addiction &lt;br&gt;- Pregnancy or nursing period&lt;br&gt;- Severe internistic illness&lt;br&gt;- Severe neurological disorder&lt;br&gt;- Mental retardation&lt;br&gt;- Accomodation via PsychKG §14&lt;br&gt;- Use of benzodiazepine&lt;br&gt;- Withdrawal of informed consent&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2;Combined vocal and multiple motor tic disorder [de la Tourette];F95.2
    </Condition>
    <Intervention>Group 1: We aim to include patients with Tourette syndrome and bilateral thalamic deep brain stimulation (DBS) electrodes. The study comprises informed consent, completion of psychmetric scales, preparation of EEG recordings and EEG recordings themselves. The on and off DBS phases will be performed pseudorandomized and counterbalanced. Each phase will last 5 minutes. The complete study will last approximatley 90 minutes.
    </Intervention>
    <Primary_outcome>Changes in EEG frequency bands evoked by thalamic deep brain stimulation. Recordings will follow an ABABAB design. The primary outcome is the EEG signal difference between on and off stimulation.
    </Primary_outcome>
    <Secondary_outcome>Predicition of EEG changes by overlap of volumes of tissue activitated with specific thalamic nuclei.
    </Secondary_outcome>
    <Source_Support>Köln Fortune
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/09/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>01/12/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00018838#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10343873
    </Internal_Number>
    <TrialID>NCT04116177
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Flexible vs. Standard Deep Brain Stimulation Programming in Parkinson Disease Patients
    </Public_title>
    <Scientific_title>Flexible vs. Standard Programming in Parkinson's Disease Patients Receiving Subthalamic Implant: a Double-blind Cross-over Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190925
    </Date_registration3>
    <Date_registration>25/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04116177
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1) Patients with a diagnosis of PD according to the British Parkinson's Disease Society&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Brain Bank criteria (Hughes, Daniel, Kilford, &amp; Lees, 1992), who fulfilled the&#x0D;&lt;br&gt;             inclusion and exclusion criteria proposed by the core assessment programme for&#x0D;&lt;br&gt;             surgical interventional therapies in PD panel (Defer, Widner, Marié, Rémy, &amp; Levivier,&#x0D;&lt;br&gt;             1999)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male and female patients with idiopathic PD, who have symptoms responsive to L-dopa&#x0D;&lt;br&gt;             medications, but who have significant impairment related to PD that is no longer well&#x0D;&lt;br&gt;             controlled with pharmacotherapy (i.e., refractory to optimized medical therapy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients considered as STN-DBS candidates as per current standard of care. These&#x0D;&lt;br&gt;             patients will subsequently undergo STN-DBS surgery and maintain stimulation therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Quality of life and social functioning influenced by levodopa-responsive signs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No major comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1) Exclusion criteria will include patients with other significant neurologic or&#x0D;&lt;br&gt;        psychiatric illnesses or cognitive deficit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change of Overall Global functioning (PGIC)
    </Primary_outcome>
    <Secondary_outcome>Measure of Quality of life (PDQ-39);Clinical change in motor symptoms using Unified Parkinson Disease Rating Scale I-IV;Clinical change in motor symptoms;Number of falls;Change in the presence and severity of depressive symptoms using the Beck Depression Inventory (BDI);Walking speed measure using Prokinetics gait analysis/Zeno Walkway;Step length measured using Prokinetics gait analysis/Zeno Walkway;Cadence measured using Prokinetics gait analysis/Zeno Walkway;Double support time measured using Prokinetics gait analysis/Zeno Walkway
    </Secondary_outcome>
    <Secondary_ID>15-9700
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10342161
    </Internal_Number>
    <TrialID>NCT04093908
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Prediction of STN DBS Motor Response in PD
    </Public_title>
    <Scientific_title>Machine Learning Prediction of Motor Response After STN DBS in Parkinson Patients, a Retrospective Multicenter Validation Study
    </Scientific_title>
    <Acronym>DBS-PREDICT
    </Acronym>
    <Primary_sponsor>Maastricht University Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190917
    </Date_registration3>
    <Date_registration>17/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04093908
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2019
    </Date_enrollement>
    <Target_size>322
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  underwent STN DBS for Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  completed one year follow up after surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - missing data in postoperative UPDRS II, III, IV&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Prediction of motor outcome after STN DBS based on preoperative variables
    </Intervention>
    <Primary_outcome>area under the curve of the receiver operator curve;predictive accuracy;true positive prediction rate;false positive prediction rate
    </Primary_outcome>
    <Secondary_ID>2019-0739-A9
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10342133
    </Internal_Number>
    <TrialID>NCT04093544
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Expanding the Therapeutic Window of Deep Brain Stimulation in Parkinson's Disease by Means of Directional Leads
    </Public_title>
    <Scientific_title>Expanding the Therapeutic Window of Deep Brain Stimulation in Parkinson's Disease by Means of Directional Leads: a Double-blind Cross-over Pilot Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190907
    </Date_registration3>
    <Date_registration>07/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04093544
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 15, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD;Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;alfonso.fasano@uhn.ca
    </Contact_Email>
    <Contact_Tel>;+1 416 603 5800
    </Contact_Tel>
    <Contact_Affiliation>University of Toronto
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        1. Patients with a diagnosis of Parkinson's disease (PD) according to the British&#x0D;&lt;br&gt;             Parkinson's Disease Society Brain Bank criteria, who fulfilled the inclusion and&#x0D;&lt;br&gt;             exclusion criteria proposed by the core assessment programme for surgical&#x0D;&lt;br&gt;             interventional therapies in PD panel&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male and female patients with idiopathic PD, who have symptoms responsive to L- dopa&#x0D;&lt;br&gt;             medications, but who have significant impairment related to PD that is no longer well&#x0D;&lt;br&gt;             controlled with pharmacotherapy (i.e., refractory to optimized medical therapy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients considered as subthalamic nucleus deep brain stimulation (STN-DBS) candidates&#x0D;&lt;br&gt;             as per current standard of care. These patients will subsequently undergo STN-DBS&#x0D;&lt;br&gt;             surgery and maintain stimulation therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients aged 18 to 80 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Quality of life and social functioning influenced by levodopa-responsive symptoms 6)&#x0D;&lt;br&gt;             No major comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria will include patients with other significant neurologic or psychiatric&#x0D;&lt;br&gt;        illnesses or cognitive deficit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Number/incidence of adverse events
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in a measure of health related quality of life and non-motor symptoms of Parkinson's disease using the Parkinson's disease Questionnaire (PDQ-39);Patients Global Impression of Change (PGIC);Change in articulation rate of speech using a Phonetics Software;Change in dysfluency of speech using a Phonetics Software;Change in intelligibility of speech using a Phonetics Software;Change in the Movement Disorders sponsored Unified Parkinson's disease Rating Scale (MDS-UPDRS), a measure of various motor and non-motor symptoms used to assess the clinical course of Parkinson's longitudinally.;Change in the presence and severity of depressive symptoms using the Beck Depression Inventory (BDI);Walking speed measured with the Zeno Walkway;Step length measured with the Zeno Walkway;Double support time measured with the Zeno Walkway;Cadence measured with the Zeno Walkway;Percentage of ON time without troublesome dyskinesias during waking hours;Number of falls or near-falls;Change in levodopa equivalent daily dose (LEDD);Measure of resting-state local field potentials and functional connectivity of the brain using magnetoencephalography (MEG)
    </Secondary_outcome>
    <Secondary_ID>17-5705
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13103349
    </Internal_Number>
    <TrialID>NCT04071847
    </TrialID>
    <Last_Refreshed_on>5 June 2023
    </Last_Refreshed_on>
    <Public_title>Abbott DBS Post-Market Study of Outcomes for Indications Over Time
    </Public_title>
    <Scientific_title>Abbott DBS Post-Market Study of Outcomes for Indications Over Time
    </Scientific_title>
    <Acronym>ADROIT
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190826
    </Date_registration3>
    <Date_registration>26/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04071847
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 26, 2019
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Australia;Finland;France;Germany;Italy;Spain;Taiwan;United Kingdom;Australia;Finland;France;Germany;Italy;Spain;Taiwan;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Devyani Nanduri;Tucker Tomlinson, PHD
    </Contact_Lastname>
    <Contact_Email>;tucker.tomlinson@abbott.com
    </Contact_Email>
    <Contact_Tel>;+19725269646
    </Contact_Tel>
    <Contact_Affiliation>Abbott Medical Devices Neuromodulation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is scheduled for a new implant or IPG device replacement surgery with a&#x0D;&lt;br&gt;             market-released Abbott DBS system within 180 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject, or a legally acceptable representative, must provide written informed consent&#x0D;&lt;br&gt;             prior to any study-related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is currently enrolled or plans to enroll in an investigational study that may&#x0D;&lt;br&gt;             confound the results of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the study or to comply with follow-up&#x0D;&lt;br&gt;             requirements, or impact the scientific soundness of the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Study center is located in the United States, and indication for DBS implant is not&#x0D;&lt;br&gt;             Parkinson's disease or disabling tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Study center is located in the United States, and the intended lead implant location&#x0D;&lt;br&gt;             is not at, or in close proximity to, the STN, GPi, or VIM thalamus.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Movement Disorders;Parkinson Disease;Essential Tremor;Tremor;Dystonia;Primary Dystonia;Secondary Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS)
    </Intervention>
    <Primary_outcome>Change from baseline to 6 months in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to1 year in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Incidence of device- and procedure-related serious adverse events at 6 months;Incidence of device- and procedure-related serious adverse events at 1 year;Incidence of device- and procedure-related serious adverse events at 2 years;Incidence of device- and procedure-related serious adverse events at 3 years;Incidence of device- and procedure-related serious adverse events at 4 years;Incidence of device- and procedure-related serious adverse events at 5 years
    </Primary_outcome>
    <Secondary_ID>ABT-CIP-10300
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10338595
    </Internal_Number>
    <TrialID>NCT04047498
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Alternating DBS for Stepping Control in Parkinson's Disease
    </Public_title>
    <Scientific_title>Studying Stepping Control in Parkinson's Disease Using Alternating DBS
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190801
    </Date_registration3>
    <Date_registration>01/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04047498
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2019
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter Brown, MD;Peter Brown, MD;Thomas Foltynie, MD PhD
    </Contact_Lastname>
    <Contact_Email>;peter.brown@ndcn.ox.ac.uk;t.foltynie@ucl.ac.uk
    </Contact_Email>
    <Contact_Tel>;01865 572 482;0845 155 5000
    </Contact_Tel>
    <Contact_Affiliation>University of Oxford;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD patients with bilateral subthalamic nucleus DBS electrodes and stimulators&#x0D;&lt;br&gt;             implanted for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of capacity to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment/lack of capacity to perform experimental task. The investigators&#x0D;&lt;br&gt;             will additionally conduct a short (10 min) quantitative assessment of cognitive&#x0D;&lt;br&gt;             function using a validated test (MMSE). Patients with a score &lt; 20 will be excluded&#x0D;&lt;br&gt;             from the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Alternating DBS
    </Intervention>
    <Primary_outcome>Stepping control will be assessed as the ability to adjust the stepping speed (m/s) in each stimulation condition.;Stepping control will be assessed as the ability to limit the variance in stepping speed (m/s) in each stimulation condition.
    </Primary_outcome>
    <Secondary_outcome>The investigators will test if patients automatically adjust to the stimulation rhythm;The investigators will how well other motor symptoms including tremor, rigidity and bradykinesia are controlled with alternating DBS.
    </Secondary_outcome>
    <Secondary_ID>230144
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University College, London
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13207732
    </Internal_Number>
    <TrialID>NCT04043403
    </TrialID>
    <Last_Refreshed_on>7 August 2023
    </Last_Refreshed_on>
    <Public_title>Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
    </Public_title>
    <Scientific_title>Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Stanford University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190730
    </Date_registration3>
    <Date_registration>30/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04043403
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 28, 2019
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Helen M. Bronte-Stewart, MD,MSE;Helen Bronte-Stewart, MD MSE;Sudeep Aditham
    </Contact_Lastname>
    <Contact_Email>;bronte-stewart-lab@stanford.edu;bronte-stewart-lab@stanford.edu
    </Contact_Email>
    <Contact_Tel>;6507232116;650-723-6709
    </Contact_Tel>
    <Contact_Affiliation>Stanford University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically-established PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meets criteria for STN DBS eligibility as part of patient's standard medical care or&#x0D;&lt;br&gt;             already implanted in the STN with Percept(TM) PC&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of complications of medication such as wearing off signs, fluctuating&#x0D;&lt;br&gt;             responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment&#x0D;&lt;br&gt;             in the quality of life on or off medication due to these factors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness to return for study visits, at the initial programming and&#x0D;&lt;br&gt;             after three, six and twelve months of DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Freezing of gait questionnaire (FOG-Q) score = 1 and/or gait sub-score (Item 3.10) of&#x0D;&lt;br&gt;             MDS- UPDRS III = 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Greater than or equal to 1.2 microVp between 8-35 Hz on either the LSTN or RSTN&#x0D;&lt;br&gt;             (Percept (TM) PC cohort only)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage 5 on or off medication (non-ambulatory)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 80&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major surgical morbidities such as severe hypertension, coagulopathy and certain&#x0D;&lt;br&gt;             metabolic conditions that might increase the risk of hemorrhage or other surgical&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a cardiac pacemaker/defibrillator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to understand/sign consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requires rTMS, ECT, MRI (Summit(R) RC+S cohort only), or diathermy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are pregnant or lactating&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a cranial metallic implant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures or epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Open Loop DBS;Device: Adaptive (Closed Loop) DBS;Device: Intermittent Open Loop DBS
    </Intervention>
    <Primary_outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to Stimulation Condition;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of life;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speech;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gait
    </Primary_outcome>
    <Secondary_outcome>The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III;Gait Parameters: Arrhythmicity;Gait Parameters: Mean Shank Angular Velocity;Gait Parameters: Mean Gait Cycle Time;Percent Time Freezing
    </Secondary_outcome>
    <Secondary_ID>52548
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13573507
    </Internal_Number>
    <TrialID>NCT04058457
    </TrialID>
    <Last_Refreshed_on>11 December 2023
    </Last_Refreshed_on>
    <Public_title>DBS and Respiration
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in Parkinson's Disease: Respiratory Testing
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190718
    </Date_registration3>
    <Date_registration>18/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04058457
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Alex Green, FRCS;Alex Green, FRCS;Alex Green, FRCS
    </Contact_Lastname>
    <Contact_Email>;alex.green@nds.ox.ac.uk;alex.green@nds.ox.ac.uk
    </Contact_Email>
    <Contact_Tel>;01865227645;01865234762
    </Contact_Tel>
    <Contact_Affiliation>University of Oxford;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant is willing and able to give informed consent for participation in the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged 18 years or above.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Planned for required DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in the English language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For experimental group: diagnosed with Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is currently participating in a clinical investigation that includes an active&#x0D;&lt;br&gt;             treatment arm which may affect the respiratory system.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute respiratory problem at time of experimental session: e.g. rhinosinusitis,&#x0D;&lt;br&gt;             pharyngitis, asthma exacerbation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Change in breathlessness;Change in breathlessness
    </Primary_outcome>
    <Secondary_outcome>Change in pulmonary function;Change in airways resistance;Change in respiratory muscle strength;Change in surface electromyography of respiratory muscles;Change in hypercapnic ventilatory response;Change in breath-hold;Change in daily activity;Change in daily activity;MRI structural connectivity
    </Secondary_outcome>
    <Secondary_ID>256825
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Oxford Brookes University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10334380
    </Internal_Number>
    <TrialID>NCT03992625
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Clinical Outcomes for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Clinical Outcomes for Deep Brain Stimulation for Parkinson Disease, Tremor, and Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Washington University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190613
    </Date_registration3>
    <Date_registration>13/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03992625
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 3, 2011
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Mwiza Ushe, M.D.;Mwiza Ushe, M.D.;Mwiza Ushe, M.D.
    </Contact_Lastname>
    <Contact_Email>;ushem@wustl.edu;ushem@wustl.edu
    </Contact_Email>
    <Contact_Tel>;3143625262;314-362-5262
    </Contact_Tel>
    <Contact_Affiliation>Washington University School of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa responsive Parkinson disease OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically refractory Essential Tremor OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically refractory Dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (Mattis Dementia Rating Scale &lt;130)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Structural abnormalities precluding intracranial surgery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Essential Tremor;Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>UPDRS
    </Primary_outcome>
    <Secondary_ID>R01NS075321;R01NS097437;R21NS098020;T32EB021955;201101744
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute for Biomedical Imaging and Bioengineering (NIBIB);National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10834372
    </Internal_Number>
    <TrialID>NCT04011449
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
    </Public_title>
    <Scientific_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190610
    </Date_registration3>
    <Date_registration>10/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04011449
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2019
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 45-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Demonstrated good response (= 30%) to Sinemet or dopamine agonist medications as&#x0D;&lt;br&gt;             assessed by total UPDRS III score (off and on meds)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical plan for unilateral STN- or GPi-DBS surgery to treat their clinical motor&#x0D;&lt;br&gt;             signs within the next four months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written documentation of willingness to participate in the study per protocol as&#x0D;&lt;br&gt;             evidenced by the informed consent process&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase the risk of developing pre-&#x0D;&lt;br&gt;             or post-operative complications (e.g., major cardiac or pulmonary disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to undergo MR imaging (e.g., due to incompatible implanted pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous pallidotomy or DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are currently pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI brain abnormalities that could indicate a neurological disorder other than&#x0D;&lt;br&gt;             idiopathic Lewy body Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with severe or poorly controlled depression defined according to DSM-V&#x0D;&lt;br&gt;             criteria and a scored on a validated depression assessment scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Immunocompromised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic&#x0D;&lt;br&gt;             stimulation (TMS) to treat a chronic condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or&#x0D;&lt;br&gt;             medication pump.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson
    </Condition>
    <Intervention>Device: Medtronic RC+S DBS system
    </Intervention>
    <Primary_outcome>Passive and Active Rigidity Quantification;Ballistic Elbow Flexion to a Target: Peak Velocity;Ballistic Elbow Flexion to a Target: Stop Reaction Time;Rapid Alternating Pronation-Supination Movements: RMS;Rapid Alternating Pronation-Supination Movements: Freezing Episodes Duration;Rapid Alternating Pronation-Supination Movements: Freezing Episodes Number;Gait: Step length;Gait: Step Time;Gait: Double Support Time;Gait: Obstacles;Gait: Freezing Episodes Duration;Gait: Freezing Episodes Number
    </Primary_outcome>
    <Secondary_ID>NEUR-2019-27724
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12359542
    </Internal_Number>
    <TrialID>NCT03884231
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
    </Public_title>
    <Scientific_title>A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190319
    </Date_registration3>
    <Date_registration>19/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03884231
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 10, 2019
    </Date_enrollement>
    <Target_size>71
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;France;Germany;Spain;Sweden;France;Germany;Spain;Sweden;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Binith Cheeran
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Abbott Medical Devices Neuromodulation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject or subject's legally acceptable representative must provide written informed&#x0D;&lt;br&gt;             consent prior to any clinical investigation related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has been implanted, or is scheduled to be implanted, with a commercially&#x0D;&lt;br&gt;             available Infinity DBS system with MR Conditional labeling per locally approved&#x0D;&lt;br&gt;             indications for use.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is scheduled to undergo a MRI procedure in compliance with the MRI Procedure&#x0D;&lt;br&gt;             Information Clinician's Manual. Anxiolytics and patient's regular medications may be&#x0D;&lt;br&gt;             administered, provided Instructions For Use (IFU) criteria are met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is willing and able to comply with study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has another implanted device (active or passive implanted device) that&#x0D;&lt;br&gt;             prohibits safe scanning.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has previously experienced an MRI-related adverse event or cannot undergo MRI&#x0D;&lt;br&gt;             for any other reason.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is pregnant or nursing, or plans to become pregnant during the clinical&#x0D;&lt;br&gt;             investigation follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject has other anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the clinical investigation or to comply with&#x0D;&lt;br&gt;             follow-up requirements, or impact the scientific soundness of the clinical&#x0D;&lt;br&gt;             investigation results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject is currently participating in another clinical investigation that may confound&#x0D;&lt;br&gt;             the results of this study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Movement Disorders;Parkinson Disease;Essential Tremor;Tremor;Dystonia
    </Condition>
    <Intervention>Device: Infinity DBS System with MR Conditional labelling (Leads-only configuration);Device: Infinity DBS System with MR Conditional labelling (Full system configuration)
    </Intervention>
    <Primary_outcome>MRI-related adverse events
    </Primary_outcome>
    <Secondary_ID>ABT-CIP-10262
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>8687587
    </Internal_Number>
    <TrialID>ISRCTN13759640
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>High-frequency deep brain stimulation in the treatment of movement disorders
    </Public_title>
    <Scientific_title>Prospective, feasibility trial for high-frequency deep brain stimulation in the treatment of movement disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Nevro Corp
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190111
    </Date_registration3>
    <Date_registration>11/01/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN13759640
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/02/2019
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Open-label prospective single-arm feasibility study (Treatment)
    </Study_design>
    <Phase>Not Specified
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Sat
    </Contact_Firstname>
    <Contact_Lastname>Pannu
    </Contact_Lastname>
    <Contact_Address>1800 Bridge Parkway
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                To participate in the study, subjects must meet all of the following inclusion criteria:&lt;br&gt;                1. Have been clinically diagnosed with either bilateral idiopathic Parkinson’s disease or unilateral or bilateral essential tremor, which has been refractory to conservative therapy for a minimum of 3 months and completed diagnostic work-up&lt;br&gt;                2. Be 18 years of age or older at the time of enrollment&lt;br&gt;                3. Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician&lt;br&gt;                4. Be capable of subjective evaluation; patient must be able to describe and rate his/her disease state progression through the UPDRS&lt;br&gt;                5. Be willing and capable of giving informed consent&lt;br&gt;                6. Be willing and able to comply with study-related requirements and procedures and attend all scheduled visits&lt;br&gt;                7. Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                To participate in this study, a subject must not meet any of the following exclusion criteria.&lt;br&gt;                1. Have a medical condition, not intended to be treated with DBS that could interfere with study procedures, accurate UPDRS or FTD reporting, and/or confound evaluation of study endpoints, as determined by the Investigator&lt;br&gt;                2. Have a current diagnosis of a focal brain tumor in a relevant DBS target region or prominent generalized cortical atrophy, as determined by the investigator&lt;br&gt;                3. Have a past medical history significant for seizures, as determined by the investigator&lt;br&gt;                4. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the investigator&lt;br&gt;                5. Have a condition that would significantly increase perioperative risk including severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, symptomatic uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the investigator&lt;br&gt;                6. Any previous history of surgery of ipsilateral basal ganglia surgery (radio frequency or ultrasound lesion or prior DBS implant)&lt;br&gt;                7. Any past medical history suggesting secondary or atypical parkinsonian symptoms including previous cerebrovascular accident, neurotoxin exposure, neuroleptic toxicity, tumor, encephalitis, abnormal iron deposits, or neurologic signs of cerebellar or upper motor neuron involvement or supranuclear gaze palsy&lt;br&gt;                8. Be benefiting from an interventional procedure and/or surgery to treat their movement disorder (Subjects should be enrolled at least 30 days from last benefit)&lt;br&gt;                9. Have an existing drug pump and/or another active implantable device such as a pacemaker&lt;br&gt;                10. Have a condition currently requiring or likely to require the use of diathermy, Transcranial Magnetic Stimulation (TMS) or MRI imaging that is inconsistent with Senza II system guideline in the US manual&lt;br&gt;                11. Have either a metastatic malignant neoplasm or untreated local malignant neoplasm&lt;br&gt;                12. Have a life expectancy of less than one year&lt;br&gt;                13. Have a local infection at the anticipated surgical entry site or an active systemic infection&lt;br&gt;                14. Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, or be surgically sterile, or be at least 2 years post-menopausal&lt;br&gt;                15. Have a significant untreated addiction to dependency producing medications or have been a substance abuser (including opioids, benzodiazepines, alcohol and illicit drugs) within 6 months of enrollment&lt;br&gt;                16. Have a metallic aneurysm clip that could interfere with device functioning&lt;br&gt;                17. Have significant cognitive impairment or dementia that would interfere with study compliance or comprehension&lt;br&gt;                18. Have untreated clinically significant depression as evidenced by a self-report score on the Beck Depression Inventory (BDI) II &gt; 20. Patients presenting with depression may also be ruled out by clinical judgement of the in
    </Exclusion_Criteria>
    <Condition>Parkinson’s disease (PD) and essential tremor (ET) &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson disease
    </Condition>
    <Intervention>This is an open label, prospective, feasibility study to collect data on high-frequency Deep Brain Stimulation (DBS) for the treatment of motor symptoms of Parkinson’s disease (PD) and essential tremor (ET). Stimulation will be delivered using the Senza System. The use of the Senza System for treatment of Parkinson’s disease (PD) and essential tremor (ET) is investigational. Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, the subject will proceed with a Senza system implantation. After successful system implant outcomes will be assessed via standardized assessments at 1 week, 1, 3, 6, 9 and 12 months.
    </Intervention>
    <Primary_outcome>&lt;br&gt;                The feasibility of a future definitive trial is determined using:&lt;br&gt;                1. The number of participants identified, approached, consented and completed, to inform the recruitment and timeline of a future fully-powered study&lt;br&gt;                2. The acceptability and experience of the study process to participants and completion of outcome measures, to refine future study procedures&lt;br&gt;                3. The performance of selected candidate primary outcome measures with respect to level of acceptability to participants (completion rates, perceived burden) and participant-perceived relevance and value, to determine the optimal primary outcome measure in a future study&lt;br&gt;                4. Data completeness at follow up (participant attrition), standard deviation of the likely primary outcome measure, and the variability of the comparator condition, treatment as usual, across individuals and sites, to estimate sample size for a future study&lt;br&gt;                Measured from enrolment until end of study (12 months follow up).&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Effectiveness and safety are assessed by the following:&lt;br&gt;                1. Motor symptoms are measured using the Unified Parkinson’s Disease Rate Scale (UPDRS) at baseline, initial DBS lead implant, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                2. Tremor is measured using the FTM (Fahn-Tolosa-Marin Tremor Rating Scale) at baseline, initial DBS lead implant, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                3. Functioning is measured using the PDQ-39 (Parkinson’s Disease Questionnaire-39) at baseline, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                4. Quality of Life in Essential Tremor is measured using the QUEST (Quality of Life in Essential Tremor) questionnaires at baseline, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                5. Neurological status (motor, sensory and reflex functions) is measured using a neurological examination at every visit&lt;br&gt;                6. Incidence of adverse events (AEs) is observed at every visit&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>CA2018EU DBS
    </Secondary_ID>
    <Source_Support>Nevro Corp
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethik-Kommission Ärztekammer Nordrhein, 22/10/2018, ref: 2018177, Eudamed-Nr: CIV-18-05-024124
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/12/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10313809
    </Internal_Number>
    <TrialID>NCT03724734
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Trial of Adaptive Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Double-blind, Cross-over Comparison of Closed Loop Versus Conventional Deep Brain Stimulation of the Subthalamic Nucleus in the Treatment of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>St. George's Hospital, London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181026
    </Date_registration3>
    <Date_registration>26/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03724734
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2019
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Erlick Pereira, DM FRCS;Erlick AC Pereira, DM FRCS
    </Contact_Lastname>
    <Contact_Email>;epereira@sgul.ac.uk
    </Contact_Email>
    <Contact_Tel>;02087252375
    </Contact_Tel>
    <Contact_Affiliation>St George's University Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study participants will be patients undergoing DBS of the subthalamic nucleus for the&#x0D;&lt;br&gt;             treatment of severe Parkinson's disease. Severe Parkinson's disease is defined as&#x0D;&lt;br&gt;             marked motor fluctuations (off periods and dyskinesias) despite optimal medical&#x0D;&lt;br&gt;             management. This is determined by the patient's clinical team.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This includes anyone&#x0D;&lt;br&gt;             who, in the opinion of the clinician taking consent, is unlikely to retain sufficient&#x0D;&lt;br&gt;             mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intracranial bleeding, confusion, cerebrospinal fluid leak or any other complication&#x0D;&lt;br&gt;             after the first stage of surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS;Device: Conventional DBS
    </Intervention>
    <Primary_outcome>Daytime Assessment;Night time assessment
    </Primary_outcome>
    <Secondary_outcome>Energy delivered;Tremor severity;Objective motor impairment;Speech impairment;Dyskinesia severity;Sleep quality: score;Power efficiency
    </Secondary_outcome>
    <Secondary_ID>256068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Oxford
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13664757
    </Internal_Number>
    <TrialID>NCT03664609
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) Retrospective Outcomes Study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) Retrospective Outcomes Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180831
    </Date_registration3>
    <Date_registration>31/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03664609
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 12, 2019
    </Date_enrollement>
    <Target_size>5000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Belgium;Germany;Belgium;Germany;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Cleo Mertz
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be previously treated with or eligible for implantation with a deep brain&#x0D;&lt;br&gt;             stimulation system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No Exclusion Criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Essential Tremor;Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline
    </Primary_outcome>
    <Secondary_ID>A4170
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10306554
    </Internal_Number>
    <TrialID>NCT03630302
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
    </Public_title>
    <Scientific_title>Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
    </Scientific_title>
    <Acronym>INVENT
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180809
    </Date_registration3>
    <Date_registration>09/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03630302
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 12, 2018
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson's disease, and DBS consensus team review supporting&#x0D;&lt;br&gt;             the placement of STN DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is not a surgical candidate;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the Investigator's opinion the subject unable to tolerate multiple programming&#x0D;&lt;br&gt;             sessions within a single setting;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject unable to comply with the follow-up schedule&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Concordance between LFP derived predictions and clinically optimized stimulation parameters
    </Primary_outcome>
    <Secondary_outcome>Characteristic of the LFP signals correlating to presence of side effects
    </Secondary_outcome>
    <Secondary_ID>CRD_931 INVENT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Baylor College of Medicine;University of Houston
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10813364
    </Internal_Number>
    <TrialID>NCT03600740
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus
    </Public_title>
    <Scientific_title>Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus: Functional Segmentation Based on Probabilistic Tractography
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180717
    </Date_registration3>
    <Date_registration>17/07/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03600740
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 17, 2018
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Erik H Middlebrooks
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Patient with the diagnosis of Parkinson's Disease selected for placement of globus pallidus&#x0D;&lt;br&gt;        internus (GPi) deep brain stimulator (DBS)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DBS Programming
    </Intervention>
    <Primary_outcome>Change in Unified Parkinson's Disease Rating Scale III (UPDRS-III)
    </Primary_outcome>
    <Secondary_ID>18-002176
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10301046
    </Internal_Number>
    <TrialID>NCT03558568
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Effect of Deep Brain Stimulation on Facial Expressions.
    </Public_title>
    <Scientific_title>The Effect of Subthalamic Nucleus Deep Brain Stimulation on Facial Expressions in Parkinson's Disease.
    </Scientific_title>
    <Acronym>STN-DBS
    </Acronym>
    <Primary_sponsor>Mustafa Kemal University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180528
    </Date_registration3>
    <Date_registration>28/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03558568
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2018
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Turkey
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Atilla YILMAZ;Atilla YILMAZ
    </Contact_Lastname>
    <Contact_Email>atillayilmaz@hotmail.com;atillayilmaz@hotmail.com
    </Contact_Email>
    <Contact_Tel>+905322253991;+905322253991
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD responsive to L-Dopa treatment,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 40-75 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having received bilateral STN DBS surgery at least one month prior to the&#x0D;&lt;br&gt;             investigation to ensure stable stimulation parameters,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mentally normal patients that could understand and respond to a questionnaire.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 75 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe dementia,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of an additional neurologic disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of a disease, such as the facial paralysis, that could affect facial&#x0D;&lt;br&gt;             expressions,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a wound on the face.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>The effect of Deep brain stimulation on facial expressions will be analyzed by volunteers via a web site then the results will evaluate by statistical analyses.
    </Primary_outcome>
    <Secondary_ID>1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13310446
    </Internal_Number>
    <TrialID>NCT03800108
    </TrialID>
    <Last_Refreshed_on>4 September 2023
    </Last_Refreshed_on>
    <Public_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS
    </Public_title>
    <Scientific_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS
    </Scientific_title>
    <Acronym>FREQUENCY
    </Acronym>
    <Primary_sponsor>Darlene Floden
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180523
    </Date_registration3>
    <Date_registration>23/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03800108
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 30, 2018
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Darlene Floden, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Cleveland Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Between 40 and 70 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to provide informed consent,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Clinical diagnosis of idiopathic Parkinson disease (PD) by a movement disorders&#x0D;&lt;br&gt;             neurologist,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Disease duration of at least 4 years,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Treated with bilateral STN DBS for at least 3 months prior to study enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of prior neurosurgical intervention for PD (e.g., DBS, thalamotomy,&#x0D;&lt;br&gt;             pallidotomy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of other central nervous system disease (excluding migraine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of active psychiatric symptoms meeting Diagnostic and Statistical Manual of&#x0D;&lt;br&gt;             Mental Disorders-4th Edition (DSM-IV) criteria for Axis-I disorder on formal&#x0D;&lt;br&gt;             psychiatric evaluation, with the exception of mild depression (Beck Depression&#x0D;&lt;br&gt;             Inventory-2 score below 19),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Cognitive impairment meeting Diagnostic and Statistical Manual of Mental Disorders-4th&#x0D;&lt;br&gt;             Edition (DSM-IV) criteria for dementia on formal neuropsychological evaluation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Current alcohol or substance abuse,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Lack of fluency in English which would invalidate cognitive testing,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Hearing or visual impairment precluding cognitive testing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Exclusion criteria for Day 2 procedures:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Inability to safely undergo MRI procedure (i.e., metal objects like prostheses,&#x0D;&lt;br&gt;             pacemakers)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Personalized DBS adjustments
    </Intervention>
    <Primary_outcome>Reaction time;Verbal Fluency;Finger tapping speed
    </Primary_outcome>
    <Secondary_ID>17-1350
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10301341
    </Internal_Number>
    <TrialID>NCT03562403
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>DBS in the Treatment of Intractable Movement Disorders
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in the Treatment of Intractable Movement Disorders ( Parkinson's Disease, Essential Tremors and Dystonia)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Assiut University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180522
    </Date_registration3>
    <Date_registration>22/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03562403
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2018
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Amr Elnaggar, MD;Ahmed Nouby, masters degree
    </Contact_Lastname>
    <Contact_Email>;ahrano2015@gmail.com
    </Contact_Email>
    <Contact_Tel>;+201222336729
    </Contact_Tel>
    <Contact_Affiliation>University of Louisville;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Dopa responsiveness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Minimum disease duration of 5 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Diagnosis of idiopathic Parkinsons disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with intractable Essential Tremors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with intractable dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Significant medical health problems.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Significant cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Bleeding tendencies&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease, Essential Tremors and Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in the unified parkinson's disease rating scale score
    </Primary_outcome>
    <Secondary_outcome>Change in antiparkinsonian medication use
    </Secondary_outcome>
    <Secondary_ID>DBS in movement disorders
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10325322
    </Internal_Number>
    <TrialID>NCT03874611
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation
    </Scientific_title>
    <Acronym>LFP-DBS
    </Acronym>
    <Primary_sponsor>University Hospital, Grenoble
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180430
    </Date_registration3>
    <Date_registration>30/04/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03874611
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 13, 2011
    </Date_enrollement>
    <Target_size>125
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Olivier David, Dr;Stephan CHABARDES, Pr
    </Contact_Lastname>
    <Contact_Email>Olivier.David@inserm.fr;
    </Contact_Email>
    <Contact_Tel>04 56 52 05 86;04 76 76 75 59
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pathology requiring brain stimulation therapy (criteria of severity, therapeutic&#x0D;&lt;br&gt;             resistance and severity of disability): motor disorders (eg Parkinson's disease,&#x0D;&lt;br&gt;             dystonia) or psychiatric disorders (eg OCD, depression).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  These pathologies therefore include motor disorders (eg Parkinson's disease, dystonia)&#x0D;&lt;br&gt;             or psychiatric disorders that can be treated with brain stimulation therapy. Note that&#x0D;&lt;br&gt;             these are independent of motor disorders. The inclusion criteria obviously depend on&#x0D;&lt;br&gt;             the pathology.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        As an example for a motor pathology treated by stimulation, in Parkinson's disease the&#x0D;&lt;br&gt;        following inclusion criteria are used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients aged 18 to 75 and affiliated to a social security scheme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's disease that meets the United Kingdom Parkinson's Disease Brain&#x0D;&lt;br&gt;             Bank (UKPDSBB) criteria or suffering from recessive autosomal juvenile parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  duration of evolution of the disease&gt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  stage of severe motor complications of levodopa despite optimal treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For dystonic patients, the following inclusion criteria are used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disabling dystonia (severe focal, segmental or generalized).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient = 18 years of age and under age 65&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of evolution of dystonia greater than one year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For patients with obsessive-compulsive disorder (OCD), the following inclusion criteria are&#x0D;&lt;br&gt;        used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD which has been diagnosed for at least 5 years according to the DSM-IV criteria as&#x0D;&lt;br&gt;             OCD with "good insight", confirmed using the Diagnostic Interview Genetic Study (DIGS)&#x0D;&lt;br&gt;             - OCD section ; score below the delusional idea threshold at the BABS (Brown&#x0D;&lt;br&gt;             Assessment of Beliefs Scale) insight scale (Eisen, Phillips et al., 1998)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD of severe intensity (total YBOCS &gt; 25, or subscale Obsessions or Compulsions &gt; 15,&#x0D;&lt;br&gt;             EGF &lt; 40, CGI &gt; 4) with prognosis considered to be bad in the absence of intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-responder OCD (an improvement of less than 25% on the Y-BOCS scale) to at least&#x0D;&lt;br&gt;             three IRS-type antidepressants, including clomipramine, used sequentially at the&#x0D;&lt;br&gt;             maximum tolerated dose for at least 12 weeks. Used alone and in combination for at&#x0D;&lt;br&gt;             least 1 month with risperidone or pimozide and any of the following products : lithium&#x0D;&lt;br&gt;             salts or clonazepam or buspirone or pindolol (Greist and Jefferson 1998) (McDougle,&#x0D;&lt;br&gt;             Epperson et al 2000) (Dannon , Sasson et al., 2000)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD having benefited from Behavioral and Cognitive Therapy for at least 1 year&#x0D;&lt;br&gt;             (application of classical programs, including exposure techniques with prevention of&#x0D;&lt;br&gt;             ritualized response, with at least two sessions per month).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient between 18 and 60 years of age who has given his signature and informed&#x0D;&lt;br&gt;             consent after receiving written information on the proposed procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sick with social security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For patients with depressive illness, the following inclusion criteria were used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  male or female between the ages of 30 and 65&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  with a diagnosis of unipolar major depression (MINI) resistant to conventional&#x0D;&lt;br&gt;             treatments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hamilton and Montgomery Depression Scale (HAMD) score&gt; 20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of the current depressive episode of more than 12 months, the patient being&#x0D;&lt;br&gt;             included in a care system has established the chronic and recurrent state of this&#x0D;&lt;br&gt;             depression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ineffective treatment of the current episode with at least 4 therapeutic attempts&#x0D;&lt;br&gt;             including antidepressant drug monotherapy treatments (MAOIs, tricyclic&#x0D;&lt;br&gt;             antidepressants, selective serotonin reuptake inhibitors, mixed serotonin reuptake&#x0D;&lt;br&gt;             inhibitors, and norepinephrine), the potentiations of antidepressant treatments (by&#x0D;&lt;br&gt;             lithium salts, thyroid hormones or neuroleptics), the psychotherapies structured&#x0D;&lt;br&gt;             according to validated techniques, the ECT carried out under conditions in conformity&#x0D;&lt;br&gt;             with the recommendations (ANAES, 1998) (at least 6 sessions in technical bilateral&#x0D;&lt;br&gt;             with control of duration of seizure)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Women of childbearing age should follow a contraceptive method that is considered&#x0D;&lt;br&gt;                  sufficiently effective by the investigator. In this case a pregnancy test will be&#x0D;&lt;br&gt;                  performed on inclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  outpatient or inpatient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  fluent in the French language and able to understand the procedures of the study&#x0D;&lt;br&gt;                  and in particular complete the self-questionnaires used&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient likely to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient affiliated with Social Security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient's written agreement to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Intellectual abilities compatible with cognitive or motor tasks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Obsessive-Compulsive Disorder;Epilepsy;Depression
    </Condition>
    <Intervention>Other: electrophysiological data from DBS
    </Intervention>
    <Primary_outcome>Number of functional markers derived from electrophysiological signals recorded during cognitive tests.;Number of functional markers derived from electrophysiological signals recorded during cognitive tests.
    </Primary_outcome>
    <Secondary_outcome>cognitive and sensorimotor tasks;functional atlas of basal ganglia;number of electrophysiological responses
    </Secondary_outcome>
    <Secondary_ID>38RC11.242
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>11462815
    </Internal_Number>
    <TrialID>NCT03548506
    </TrialID>
    <Last_Refreshed_on>11 October 2021
    </Last_Refreshed_on>
    <Public_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease
    </Public_title>
    <Scientific_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease
    </Scientific_title>
    <Acronym>SANTOP
    </Acronym>
    <Primary_sponsor>University Hospital Tuebingen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180418
    </Date_registration3>
    <Date_registration>18/04/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03548506
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 19, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alireza Gharabaghi, MD;Daniel Weiss, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Division of Functional and Restorative Neurosurgery, Department of Neurosurgery, Tuebingen, Germany;Department for Neurodegenerative Diseases, Centre for Neurology, Tuebingen, Germany, and Hertie-Institute for Clinical Brain Research
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's disease (according to the "British Brain Bank criteria"&#x0D;&lt;br&gt;             (Hughes, 1992) including genetic forms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Mini Mental State Exam &lt; 20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suicidality, Psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other severe pathological chronic condition that might confound treatment effects or&#x0D;&lt;br&gt;             interpretation of the data&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Omnidirectional Deep Brain Stimulation of STN;Device: Directional Deep Brain Stimulation of STN
    </Intervention>
    <Primary_outcome>Muscle Rigidity
    </Primary_outcome>
    <Secondary_outcome>Clinical motor and non-motor symptoms (1);Clinical motor and non-motor symptoms (2);Clinical motor and non-motor symptoms (3);Clinical motor and non-motor symptoms (4);Clinical motor and non-motor symptoms (5);Clinical motor and non-motor symptoms (6);Clinical motor and non-motor symptoms (7);Clinical motor and non-motor symptoms (8);Neurocognitive and non-motor symptoms (1);Neurocognitive and non-motor symptoms (2);Neurocognitive and non-motor symptoms (3);Neurocognitive and non-motor symptoms (4);Neurocognitive and non-motor symptoms (5);Neurocognitive and non-motor symptoms (6);Neurocognitive and non-motor symptoms (7);Neuropsychiatric symptoms (1);Neuropsychiatric symptoms (2);Freezing of gait (1);Freezing of gait (2);Quality of life
    </Secondary_outcome>
    <Secondary_ID>SANTOP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Abbott
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10293644
    </Internal_Number>
    <TrialID>NCT03462082
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
    </Public_title>
    <Scientific_title>A Single-center, Randomized, Double-blinded, Double-crossover Trial of Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180305
    </Date_registration3>
    <Date_registration>05/03/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03462082
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 14, 2018
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Toronto
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Parkinson's disease (PD) (previously diagnosed according to the UK brain&#x0D;&lt;br&gt;             bank criteria) who develop treatment-resistant postural instability gait dysfunction&#x0D;&lt;br&gt;             (PIGD) more than 6 months but less than 5 years after bilateral subthalamic nucleus&#x0D;&lt;br&gt;             deep brain stimulation (STN-DBS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment-resistant PIGD will be defined as freezing of gait and UPDRS or MDS-UPDRS&#x0D;&lt;br&gt;             PIGD subscales of more than 6 points despite optimization of medications and bilateral&#x0D;&lt;br&gt;             STN-DBS programming.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment-resistant PIGD less than 6 months or more than 5 years after STN-DBS&#x0D;&lt;br&gt;             surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PIGD responsive to optimization of medications and/or bilateral STN-DBS programming.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment or psychiatric comorbidities (including substance abuse) that&#x0D;&lt;br&gt;             would interfere with the informed consent process, study adherence or outcome&#x0D;&lt;br&gt;             assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced PD or any other neurological, cardiovascular or musculoskeletal&#x0D;&lt;br&gt;             co-morbidities that would preclude or require assistance to complete the 10-meter&#x0D;&lt;br&gt;             walking test.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not able to comply with 4-week interval evaluations following their potential&#x0D;&lt;br&gt;             enrollment due to personal reasons.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious illness (requiring systemic treatment and/or hospitalization) until subject&#x0D;&lt;br&gt;             either completes therapy or is clinically-stable on therapy, in the opinion of the&#x0D;&lt;br&gt;             site investigator, for at least 30 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability or unwillingness of subject or legal guardian/representative to give written&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Asymmetric STN-DBS
    </Intervention>
    <Primary_outcome>Change in gait velocity
    </Primary_outcome>
    <Secondary_outcome>Change in postural instability gait dysfunction (1);Change in postural instability gait dysfunction (2);Change in postural instability gait dysfunction (3);Change in freezing of gait;Change in speech dysfunction;Change in the MDS-UPDRS;Change in cognitive tasks;Change in quality of life
    </Secondary_outcome>
    <Secondary_ID>17-5785
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13640657
    </Internal_Number>
    <TrialID>DRKS00013789
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Concordance of MR-imaging based automatic segmentation of the Subthalamic Nucleus and intraoperatively recorded electrophysiology.
    </Public_title>
    <Scientific_title>Concordance of MR-imaging based automatic segmentation of the Subthalamic Nucleus and intraoperatively recorded electrophysiology. - CONCISE (CONCordance of Imaging Segmentation and Electrophysiology)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180122
    </Date_registration3>
    <Date_registration>22/01/2018
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00013789
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>10/01/2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Peter
    </Contact_Firstname>
    <Contact_Lastname>Reinacher
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>peter.reinacher@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050680
    </Contact_Tel>
    <Contact_Affiliation>Abteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with intraoperative electrophysiological testing and complete preoperative MR and CT images. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: We retrospectively record the borders of the STN in 30 patients, who underwent an operation for deep brain stimulation in Parkinson´s disease, according to the automatic segmentation of MR images and according to the intraoperative electrophysiological measurement.
    </Intervention>
    <Primary_outcome>Distance of the electrophysiologically defined entry and exit points to the target region to the entry and exit points defined with automatic image segmentation.
    </Primary_outcome>
    <Secondary_outcome>Determining the average direction and difference between the electrophysiologiscally defined borders and the borders defined with automatic image segmentation. 
    </Secondary_outcome>
    <Secondary_ID>U1111-1207-7147
    </Secondary_ID>
    <Source_Support>Universitätsklinikum Freiburg
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/01/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00013789#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>11290341
    </Internal_Number>
    <TrialID>NCT03409120
    </TrialID>
    <Last_Refreshed_on>30 August 2021
    </Last_Refreshed_on>
    <Public_title>Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
    </Public_title>
    <Scientific_title>Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180113
    </Date_registration3>
    <Date_registration>13/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03409120
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Harrison C Walker, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Associate Professor of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrollment in "Biomarkers to Guide Directional DBS for Parkinson's Disease"&#x0D;&lt;br&gt;             (ClinicalTrials.gov Identifier: NCT03353688)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson's disease with and without dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not enrolled in "Biomarkers to Guide Directional DBS for Parkinson's Disease"&#x0D;&lt;br&gt;             (ClinicalTrials.gov Identifier: NCT03353688)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia-Parkinsonism, Adult-Onset;Parkinson Disease
    </Condition>
    <Intervention>Device: Boston Scientific Vercise PC IPG with directional DBS lead
    </Intervention>
    <Primary_outcome>Burke-Fahn-Marsden Dystonia Rating Scale
    </Primary_outcome>
    <Secondary_ID>IRB-300001136
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13552403
    </Internal_Number>
    <TrialID>JPRN-UMIN000030460
    </TrialID>
    <Last_Refreshed_on>20 November 2023
    </Last_Refreshed_on>
    <Public_title>A 3D gait analysis after deep brain stimulation in Parkinson&amp;#39;s disease
    </Public_title>
    <Scientific_title>A 3D gait analysis after deep brain stimulation in Parkinson&amp;#39;s disease - 3DGA-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Juntendo University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171219
    </Date_registration3>
    <Date_registration>19/12/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034748
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>Not applicable
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2017/12/19
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Genko
    </Contact_Firstname>
    <Contact_Lastname>Oyama
    </Contact_Lastname>
    <Contact_Address>2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8431, JAPAN
    </Contact_Address>
    <Contact_Email>g_oyama@juntendo.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-3-3813-3111
    </Contact_Tel>
    <Contact_Affiliation>Juntendo University Hospital Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Any significant psychiatric problems including unrelated clinically significant depression  -Any current drug or alcohol abuse  -Any history of recurrent or unprovoked seizures.   -Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival less than 12 months.   -Subjects with &amp;quot;the 3rd grade: red patient&amp;quot; in &amp;quot;the grade of fall risk&amp;quot; of Juntendo University Hospital  -Subjects with large body frame expected not to be assisted by researchers in the case of their fall  -Subjects who was considered  inappropriate to participate in this study by the researchers
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>The setting of deep brain stimulation is set to 0 mA as a placebo control.&lt;br&gt;To change 31 patterns of deep brain stimulation settings
    </Intervention>
    <Primary_outcome>Number of steps and time on 6m walking and Time up and go test after the steering of deep brain stimulation
    </Primary_outcome>
    <Secondary_outcome>Gait parameters and side effect on 6m walking and Time up and go test using 3D gait analysis system after steering of deep brain stimulation and Unified Parkinson&amp;#39;s disease rating scale partIII
    </Secondary_outcome>
    <Source_Support>Kao Corporation;None
    </Source_Support>
    <Secondary_Sponsor>Kao Corporation
    </Secondary_Sponsor>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>12/10/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>N/A
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Juntendo University Hospital Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>03-5802-1584
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>N/A
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>01/08/2023
    </results_date_posted>
    <results_date_completed>21/09/2018
    </results_date_completed>
    <results_url_link>https://authors.elsevier.com/sd/article/S1353-8020(23)00849-0
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10290627
    </Internal_Number>
    <TrialID>NCT03422757
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Adaptive DBS Vs Conventional DBS in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>A Double Blind, Crossover Study to Evaluate Safety and Efficacy of an Adaptive Deep Brain Stimulation Closed-loop Method Compared With Conventional Deep Brain Stimulation in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Newronika
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171215
    </Date_registration3>
    <Date_registration>15/12/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03422757
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2017
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS implant since at least 3 years and in need of battery replacement, defined by&#x0D;&lt;br&gt;             battery level &lt;25%;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be able to sign the informed consent document to participate in the&#x0D;&lt;br&gt;             clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a suboptimal response to DBS treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe cognitive decline (MMSE &lt;25);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with major psychiatric issues;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any medical condition potentially interfering with DBS battery&#x0D;&lt;br&gt;             replacement surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that cannot tolerate an interruption of DBS stimulation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients taking only one levodopa dose per day;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with no LFPs recorded from any contacts pair, during intraoperatory IPG&#x0D;&lt;br&gt;             replacement procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: adaptive Deep Brain Stimulation;Device: conventional Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Total Electrical Energy Delivered (TEED) to the patient
    </Primary_outcome>
    <Secondary_outcome>Incidence of device related Adverse Events (safety and tolerability);Unified Parkinson's Disease Rating Scale (UPDRS) part III;Unified Dyskinesia Rating Scale (UDysRS)
    </Secondary_outcome>
    <Secondary_ID>NWK_aDBSext_01_2017
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12820166
    </Internal_Number>
    <TrialID>NCT03377569
    </TrialID>
    <Last_Refreshed_on>13 February 2023
    </Last_Refreshed_on>
    <Public_title>Subcortical Oscillations in Human Sleep Dysregulation
    </Public_title>
    <Scientific_title>Understanding the Role of Subcortical Oscillations in Human Sleep Dysregulation.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171129
    </Date_registration3>
    <Date_registration>29/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03377569
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 27, 2018
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>John A Thompson, Ph.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Principal Investigator
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects with Parkinson's Disease (PD) who are planning to have staged, bilateral deep&#x0D;&lt;br&gt;        brain stimulation surgery at the University of Colorado Hospital and willing and able to do&#x0D;&lt;br&gt;        the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Have a computer and be willing to use it as part of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Be able to learn to use and maintain a wristband-style sleep monitor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Turn off their Implantable Pulse Generator (IPG, implanted battery).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Wear a wristband-style sleep monitor for 3 weeks, 6 weeks prior to surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Spend one overnight research stay in the UCH Sleep lab, 3 weeks prior to DBS surgery .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Spend one overnight research stay in the UCH Sleep lab, immediately prior to IPG&#x0D;&lt;br&gt;             surgery, to record brain activity from the DBS electrode .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Have a 15 minute surgery to externalize the DBS lead cable to allow overnight&#x0D;&lt;br&gt;             recordings to occur.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Be pseudo-randomized to one of 2 conditions: OFF stimulation or ON stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Wear a wristband-style sleep monitor for 3 weeks, 3 months post-DBS surgery, in one of&#x0D;&lt;br&gt;             the 2 pseudo-randomized conditions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Spend one overnight research stay in the UCH Sleep lab, 4 months post DBS surgery, in&#x0D;&lt;br&gt;             one of the pseudo-randomized conditions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects will have a sleep disorder documented in their medical history as determined by a&#x0D;&lt;br&gt;        single question screen for REM sleep behavior disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subjects with Parkinson's Disease (PD) who are not planning to have staged, bilateral&#x0D;&lt;br&gt;             deep brain stimulation surgery at the University of Colorado Hospital.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects without a documented sleep disorder.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;REM Behavior Disorder
    </Condition>
    <Intervention>Other: Sleep, PD and DBS
    </Intervention>
    <Primary_outcome>Measuring brain physiological activity via local field potentials and correlation to sleep states (REM, non-REM, etc.);Chronic actigraphy to characterize sleep-wake behavior;Test the functional impact of STN-DBS on sleep-wake behavior through actigraphy
    </Primary_outcome>
    <Secondary_ID>17-0868
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13640378
    </Internal_Number>
    <TrialID>DRKS00013232
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Salivary secretion in Parkinson's Disease patients with and without deep brain stimulation
    </Public_title>
    <Scientific_title>Salivary secretion in Parkinson's Disease patients with and without deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171113
    </Date_registration3>
    <Date_registration>13/11/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00013232
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/12/2017
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Greta
    </Contact_Firstname>
    <Contact_Lastname>Barbe
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 32
    </Contact_Address>
    <Contact_Email>anna.barbe@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-96743
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •  Patients with Parkinson's disease: after DBS (Deep Brain Stimulation) at least 3 months ago (Arm 1) or without DBS (Arm 2) &lt;br&gt;•  written informed consent &lt;br&gt;•  minimum 18 years old
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •  actual or planned pregnancy during the study&lt;br&gt;•  actual or anamnestic radiation or chemotherapy in the head/neck region&lt;br&gt;•  actual or anamnestic parotid tumor&lt;br&gt;•  actual or anamnestic surgery in the head/neck region&lt;br&gt;•  Sjögren-Syndrome&lt;br&gt;•  daily intake of symptom-relieving products against xerostomia, besides frequent water intake
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;R68.2;Parkinson disease;Dry mouth, unspecified;R68.2
    </Condition>
    <Intervention>Group 1: PD (Parkinson's disease) patients with DBS (Deep Brain Stimulation) receive a salivation rate measurement and a masticatory function test via chewing gum in the  medication-OFF Status (no medication intake since the evening before) with DBS switched on and OFF.&lt;br&gt;Group 2: PD patients without DBS receive a salivation rate measurement and a masticatory function test via chewing gum in the  medication-OFF status (no medication intake since the evening before) and after standardized 200 mg Madopar intake.
    </Intervention>
    <Primary_outcome>Effect of Deep Brain Stimulation on salivation rates&lt;br&gt;&lt;br&gt;Therefore among Parkinson's disease patients with and without deep brain Stimulation in the Medication- OFF Status, there is Salivation amount measurement. Salivation rates is done by collecting all produced saliva for five minutes, afterwards saliva amount is measured. Finally the Stimulator is turned on again.
    </Primary_outcome>
    <Secondary_outcome>Effect of Dopamine on salivation rates, therefore, in the medication-OFF Status of Parkinson's disease patients without Deep Brain Stimulation, patients receive a standardized L-Dopa amount (200 mg), before and directly after salivation amounts are measured according to the primary endpoint. Masticatory function: participants chew 20 chewing cycles on two differently coloured chewing gums. Afterwards the degree of intermixing is documented by a specialized Software.
    </Secondary_outcome>
    <Source_Support>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/11/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00013232#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13161208
    </Internal_Number>
    <TrialID>NCT03353688
    </TrialID>
    <Last_Refreshed_on>10 July 2023
    </Last_Refreshed_on>
    <Public_title>Biomarkers to Guide Directional DBS for Parkinson's Disease
    </Public_title>
    <Scientific_title>Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson's Disease (SUNDIAL, SUbthalamic Nucleus DIrectionAL vs Circular Stimulation Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170926
    </Date_registration3>
    <Date_registration>26/09/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03353688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 3, 2017
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Harrison Walker, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Alabama at Birmingham
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age =18 years and =70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clinically definite, advanced idiopathic PD based on at least 2 of 3 cardinal PD&#x0D;&lt;br&gt;             features (tremor, rigidity, or bradykinesia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Disease duration of 4 years or more.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participant has elected to undergo DBS surgery as part of routine care, and the&#x0D;&lt;br&gt;             subthalamic nucleus (STN) is recommended as the surgical target.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant agrees to not undergo contralateral DBS for the other side of the brain&#x0D;&lt;br&gt;             until = 12 months after initial DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Participant is healthy enough to undergo surgery and the research protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Normal, or essentially normal, preoperative brain MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Willingness and ability to cooperate during awake DBS surgery, as well as during&#x0D;&lt;br&gt;             post-operative evaluations, adjustments of medications and stimulator settings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Participant's health insurance and/or Medicare covers DBS surgery as part of routine&#x0D;&lt;br&gt;             care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Refractory motor symptoms such as tremor, dyskinesias, wearing off, and/or motor&#x0D;&lt;br&gt;             fluctuations, causing significant disability or occupational dysfunction, despite&#x0D;&lt;br&gt;             reasonable attempts at medical management, as determined by our consensus DBS&#x0D;&lt;br&gt;             committee.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Stable doses of PD medications for at least 28 days prior to baseline assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Improvement of motor signs =30% with dopaminergic medication as assessed with the use&#x0D;&lt;br&gt;             of the Movement Disorders - Unified Parkinson's Disease Rating Scale, part III&#x0D;&lt;br&gt;             (MDS-UPDRS III; scores range from 0 to 108, with higher scores indicating worse&#x0D;&lt;br&gt;             functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Disease severity ratings above Hoehn and Yahr stage 1, defined as unilateral&#x0D;&lt;br&gt;             involvement only with minimal or no functional disability, with scores ranging from 0&#x0D;&lt;br&gt;             to 5 and higher scores indicating more severe disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Score of more than 6 for activities of daily living in the worst "off" medication&#x0D;&lt;br&gt;             condition despite medical treatment, as assessed with the use of the MDS-UPDRS II&#x0D;&lt;br&gt;             (scores range from 0 to 52, with higher scores indicating worse functioning), or&#x0D;&lt;br&gt;             mild-to-moderate impairment in social and occupational functioning (score of 51 to 80%&#x0D;&lt;br&gt;             on the Social and Occupational Functioning Assessment Scale with scores ranging from 1&#x0D;&lt;br&gt;             to 100 and lower scores indicating worse functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Dementia Rating Scale-2 (DRS-2) score of =130 on medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Beck Depression Inventory II (BDI-II) score of =25 on medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Participant expresses understanding of the consent process, terms of the study&#x0D;&lt;br&gt;             protocol, is available for follow-up over the length of the study, and signs informed&#x0D;&lt;br&gt;             consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age &lt;18 years or &gt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Participant's insurance will not cover the costs of surgery with the investigational&#x0D;&lt;br&gt;             device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Medical contraindications such as current uncontrolled hypertension, heart disease,&#x0D;&lt;br&gt;             coagulopathy, or other conditions contraindicating DBS surgery or stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Duration of disease of &lt;4 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant or care team determine that contralateral DBS for the other side of the&#x0D;&lt;br&gt;             brain will likely be clinically indicated &lt;12 months after initial DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Diagnosis or suspicion of atypical parkinsonism (progressive supranuclear palsy,&#x0D;&lt;br&gt;             multiple system atrophy, corticobasal syndrome) or drug-induced parkinsonism, or&#x0D;&lt;br&gt;             significant neurological disease other than Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Disease severity ratings of Hoehn and Yahr stage 1, defined as unilateral involvement&#x0D;&lt;br&gt;             only with minimal or no functional disability, with scores ranging from 0 to 5 and&#x0D;&lt;br&gt;             higher scores indicating more severe disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Diagnosis of psychogenic movement disorder based on consensus criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Score of &gt;25 on the Beck Depression Inventory II, with scores ranging from 0 to 63 and&#x0D;&lt;br&gt;             higher scores indicating worse functioning), or history of suicide attempt.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any current acute psychosis, alcohol abuse or drug abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Clinical dementia (score of =130 on the Mattis Dementia Rating Scale with scores&#x0D;&lt;br&gt;             ranging from 0 to 144 and higher scores indicating better functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Ongoing or pervasive impulse control disorder not resolved by reduction of&#x0D;&lt;br&gt;             dopaminergic medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Use of anticoagulant medications that cannot be discontinued during perioperative&#x0D;&lt;br&gt;             period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. History of hemorrhagic stroke.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Current or future risk of immunocompromise that might significantly increase risk of&#x0D;&lt;br&gt;             infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. History of recurrent of unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Lack of clear levodopa responsiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Any medical condition requiring repeated MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. The presence of an implanted device (e.g., cochlear implant, pacemaker,&#x0D;&lt;br&gt;             neurostimulators), whether turned on or off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Prior DBS surgery or ablation within the affected basal ganglion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. A condition requiring or likely to require the use of diathermy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Structural lesions such as basal ganglionic stroke, tumor or vascular malformation as&#x0D;&lt;br&gt;             etiology of the movement disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Any medical or psychological problem that would interfere with the conduction of the&#x0D;&lt;br&gt;             study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. A female who is breastfeeding or of child-bearing potential with a positive urine&#x0D;&lt;br&gt;             pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Boston Scientific Vercise PC IPG with directional DBS lead
    </Intervention>
    <Primary_outcome>Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Treatment Preference Survey
    </Primary_outcome>
    <Secondary_outcome>Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form
    </Secondary_outcome>
    <Secondary_ID>1UH3NS100553-01;IRB-161018001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10281027
    </Internal_Number>
    <TrialID>NCT03267550
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Safety of Remote DBS Programming System
    </Public_title>
    <Scientific_title>A Pilot Study to Investigating Safety of A Remote and Wireless Deep Brain Stimulation Programming System for Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170823
    </Date_registration3>
    <Date_registration>23/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03267550
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 8, 2017
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Device Feasibility. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Zhang Chencheng, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ruijin Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary PD patients volunteered to receive DBS surgery with SceneRay wireless and&#x0D;&lt;br&gt;             remote DBS system,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-75 years,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Achieved optimal control of clinical symptoms after coventional programming for 3-12&#x0D;&lt;br&gt;             months,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant difference in motor function when DBS is switched on/off,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good compliance and easy to follow-up,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No significant improvement or clinical efficacy in symptoms after surgery,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe cognitive impairment due to dementia (Mini-Mental State Examination score:&#x0D;&lt;br&gt;             illiteracy &lt;17, elementary school &lt;20, junior high school or above &lt;24) or inability&#x0D;&lt;br&gt;             to accurately record in a diary,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active psychosis or a history of psychosis,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious heart, liver, or kidney diseases,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe hypertension or orthostatic hypotension, severe diabetes, or diabetes&#x0D;&lt;br&gt;             accompanied by brain and cardiovascular diseases,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Malignant cancer, brain injuries, epilepsy, or other unstable medical conditions,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe alcohol dependence or drug abuse,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any situation that may jeopardize the patient's safety or lead to a failure to&#x0D;&lt;br&gt;             participate in the study (medical, psychological, social, or georational factors) at&#x0D;&lt;br&gt;             present or in the future,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participating in other clinical trials,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other factors that researchers think may not be suitable for research.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: SceneRay wireless and remote DBS system
    </Intervention>
    <Primary_outcome>The Unified Parkinson's Disease Rating Scale III&amp;IV;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Serious Adverse Event
    </Primary_outcome>
    <Secondary_ID>DBS telemedicine
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12819973
    </Internal_Number>
    <TrialID>NCT03212885
    </TrialID>
    <Last_Refreshed_on>13 February 2023
    </Last_Refreshed_on>
    <Public_title>Stimulation of the Rostral Zona Incerta for Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Clinical Efficacy and Evaluation of Adverse Effects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170707
    </Date_registration3>
    <Date_registration>07/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03212885
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 3, 2017
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Drew S Kern, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Colorado, Denver
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's Disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No current deep brain stimulating electrodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other movement disorders,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's Disease with already implanted electrode.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Motor testing
    </Primary_outcome>
    <Secondary_outcome>Dyskinesias;Cognition;Depression;Anxiety;Suicide;Non-motor features of Parkinson's disease;Motor aspects of daily living
    </Secondary_outcome>
    <Secondary_ID>16-1443
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10331771
    </Internal_Number>
    <TrialID>NCT03958617
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Tourette Syndrome
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Tourette's Syndrome: a Pragmatic Trial With Brief Randomized, Double-blinded Sham Controlled Sequences
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170626
    </Date_registration3>
    <Date_registration>26/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03958617
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2014
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jens Kuhn, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital of Cologne
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Das Tourette-Syndrom (ICD-10: F 95.2; DSM IV: 307.23) als Hauptdiagnose. Bei dem&#x0D;&lt;br&gt;             Patienten ist aufgrund einer chronischen, schwergradigen und therapieresistenten&#x0D;&lt;br&gt;             Verlaufsform des TS eine Behandlung mittels THS thalamischer Strukturen im Sinne einer&#x0D;&lt;br&gt;             ultima ratio vorgesehen.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alter des Patienten 18 bis 65 Jahre&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sicher im Verstehen der deutschen Sprache&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unterzeichnete Einverständniserklärung&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Klinisch manifeste Psychose&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Schwangerschaft und Stillzeit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unterbringung nach PsychKG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kontraindikationen einer MRT-Untersuchung wie z. B. implantierter Herzschrittmacher /&#x0D;&lt;br&gt;             Defibrillator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neoplastische neurologische Erkrankungen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kontraindikationen einer stereotaktischen Operation, wie z. B.: erhöhte&#x0D;&lt;br&gt;             Blutungsneigung, cerebrovaskuläre Erkrankungen (z. B. arteriovenöse Malformationen,&#x0D;&lt;br&gt;             Aneurysmata, systemische Gefäßerkrankungen, die auf das Cerebrum übergreifen).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Teilnahme an einer anderen klinischen Studie&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hirnassoziierte Kriterien, die eine OP ausschließen (Gefäßanomalien, große&#x0D;&lt;br&gt;             arteriovenöse Malformationen, Hirnmetastasen, Neoplasien des ZNS (Ausnahme&#x0D;&lt;br&gt;             asymptomatisches inzidentielles Meningeom))&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antikoagulationtherapie, die in der perioperativen Phase nicht ausgesetzt werden kann&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OP am Gehirn in der Anamnese, die mit der Platzierung/Funktion des MP interferieren&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Med. Gegebenheiten, die mit der Studienprozedur interferieren oder Evaluation der&#x0D;&lt;br&gt;             Studienparameter beeinträchtigen inkl. Erkrankungen im terminalen Stadium&#x0D;&lt;br&gt;             (Lebenserwartung &lt; 12 Monate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Akute Suizidalität&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abhängigkeit von Alkohol oder Drogen (exklusive Cannabis, da es von schwer betroffenen&#x0D;&lt;br&gt;             Patienten teilweise zur Ticreduktion im Sinne einer Selbstmedikation eingesetzt wird&#x0D;&lt;br&gt;             sowie exklusive Opioide und Benzodiazepine, wenn diese initial zur Ticreduktion im&#x0D;&lt;br&gt;             Sinne einer Selbstmedikation eingesetzt wurden)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Klinisch relevante internistische oder neurologische Erkrankungen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intelligenzminderung&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alle aktiv implantierten Medizinprodukte&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Schweres Schädel-Hirn-Trauma in der Anamnese&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metallimplantate im Kopfbereich ( Bsp. Aneurysmaclips)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Bilateral Deep brain stimulation of the thalamus, Medtronic Device
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS)
    </Primary_outcome>
    <Secondary_outcome>Modified Rush video rating scale (MRVRS)
    </Secondary_outcome>
    <Secondary_ID>1648
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>German Research Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>6248363
    </Internal_Number>
    <TrialID>ChiCTR-OOC-17011684
    </TrialID>
    <Last_Refreshed_on>19 June 2017
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation of subthalamic nucleus to treat Meige Syndrome: registry study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of subthalamic nucleus to treat Meige Syndrome: registry study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Aviation General Hospital of China Medical University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170617
    </Date_registration3>
    <Date_registration>2017-06-17
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=19379
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>80
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2017-06-17
    </Date_enrollement>
    <Target_size>Case series:10;
    </Target_size>
    <Study_type>Observational study
    </Study_type>
    <Study_design>Case series
    </Study_design>
    <Phase>Other
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Lin Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>3 Beiyuan, Anwai, Chaoyang District, Beijing, China
    </Contact_Address>
    <Contact_Email>wanglin70321@126.com
    </Contact_Email>
    <Contact_Tel>+86 15810362938
    </Contact_Tel>
    <Contact_Affiliation>Aviation General Hospital of China Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The diagnosis of idiopathic cranial facial focal or segmental dystonia, including simple blepharospasm or oromandibular dystonia patients, as well as other parts of the muscle of any of the above symptoms involving the craniofacial;&#x0D;&lt;br&gt;2. Patients who have failed to effectively control symptoms and / or have been treated with oral botulinum toxin for at least 6 months, and who have severe impact on their quality of life, are required to undergo surgical treatment;&#x0D;&lt;br&gt;3. Except for symptoms of dystonia, the body is in good health;&#x0D;&lt;br&gt;4. The MMSE showed normal screening results;&#x0D;&lt;br&gt;5. The subjects or their families can fully understand the treatment and sign informed consent;&#x0D;&lt;br&gt;6. The subjects with good compliance, can be required to complete the follow-up after operation.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Imaging findings of patients with abnormal basal ganglia;&#x0D;&lt;br&gt;2. Patients suffer from severe progressive neurological, cardiovascular, respiratory, or digestive diseases;&#x0D;&lt;br&gt;3. The patient's mental state is unstable;&#x0D;&lt;br&gt;4. Patients with contraindications to surgery or anesthesia, such as long-term use of anticoagulant, antiplatelet drugs;&#x0D;&lt;br&gt;5. Female patients who are planning to conceive or are pregnant and lactating women.&#x0D;&lt;br&gt;6. The patients have or need other implantable devices, such as pacemakers, defibrillators, cochlear and spinal nerve  stimulator;&#x0D;&lt;br&gt;7. The patients need do repeated MRI because of their own reasons during clinical trials in the future;&#x0D;&lt;br&gt;8. The patients have participated in other clinical trials.
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>Case series:STN DBS;
    </Intervention>
    <Primary_outcome>BFMDRS scale;
    </Primary_outcome>
    <Secondary_outcome>SF-36 scale;Score of HAMD;Score of YALE-BROWN;Cognitive Tests;
    </Secondary_outcome>
    <Source_Support>Self funding
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>6197521
    </Internal_Number>
    <TrialID>ChiCTR-ORC-17011398
    </TrialID>
    <Last_Refreshed_on>22 May 2017
    </Last_Refreshed_on>
    <Public_title>A Retrospective Study of Meige Patients After Bilateral STN DBS
    </Public_title>
    <Scientific_title>A Retrospective Study of Meige Patients After Bilateral STN DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Aviation General Hospital of China Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170514
    </Date_registration3>
    <Date_registration>2017-05-14
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=19378
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>75
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2017-05-13
    </Date_enrollement>
    <Target_size>Case series:15;
    </Target_size>
    <Study_type>Observational study
    </Study_type>
    <Study_design>Case series
    </Study_design>
    <Phase>Retrospective study
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Lin Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>3 North Anwai Yard, Chaoyang District, Beijing
    </Contact_Address>
    <Contact_Email>wanglin70321@126.com
    </Contact_Email>
    <Contact_Tel>+86 15810362938
    </Contact_Tel>
    <Contact_Affiliation>Aviation General Hospital of China Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Experience bilateral STN DBS surgery in the Aviation General Hospital of China Medical University, China.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Loss to follow-up
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>Case series:STN DBS;
    </Intervention>
    <Primary_outcome>BFMDRS scale;
    </Primary_outcome>
    <Secondary_outcome>SF-36 scale;
    </Secondary_outcome>
    <Source_Support>self-financing
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13639052
    </Internal_Number>
    <TrialID>DRKS00010876
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Social maladaptation after subthalamic deep brain stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Social maladaptation after subthalamic deep brain stimulation for Parkinson's Disease - SOMA-PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Medizinische Psychologie: Neuropsychologie und Gender Studies, Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170511
    </Date_registration3>
    <Date_registration>11/05/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00010876
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>12/01/2017
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Alexandra
    </Contact_Firstname>
    <Contact_Lastname>Zapf
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>alexandra.zapf@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147887871
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnMedizinische Psychologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria patients with Parkinson's Disease with STN-DBS&lt;br&gt;• Clinical diagnosis of idiopathic PD (UK Brain Bank criteria, Hughes et al., 1992)&lt;br&gt;• Planned STN-DBS surgery&lt;br&gt;• Patients up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;&lt;br&gt;Inclusion criteria patients with Parkinson's Disease without STN-DBS&lt;br&gt;• Clinical diagnosis of idiopathic PD (UK Brain Bank criteria, Hughes et al., 1992)&lt;br&gt;• Patients up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;&lt;br&gt;Inclusion criteria healthy controls&lt;br&gt;• Individuals up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria patients:&lt;br&gt;• Any other neurological diseases besides PD (e.g., stroke, TBI, epilepsy)&lt;br&gt;• Psychiatric diseases (e.g. schizophrenia, bipolar disorder)&lt;br&gt;• Drug/medication addiction and/or alcohol addiction&lt;br&gt;• Patients at a late stage of the disease (stage 4 H &amp;Y)&lt;br&gt;• Signs of dementia (MMSE &lt; 25)&lt;br&gt;• Patients who are under medication for another disease indication with possible effects on the CNS&lt;br&gt;&lt;br&gt;Exclusion criteria healthy controls:&lt;br&gt;• Indviduals with a clinical diagnosis of idiopathic PD&lt;br&gt;• Any other neurological or psychiatric disease&lt;br&gt;• Individuals who are cognitively impaired (e.g., vascular incidents, dementia, etc.)&lt;br&gt;• 1 week before the testing: intake of substances that impact on the CNS&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Patients with Parkinson's Disease with STN-DBS; conduct of neuropsychological and clinical assessments&lt;br&gt;Group 2: Patients with Parkinson's Disease without STN-DBS; conduct of neuropsychological and clinical assessments&lt;br&gt;Group 3: Healthy participants (control group); conduct of neuropsychological assessments
    </Intervention>
    <Primary_outcome>Social maladaption, measured by: self estimation and risk-seeking behavior in a social context, Reading the Mind in the Eyes Test, Ultimatum Game, Emotional competence questionnaire, NEO-FFI, DASS, Mild Behavioral Checklist; conduct of all tests and questionnaires at all time points of measurement (pre-surgery, 3-months post-surgery and 12-months post-surgery)
    </Primary_outcome>
    <Secondary_outcome>General cognitive state:&lt;br&gt;Mini Mental State Examination, PANDA, Dementia Rating Scale (Mattis)&lt;br&gt;executive functions:&lt;br&gt;Trail Making Test A/B, verbal fluency, modified Wisconsin Card Sortng Test, BADS (key search test), Stroop test, LPS-4&lt;br&gt;memory:&lt;br&gt;CERAD subtest (word list immediate &amp; delayed recall)&lt;br&gt;attention:&lt;br&gt;Brief Test of Attention&lt;br&gt;visuo-constructive abilities:&lt;br&gt;CERAD subtest (figure copying)&lt;br&gt;Psychiatric symptoms:&lt;br&gt;Beck-Depression Inventory, mania self-evaluation scale, apathy evaluation scale, QUIP-RS&lt;br&gt;quality of life:&lt;br&gt;PDQ-39&lt;br&gt;social desirability:&lt;br&gt;SES; conduct of all tests and questionnaires at all time points of measurement (pre-surgery, 3-months post-surgery and 12-months post-surgery)
    </Secondary_outcome>
    <Source_Support>Medizinische Psychologie, Uniklinik Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>11/10/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>15/08/2020
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00010876#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12637689
    </Internal_Number>
    <TrialID>NCT03088592
    </TrialID>
    <Last_Refreshed_on>7 November 2022
    </Last_Refreshed_on>
    <Public_title>Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
    </Public_title>
    <Scientific_title>Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
    </Scientific_title>
    <Acronym>DBSMER
    </Acronym>
    <Primary_sponsor>St. Joseph's Hospital and Medical Center, Phoenix
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170302
    </Date_registration3>
    <Date_registration>02/03/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03088592
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2016
    </Date_enrollement>
    <Target_size>34
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Francisco A Ponce, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Barrow Brain and Spine physician with SJHMC privileges
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease per Queens Square criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Appropriate DBS candidate for multi-disciplinary team consensus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 - 85 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Motor skills allowing for capability to complete evaluations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically cleared for undergoing anesthesia and DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia per DSM-V criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical or other condition precluding MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of supraspinal CNS disease other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol use of more than 4 drinks per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of suicide attempt&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently uncontrolled clinically significant depression (BDI&gt;20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of schizophrenia, delusions, or currently uncontrolled visual hallucinations&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Neural Recordings
    </Primary_outcome>
    <Secondary_ID>PHX-16-0017-70-06
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Arizona State University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13639610
    </Internal_Number>
    <TrialID>DRKS00011748
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Characterization of performance monitoring in Tourette syndrome and its modulation through deep brain stimulation
    </Public_title>
    <Scientific_title>Characterization of performance monitoring in Tourette syndrome and its modulation through deep brain stimulation - TOSHI
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170209
    </Date_registration3>
    <Date_registration>09/02/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00011748
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/07/2017
    </Date_enrollement>
    <Target_size>65
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: active//No treatment / Standard of care; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Canan
    </Contact_Firstname>
    <Contact_Lastname>Peisker
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr.62
    </Contact_Address>
    <Contact_Email>canan.peisker@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147898843
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • Age 18-60&lt;br&gt;• Patient approves to be evaluated&lt;br&gt;• Patients have to be capable to give consent&lt;br&gt;• Written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -clinical relevant psychiatric disorder&lt;br&gt;- severe and instable physical disorder and brain tumors&lt;br&gt;-clinical relevent internal or neurological disorder&lt;br&gt;- pregnancy or breat feeding&lt;br&gt;- suicidal tendencies or violent behavior in the last six months&lt;br&gt;- acute psychotic symptoms&lt;br&gt;- participation in a clinical study prior this study in the last thirty days&lt;br&gt;-withdrawal of informed consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2;Combined vocal and multiple motor tic disorder [de la Tourette];F95.2
    </Condition>
    <Intervention>Group 1: Patients with Tourette-Syndrom: follow-up after dbs &lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;Patients perform all paradigms und test twice, once in the on-condition and once in the off-condition&lt;br&gt;&lt;br&gt;Deep brain stimulation: Frquency between 1,5 and 7 Volt, stength: 120 Hz, continous stimulation. Patients are operated (no relevant date for this study), then come to a 6 month follow-up (at this date our tests are assessed) and to a 12 month follow-up (no relevant date for this study). &lt;br&gt;Group 2: Patients with Tourette-Syndrom, recruited from our medical consultation for Tourette-Syndrom&lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;&lt;br&gt;Patients with Tourette-Syndrom perform all paradigms und test twice.&lt;br&gt;Group 3: healthy controls&lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;&lt;br&gt;&lt;br&gt;Healthy controls perform all paradigms und test twice.
    </Intervention>
    <Primary_outcome>Change of impulsivity will be assesed with a delay discounting paradigma which results in a k-parameter (a high k-paramater indicates high impulsivity and a low k-parameter indicates low impuslvity) and the the baseline k-parameter (assesment before operation) will be compared to the acute effects of the on/off condition. Additionally, a comparison between patients with Tourette's syndrom, DBS-patients with Tourette's syndrom and heathy control subjects will be made.
    </Primary_outcome>
    <Secondary_outcome>Parameter of effort discounting and task switching.&lt;br&gt;Effects of modulation shall be visualised by comparing the on and off condition.&lt;br&gt;Additionally, a comparison between patients with Tourette's syndrom, DBS-patients with Tourette's syndrom and heathy control subjects will be made.
    </Secondary_outcome>
    <Secondary_ID>U1111-1192-7646
    </Secondary_ID>
    <Source_Support>Marga und Walter Boll -Stiftung
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/02/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>29/11/2018
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00011748#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13626190
    </Internal_Number>
    <TrialID>NCT03037398
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>CLOVER
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170112
    </Date_registration3>
    <Date_registration>12/01/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03037398
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 11, 2017
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Heleen Scholtes
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted bilaterally in STN with a Vercise™ DBS system for Parkinson's disease for at&#x0D;&lt;br&gt;             least four months and programming optimized according to standard of care with no&#x0D;&lt;br&gt;             changes to electrode configuration of primary settings for at least four weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study requirements and the treatment procedures and provides&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be at least 18 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including unrelated clinically significant&#x0D;&lt;br&gt;             depression as determined by the investigator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Device must be implanted on label.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Vercise Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Difference in time to program between the two arms at Programming Visit
    </Primary_outcome>
    <Secondary_ID>A4063
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10277517
    </Internal_Number>
    <TrialID>NCT03204526
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Public_title>
    <Scientific_title>Safety and Feasibility of Using Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus to Improve Cognitive Performance in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Davis
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161209
    </Date_registration3>
    <Date_registration>09/12/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03204526
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease, undergoing deep brain stimulation implantation as part of their&#x0D;&lt;br&gt;             routine management of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognitive Impairment
    </Condition>
    <Intervention>Device: deep brain stimulation
    </Intervention>
    <Primary_outcome>Beck's Depression Index;Mini Mental Status Exam;Anxiety Scores
    </Primary_outcome>
    <Secondary_outcome>N-back;Stroop
    </Secondary_outcome>
    <Secondary_ID>693382
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13638998
    </Internal_Number>
    <TrialID>DRKS00010783
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Directional Stimulation in Parkinson’s Disease
    </Public_title>
    <Scientific_title>Directional Stimulation in Parkinson’s Disease - DISPLAy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Steroetaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161122
    </Date_registration3>
    <Date_registration>22/11/2016
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00010783
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>23/05/2017
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Open (masking not used); Control: active; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Peter
    </Contact_Firstname>
    <Contact_Lastname>Reinacher
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>peter.reinacher@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+49 761 270-50680
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female patients aged =35 and = 75 years&#x0D;&lt;br&gt;2. Patients with the diagnosis of Parkinson’s disease according to the criteria of the British PD Brain Bank. Parkinson patients are included with a prominent hypokinetic-rigid component of their disease and beginning or severe motor fluctuations&#x0D;&lt;br&gt;3. Disease duration = 4 years&#x0D;&lt;br&gt;4. Written informed consent&#x0D;&lt;br&gt;5. UPDRS part III (off) 30-50
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Major Depression with suicidal thoughts or suicidal thoughts in history&#x0D;&lt;br&gt;2. Signs of dementia in neuropsychological testing (part of clinical routine assessment)&#x0D;&lt;br&gt;3. Acute psychosis stated by a psychiatric physician&#x0D;&lt;br&gt;4. Nursing care at home&#x0D;&lt;br&gt;5. Unable to give written informed consent&#x0D;&lt;br&gt;6. Surgical contraindications&#x0D;&lt;br&gt;7. Medications that are likely to cause interactions in the opinion of the investigator&#x0D;&lt;br&gt;8. Known or persistent abuse of medication, drugs or alcohol&#x0D;&lt;br&gt;9. Current or planned pregnancy, nursing period
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: 12 patients will be randomized into group 1 and group 2 and will receive deep brain stimulation paradigms in the following order:&lt;br&gt;&lt;br&gt;Group 1:&lt;br&gt;Acute A (monopolar review)&lt;br&gt;Acute B (intraoperative testing)&lt;br&gt;Chronic A (monopolar review, DBS for 8 weeks)&lt;br&gt;Chronic B (intraoperative testing, DBS for 8 weeks)&lt;br&gt;Group 2: 12 patients will be randomized into group 1 and group 2 and will receive deep brain stimulation paradigms in the following order:&lt;br&gt;&lt;br&gt;Group 2:&lt;br&gt;Acute B (monopolar review)&lt;br&gt;Acute A (intraoperative testing)&lt;br&gt;Chronic B (monopolar review, DBS for 8 weeks)&lt;br&gt;Chronic A (intraoperative testing, DBS for 8 weeks)
    </Intervention>
    <Primary_outcome>Therapeutic width of a directed current paradigm compared to a conventional (“spherical”) stimulation
    </Primary_outcome>
    <Secondary_outcome>-	Therapeutic widths of directed current paradigms (conventional (“spherical”) mode stimulation, stimulation based on a computational model of an optimal electric field,  electrophysiology-based stimulation paradigm).&#x0D;&lt;br&gt;-	Unified Parkinson’s Disease rating scale (UPDRS) Part III (Stim On, Med Off) immediately after programming of the DBS-System. For this assessment, an amplitude will be selected that is just below the threshold of side effects (including On-state dyskinesia).&#x0D;&lt;br&gt;-	UPDRS Part III (Stim On, Med. On) after 4 weeks for each paradigm (spherical mode stimulation, modulation of the electric field based on a computational model, modulation of the electric field based on intraoperative electrophysiological measurements) &#x0D;&lt;br&gt;-	Description of side effects
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/11/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_date_completed>08/08/2018
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00010783#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10639853
    </Internal_Number>
    <TrialID>NCT02975193
    </TrialID>
    <Last_Refreshed_on>22 February 2021
    </Last_Refreshed_on>
    <Public_title>Neural Correlates of Cognition in Parkinson's Disease
    </Public_title>
    <Scientific_title>Neural Correlates of Cognition in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161110
    </Date_registration3>
    <Date_registration>10/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02975193
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2017
    </Date_enrollement>
    <Target_size>64
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Aysegul Gunduz, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        PD-DBS Participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria: Persons undergoing DBS surgery for the implantation of electrodes&#x0D;&lt;br&gt;             for the treatment of motor disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion Criteria: Failure of the DBS surgical candidacy screening process&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Non-DBS PD Participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria:Persons diagnosed with idiopathic Parkinson's disease and have not&#x0D;&lt;br&gt;             received and are not currently scheduled for DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion Criteria: Individuals that :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  that have been diagnosed with dementia or other serious brain diseases or&#x0D;&lt;br&gt;                  disorders such as strokes, traumatic brain injury, or brain tumor (the exception&#x0D;&lt;br&gt;                  is Parkinson's disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  who have had drug or alcohol abuse within the past 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  with severe sensory difficulties such as impaired vision or hearing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  currently experiencing significant depression or sadness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  with a history of schizophrenia or other serious mental health problems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  using cognitive medications (e.g., Aricept) or stimulants (e.g., Adderall)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  who have undergone deep brain stimulation, fetal cell implants, or other brain&#x0D;&lt;br&gt;                  surgeries&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Behavioral: Computer task assessing cognition;Behavioral: Impulsive-Compulsive Disorders in Parkinson's Disease;Procedure: Deep Brain Stimulation Surgery
    </Intervention>
    <Primary_outcome>Change in behavioral performance
    </Primary_outcome>
    <Secondary_outcome>Change in Score on Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS);Local field potential brain signal
    </Secondary_outcome>
    <Secondary_ID>F30NS111841;IRB201601780
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10743676
    </Internal_Number>
    <TrialID>NCT02963259
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>IPG Replacement Study (PREFERENCE-H)
    </Public_title>
    <Scientific_title>Prospective Evaluation Comparing the Effects of Constant Current Versus Constant Voltage in Deep Brain Stimulation Using Hybrid Systems
    </Scientific_title>
    <Acronym>PREFERENCE-H
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161110
    </Date_registration3>
    <Date_registration>10/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02963259
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>74 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 30, 2017
    </Date_enrollement>
    <Target_size>17
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Germany;Italy;Germany;Italy;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Edward Karst
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Abbott
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject signed the approved Informed Consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is =18 and = 74 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is bilaterally treated with deep brain stimulation (DBS) in the subthalamic&#x0D;&lt;br&gt;             nucleus (STN) using a constant voltage device (i.e. Soletra™, Itrel™, Kinetra™,&#x0D;&lt;br&gt;             ActivaPC™ or ActivaRC™ IPG) and in the Investigator's opinion, is responding&#x0D;&lt;br&gt;             satisfactory to CV stimulation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the physician's opinion the subject is a suitable candidate for an IPG replacement&#x0D;&lt;br&gt;             with different stimulation paradigm;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject needs and/or requests an IPG replacement within 12 months after consent and&#x0D;&lt;br&gt;             the current IPG has at least 2.6 V output left (i.e. approx. 30% of full battery&#x0D;&lt;br&gt;             capacity) at the time of subject enrollment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD symptom onset is no longer than 20 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has a Hoehn &amp; Yahr score &lt;IV (on stim);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with a normal cognitive function (MMSE = 25);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is fluent speaker (as judged by the investigator) of the language spoken in&#x0D;&lt;br&gt;             the country where the investigational site is located.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IPG battery has less than 30% battery life at the time of consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Need to replace or reposition the leads or extensions during the IPG replacement&#x0D;&lt;br&gt;             procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had &gt;10 recurrent falls experienced in the 3 months prior to consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is unwilling to change to either a St Jude Medical Infinity™ or a St Jude&#x0D;&lt;br&gt;             Medical Brio™ DBS system for the IPG replacement;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is unable to attend the study visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system
    </Intervention>
    <Primary_outcome>The proportion of subjects who indicate preference on constant current over constant voltage at the 3 Month follow-up visit.
    </Primary_outcome>
    <Secondary_outcome>Rate of safety events related to battery replacement procedures for hybrid systems
    </Secondary_outcome>
    <Secondary_ID>SJM-CIP-10135
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12628446
    </Internal_Number>
    <TrialID>NCT02937688
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) for Parkinson's Disease International Study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) for Parkinson's Disease International Study (REACH-PD)
    </Scientific_title>
    <Acronym>REACH-PD
    </Acronym>
    <Primary_sponsor>MedtronicNeuro
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161017
    </Date_registration3>
    <Date_registration>17/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02937688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 26, 2017
    </Date_enrollement>
    <Target_size>212
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Brazil;China;Brazil;China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Indication of DBS for PD consistent with the country specific approved labeling.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Levodopa-responsive Parkinson's disease (UPDRS III = 30% improvement on Levodopa&#x0D;&lt;br&gt;             challenge test).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Symptoms treatable by medications but not adequately controlled with medications (with&#x0D;&lt;br&gt;             persistent disabling symptoms, such as motor fluctuations, dyskinesia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. At least 22 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Screening cranial MRI, performed within 12 months of entry into the study, that is&#x0D;&lt;br&gt;             normal or with a non-significant abnormality that does not present any incremental&#x0D;&lt;br&gt;             risks or concerns for the patient as a result of the DBS procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Understand potential risk/benefit, consent to the study, study procedures, and agree&#x0D;&lt;br&gt;             to complete the study follow-up visits and comply with the study protocol&#x0D;&lt;br&gt;             requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Secondary Parkinson's disease, atypical syndromes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Previous stereotactic functional neurosurgery or ablative therapy (e.g., pallidotomy,&#x0D;&lt;br&gt;             subthalamotomy), surgical contraindications related to DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Dementia (Mattis Dementia Rating Scale = 130), major depression with suicidal thoughts&#x0D;&lt;br&gt;             (Beck Depression Inventory II &gt; 25), acute psychosis, active alcohol or drug abuse,&#x0D;&lt;br&gt;             terminal illness, and any major medical or psychological histories, diagnoses,&#x0D;&lt;br&gt;             conditions, or comorbidities that would interfere with participation in the study per&#x0D;&lt;br&gt;             the investigator's medical judgment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Electrical or electromagnetic implant (e.g., Cochlear prosthesis, cardiac pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Surgical or medical contraindications to DBS surgery or therapy (e.g., uncontrolled&#x0D;&lt;br&gt;             hypertension, advanced coronary artery disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Participation in a drug, device, or biologics trial within the preceding 30 days that&#x0D;&lt;br&gt;             may confound the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Pregnant female.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Medtronic DBS Therapy for Parkinson's disease
    </Intervention>
    <Primary_outcome>Change in Parkinson's disease-related quality of life, as measured by the Parkinson's Disease Questionnaire (PDQ-8).;Change in motor score, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) III, off medication
    </Primary_outcome>
    <Secondary_ID>1678
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13456772
    </Internal_Number>
    <TrialID>JPRN-UMIN000022646
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Pathophysiology of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with deep brain stimulation
    </Public_title>
    <Scientific_title>Pathophysiology of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with deep brain stimulation - Speech and voice disorders after deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Nagoya university
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160728
    </Date_registration3>
    <Date_registration>28/07/2016
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026103
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2016/10/01
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takashi Tsuboi
    </Contact_Lastname>
    <Contact_Address>Showa-ku, Nagoya 466-8550, Japan
    </Contact_Address>
    <Contact_Email>takashi80@gmail.com
    </Contact_Email>
    <Contact_Tel>052-744-2391
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University Graduate School of Medicine Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with further neurological disease, severe cognitive impairment or psychiatric disorders that may hinder the assessment.
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>One month after deep brain stimulation surgery, we perform the contact-screeing test. The correlation between speech and voice disorders and the electrode positions is analyzed.
    </Intervention>
    <Primary_outcome>The correlation between speech and voice disorders and the electrode positions
    </Primary_outcome>
    <Source_Support>Japan Science and Technology Agency
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10258669
    </Internal_Number>
    <TrialID>NCT02835274
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Directional Lead: Investigation of Rotational Current Steering, Ease of Use of Clinical Effects Map, and Therapeutic Outcomes of Deep Brain Stimulation
    </Scientific_title>
    <Acronym>DIRECT-DBS
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160624
    </Date_registration3>
    <Date_registration>24/06/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02835274
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 19, 2016
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;Germany;Netherlands;France;Germany;Netherlands;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Roshini Jain
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one&#x0D;&lt;br&gt;             (1) of the following: resting tremor or bradykinesia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  UPDRS III score of &gt;25 in the meds OFF condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication must improve PD symptoms by =30%, as measured by UPDRS subset III score&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including unrelated clinically significant&#x0D;&lt;br&gt;             depression as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any current drug or alcohol abuse as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of recurrent or unprovoked seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant medical condition that is likely to interfere with study procedures or&#x0D;&lt;br&gt;             likely to confound evaluation of study endpoints, including any terminal illness with&#x0D;&lt;br&gt;             survival &lt;12 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: BSC Deep Brain Stimulation System with Directional Lead
    </Intervention>
    <Primary_outcome>Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores - Motor Section (Part III) at End of Randomized Phase
    </Primary_outcome>
    <Secondary_ID>A4150
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>07/02/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02835274
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12930943
    </Internal_Number>
    <TrialID>NTR5809
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>GALAXY (General Anesthesia vs. Local Anesthesia in stereotaXY) study
    </Public_title>
    <Scientific_title>The GALAXY study: General Anesthesia versus Local Anesthesia in Stereotaxy for Deep Brain Stimulation in Parkinson’s disease: a randomized controlled trial&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160423
    </Date_registration3>
    <Date_registration>2016-04-23
    </Date_registration>
    <Source_Register>NTR
    </Source_Register>
    <web_address>https://www.onderzoekmetmensen.nl/en/trial/26420
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2016-05-01
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Single blinded (masking used), Active, Parallel
    </Study_design>
    <Phase/>
    <Contact_Firstname>Rozemarije
    </Contact_Firstname>
    <Contact_Lastname>Holewijn
    </Contact_Lastname>
    <Contact_Address>Locatie AMC&#x0D;

    </Contact_Address>
    <Contact_Email>r.a.holewijn@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>020 566 3542
    </Contact_Tel>
    <Contact_Affiliation>Amsterdam University Medical Centers, Department of Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •	Age &gt; 18 years; &lt;br /&gt;&#x0D;&lt;br&gt;•	Idiopathic PD with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;&lt;br /&gt;&#x0D;&lt;br&gt;•	Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia; &lt;br /&gt;&#x0D;&lt;br&gt;•	A life expectancy of at least two years. &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •	Legally incompetent adults;&lt;br /&gt;&#x0D;&lt;br&gt;•	Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy); &lt;br /&gt;&#x0D;&lt;br&gt;•	Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;&lt;br /&gt;&#x0D;&lt;br&gt;•	Hoehn and Yahr  stage 5 at the best moment during the day;&lt;br /&gt;&#x0D;&lt;br&gt;•	Psychosis;&lt;br /&gt;&#x0D;&lt;br&gt;•	Current depression;&lt;br /&gt;&#x0D;&lt;br&gt;•	No written informed consent.
    </Exclusion_Criteria>
    <Condition>Parkinson's Disease (PD)/ Ziekte van Parkinson&#x0D;
Deep Brain Stimulation (DBS)/ Diepe hersenstimulatie&#x0D;
Stereotaxy/ Stereotaxie&#x0D;
Subthalamic Nucleus (STN)/ Nucleus Subthalamicus
    </Condition>
    <Intervention>Patients will be randomized to DBS under general anesthesia or DBS under local anesthesia. For DBS, two electrodes will be implanted in the brain connected to an implanted pulse generator, which will be placed subcutaneously in the subclavian area.
    </Intervention>
    <Primary_outcome>The primary outcome measures is a composite score of the postoperative cognitive, mood and behavioral adverse effects. 
    </Primary_outcome>
    <Secondary_outcome>The secondary outcome measures consist of motor symptoms, adverse effects and complications, surgery time, functional health, quality of life, patient satisfaction on the outcome of treatment, patient evaluation of the burden of therapy, and medication 
    </Secondary_outcome>
    <Secondary_ID>NL5513;NTR5809;NL53375.018.15
    </Secondary_ID>
    <Source_Support>Dutch Brain Foundation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/04/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>14/11/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10258136
    </Internal_Number>
    <TrialID>NCT02823158
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
    </Public_title>
    <Scientific_title>A Prospective Randomized Controlled Trial of Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease With Motor Complications and Relative or Absolute Contraindications for Subthalamic Stimulation
    </Scientific_title>
    <Acronym>LATESTIM
    </Acronym>
    <Primary_sponsor>University Hospital Inselspital, Berne
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160418
    </Date_registration3>
    <Date_registration>18/04/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02823158
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Michael Schüpbach, PD Dr. med;Ines Debove, Dr. med
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Inselspital University Hospital Bern;Inselspital University Hospital Bern
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease according to the UKBB criteria, with the exception that familial&#x0D;&lt;br&gt;             forms of otherwise typical parkinsonian syndromes may also be included&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  motor complications of dopaminergic medication (dyskinesia or motor fluctuations or&#x0D;&lt;br&gt;             both) that are at least moderately bothersome to the patient [on a scale of 5 possible&#x0D;&lt;br&gt;             levels: not at all / mildly / moderately / severely / extremely bothersome]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of at least one of the following absolute exclusion criteria for STN&#x0D;&lt;br&gt;             stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mattis dementia rating scale &lt;130 points&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  postural instability of &gt;1 in the item of MDS-UPDRS III [item #12] "on"&#x0D;&lt;br&gt;                  medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  less than 30% improvement of axial score in the acute levodopa challenge test&#x0D;&lt;br&gt;                  [axial score =sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  or presence of at least two of the following relative exclusion criteria for STN&#x0D;&lt;br&gt;             stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  age &gt; 70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mattis dementia rating scale &lt;134 points&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  gait freezing "on" medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  dysarthria of &gt; 2 in the item of the MDS-UPDRS III [item #3.1]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  less than 50% improvement of axial score in the acute levodopa challenge test&#x0D;&lt;br&gt;                  [axial score = sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Starkstein apathy score of =14&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Complete baseline PDQ-39-SI and patient diary available&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 85 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  surgical or medical contraindications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  abnormalities on brain MRI that preclude the implantation of electrodes into the GPi&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindication for 3T MRI (baseline imaging)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe medical illness that is likely to hamper the benefit of DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe personality disorder that may interfere with optimization of DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia according to DSM-V and MMSE &lt; 20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ongoing psychosis (except pseudohallucinations)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ongoing major depression (BDI-II &gt; 23) or depression of any severity with suicidal&#x0D;&lt;br&gt;             ideation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Central Nervous System Disease;Basal Ganglia Disease;Movement Disorders;Neurodegenerative Disorders;Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT);Procedure: Best medical treatment
    </Intervention>
    <Primary_outcome>Difference of change of the score of the Parkinson's disease questionnaire 39 (PDQ-39-SI) from baseline to follow-up between the two treatment groups.;Difference of change in number of hours per day spent in motor "on" without troublesome dyskinesia from baseline to follow-up between the two treatment groups.
    </Primary_outcome>
    <Secondary_outcome>Difference of change of the score of the MDS-UPDRS part III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part III) from baseline to follow up between the two trial groups.;Difference of change of the score of the MDS-UPDRS part IV (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part IV) (MDS-UPDRS) from baseline to follow up between the two trial groups.;Difference of change in number of hours per day spent in motor "on" with troublesome dyskinesia from baseline to follow-up between the two treatment groups.
    </Secondary_outcome>
    <Secondary_ID>2016-000334
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12762797
    </Internal_Number>
    <TrialID>NCT02994719
    </TrialID>
    <Last_Refreshed_on>16 January 2023
    </Last_Refreshed_on>
    <Public_title>Gait Analysis in Neurological Disease
    </Public_title>
    <Scientific_title>Gait Pattern Analysis in Neurological Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beth Israel Deaconess Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151221
    </Date_registration3>
    <Date_registration>21/12/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02994719
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2016
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-85 (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural&#x0D;&lt;br&gt;             instability (UK PD Brain Bank Criteria) (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Montreal Cognitive Assessment will be employed to determine whether subjects will need&#x0D;&lt;br&gt;             the assent of a legally authorized representative. Subjects with MOCA = 21 will be&#x0D;&lt;br&gt;             consented only with the assent of the subject and informed consent of the authorized&#x0D;&lt;br&gt;             legal representative (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  These may include subjects who may have indeterminate parkinsonism, when it is not&#x0D;&lt;br&gt;             clear whether they have idiopathic Parkinson's Disease versus one of the Atypical&#x0D;&lt;br&gt;             Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive&#x0D;&lt;br&gt;             Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration&#x0D;&lt;br&gt;             (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with assistive devices will be eligible for the study and may use them during&#x0D;&lt;br&gt;             the study (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of complaints regarding difficulty walking such as arthritic pain, fatigue&#x0D;&lt;br&gt;             during walking or slowness of walking (Healthy subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of alternative explanation for parkinsonism such as head trauma, drug-induced&#x0D;&lt;br&gt;             parkinsonism (affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently being treated for major medical illness requiring recent hospitalization&#x0D;&lt;br&gt;             (&lt;14 days) (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently participating in another clinical study with an intervention arm (for both&#x0D;&lt;br&gt;             healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent due to cognitive impairment and absence of legally authorized&#x0D;&lt;br&gt;             representative (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring&#x0D;&lt;br&gt;             hospitalization within the past 90 days, recent myocardial infarction &lt; 90 days,&#x0D;&lt;br&gt;             supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that&#x0D;&lt;br&gt;             limit their ability to safely participate in a walking trial (for both healthy and&#x0D;&lt;br&gt;             affected subjects).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease
    </Condition>
    <Intervention>Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Gait speed
    </Primary_outcome>
    <Secondary_outcome>Swing duration;Stance duration;Cadence;Stride length
    </Secondary_outcome>
    <Secondary_ID>2015P000310
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13454162
    </Internal_Number>
    <TrialID>JPRN-UMIN000020030
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Assessment of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with subthalamic nucleus deep brain stimulation
    </Public_title>
    <Scientific_title>Assessment of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with subthalamic nucleus deep brain stimulation - The effect of deep brain stimulation on speech and voice disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Nagoya university graduate school of medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151202
    </Date_registration3>
    <Date_registration>02/12/2015
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023132
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2013/03/01
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takashi Tsuboi
    </Contact_Lastname>
    <Contact_Address>65, Tsurumaicho, Showa-ku, Nagoya city, Aichi
    </Contact_Address>
    <Contact_Email>takashi80@gmail.com
    </Contact_Email>
    <Contact_Tel>88-52-741-2111
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University Graduate School of Medicine Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who had Cerebral vascular disorder or any other neurodegenerative diseases  Patients who had severe dementia  Patients who are pregnant
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Patients with Parkinson&amp;#39;s disease who had undergone bilateral DBS in the Movement Disorders Clinic of the Nagoya University Hospital and had 6-month follow-up period after subthalamic implantation&lt;br&gt;Age, sex, disease duration and motor and cognitive function matched PD patients
    </Intervention>
    <Primary_outcome>Assessment of Motor Speech Dysarthria (AMSD)  Patients treated with DBS are assessed at least 6 months after subthalamic implantation. Patients treated without DBS are assessed when they are recruited in this study.
    </Primary_outcome>
    <Secondary_outcome>Stuttering Severity Instrument (SSI-3)  Multi Dimensional Voice Program (MDVP)  Voice Handicap Index (VHI)  GRBAS scale  Maximum phonation time (MPT)  UPDRS
    </Secondary_outcome>
    <Source_Support>Health and Labour Sciences Research  grants
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10920074
    </Internal_Number>
    <TrialID>NCT02585154
    </TrialID>
    <Last_Refreshed_on>10 May 2021
    </Last_Refreshed_on>
    <Public_title>Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151008
    </Date_registration3>
    <Date_registration>08/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02585154
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>74 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 8, 2016
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study participants will be Parkinson's disease patients undergoing deep brain&#x0D;&lt;br&gt;             stimulation of the subthalamic nucleus (STN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Whether or not a patient is selected for deep brain stimulation surgery is&#x0D;&lt;br&gt;                  determined by the patient's clinical team purely on independent clinical grounds.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Only those patients who have been accepted for deep brain stimulation treatment&#x0D;&lt;br&gt;                  by their clinical neurologist and functional neurosurgeon will be introduced to&#x0D;&lt;br&gt;                  the project and have their details passed on to the research team for further&#x0D;&lt;br&gt;                  information and formal consenting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of capacity to consent (judged by the clinician taking consent as not having&#x0D;&lt;br&gt;             sufficient mental capacity to understand the study and its requirements). This is&#x0D;&lt;br&gt;             including anyone who, in the opinion of the clinician taking consent, is unlikely to&#x0D;&lt;br&gt;             retain sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment/lack of capacity to perform experimental task.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015);Procedure: closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015);Procedure: Deep Brain Stimulation off;Device: local field potentials and electroencephalography recordings
    </Intervention>
    <Primary_outcome>Ability to suppress inappropriate movements as measured by motor tasks (accuracy measured in %);Ability to suppress inappropriate movements as measured by motor tasks (response time measured in s)
    </Primary_outcome>
    <Secondary_outcome>Local field potential spectra during open-loop deep brain stimulation, closed-loop deep brain stimulation and no deep brain stimulation;Connectivity between neural regions during open-loop deep brain stimulation, closed-loop deep brain stimulation and no deep brain stimulation
    </Secondary_outcome>
    <Secondary_ID>168287
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>5396245
    </Internal_Number>
    <TrialID>NCT02619084
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>Subthalamic Stimulation in Tourette's Syndrome
    </Public_title>
    <Scientific_title>Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome
    </Scientific_title>
    <Acronym>STN-DBSinTS
    </Acronym>
    <Primary_sponsor>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151002
    </Date_registration3>
    <Date_registration>02/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02619084
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2011
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Luigi M Romito, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age at least of 18 years (with potential exceptions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TS based on the diagnostic criteria of the Tourette Syndrome&#x0D;&lt;br&gt;             Classification Study Group&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A Yale Tic Global Severity Scale (YTGSS) &gt; 35/50 for at least 12 months, with tic&#x0D;&lt;br&gt;             severity documented by a standardized videotape assessment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inadequate response to standard drug treatment or botulinum toxin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of secondary tic disorder, of heredodegenerative or neurometabolic diseases&#x0D;&lt;br&gt;             or history of toxic exposures or encephalitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous surgery for TS (with potential exceptions)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette's Syndrome;Tourette Syndrome;Gilles de la Tourette Syndrome;Tourette Disorder
    </Condition>
    <Intervention>Procedure: STN DBS
    </Intervention>
    <Primary_outcome>Change in Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_outcome>Change in Milan Overall Dementia Assessment (MODA);Change in brain activity recorded by PET;STN DBS safety in treating medically-refractory Tourette syndrome;Change in Yale-Brown Obsessive Compulsive scale (Y-BOCS);Change in Global assessment scale (GAS).;Change in Global Clinical Impression Scale (GCI-S);Change in Gilles de la Tourette syndrome-quality of life scale (GTS-QOL);Change in Montgomery-Åsberg Depression Rating Scale (MADRS);Change in ADHD Rating Scale-IV (ADHD-RS);Change in Hamilton Anxiety Rating Scale (HAM-A)
    </Secondary_outcome>
    <Secondary_ID>GR-2009-1594645;RF-131
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Italy
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10247881
    </Internal_Number>
    <TrialID>NCT02589925
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Combined Subthalamic and Nucleus Basalis Meynert Deep Brain Stimulation for Parkinson's Disease With Dementia
    </Public_title>
    <Scientific_title>Kombinierte Tiefe Hirnstimulation Des Nucleus Subthalamicus Und Nucleus Basalis Meynert Zur Behandlung Der Parkinson-Krankheit Mit Demenz
    </Scientific_title>
    <Acronym>Dempark-DBS
    </Acronym>
    <Primary_sponsor>Wuerzburg University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150928
    </Date_registration3>
    <Date_registration>28/09/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02589925
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2016
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jens Volkmann, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Wuerzburg University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age at the time of enrollment: 35 - 75 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosis of idiopathic PD with probable Parkinson's disease dementia (PDD) as defined&#x0D;&lt;br&gt;             by the MDS consensus guidelines (Emre et al., 2007)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Mild to moderately severe dementia as defined by a Mini-Mental State Examination&#x0D;&lt;br&gt;             (MMSE) score of 10 to 24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Duration of bilateral idiopathic PD: =5 years of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Severity of bilateral idiopathic PD in the meds off state: modified Hoehn and Yahr&#x0D;&lt;br&gt;             stage =2.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. UPDRS subset III score of =30 in the meds off, stim off state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Levodopa must improve PD symptoms by =30% in a levodopa challenge test, as measured by&#x0D;&lt;br&gt;             UPDRS subset III score.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. PDD with a symptom onset at least 2 years after first symptoms of PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Be willing and able to comply with all visits and study related procedures (e.g.,&#x0D;&lt;br&gt;             using the remote control, charging systems and completing the motor diary) if mentally&#x0D;&lt;br&gt;             competent or, if incompetent, their legally authorized representatives.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Able to understand the study requirements and the treatment procedures and to provide&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;             If mentally incompetent, the legally authorized representative provides written&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any significant psychiatric problems, including acute confusional state (delirium),&#x0D;&lt;br&gt;             ongoing psychosis, or clinically significant depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Any current drug or alcohol abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any history of recurrent or unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any prior movement disorder treatments that involved intracranial surgery or device&#x0D;&lt;br&gt;             implantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. A history of neurostimulation intolerance in any area of the body.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any significant medical condition that is likely to interfere with study procedures or&#x0D;&lt;br&gt;             likely to confound evaluation of study endpoints, including any terminal illness with&#x0D;&lt;br&gt;             survival &lt;12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Participation in another drug, device, or biologics trial concurrently or within the&#x0D;&lt;br&gt;             preceding 30 days. Any other trial participation should be approved by the Principal&#x0D;&lt;br&gt;             Investigators.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pregnancy, breast-feeding, or lack of reliable contraception&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dementia
    </Condition>
    <Intervention>Device: Vercise deep brain stimulation;Procedure: subthalamic nucleus (STN) stimulation;Procedure: NBM stimulation;Procedure: sham stimulation
    </Intervention>
    <Primary_outcome>safety as determined by spontaneously reported adverse events
    </Primary_outcome>
    <Secondary_ID>DEMPARK-DBS V2.01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>6649924
    </Internal_Number>
    <TrialID>NCT02524886
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Effects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>GGZ Centraal
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150727
    </Date_registration3>
    <Date_registration>27/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02524886
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Netherlands;Netherlands;Netherlands;Netherlands;Netherlands
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>GGZ Centraal;GGZ Centraal;GGZ Centraal;GGZ Centraal;GGZ Centraal
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia
    </Condition>
    <Intervention>Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
    </Intervention>
    <Primary_outcome>DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS);DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS);DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS)
    </Primary_outcome>
    <Secondary_outcome>Psychiatric safety as measured on the Brief Psychiatric Rating Scale (BPRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS);Cognitive side effects as measured using neuropsychological test battery;Quality of life as measured on the Short Form 36 (SF-36) and the World Health Organiasation Brief Quality of Life Score (WHO-Bref)
    </Secondary_outcome>
    <Secondary_ID>DBS for TD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Medical Center Groningen;Maastricht University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13637501
    </Internal_Number>
    <TrialID>DRKS00006778
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep brain stimulation before the age of 18 in patients with childhood-onset dyskinetic movement disorders - a German registry for quality assurance
    </Public_title>
    <Scientific_title>Deep brain stimulation before the age of 18 in patients with childhood-onset dyskinetic movement disorders - a German registry for quality assurance - GEPESTIM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20141201
    </Date_registration3>
    <Date_registration>01/12/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00006778
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>14/10/2013
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Anne
    </Contact_Firstname>
    <Contact_Lastname>Koy
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>anne.koy@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147887353
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria:  - Diagnosis of childhood-onset dyskinetic movement disorders &lt;br&gt;- Deep brain stimulation before the age of 18 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  - No diagnosis of childhood-onset dyskinetic movement disorders &lt;br&gt;- Deep brain stimulation after the age of 18 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G80.3 &lt;br&gt;G24.1 &lt;br&gt;G23.0 &lt;br&gt;E79.1 &lt;br&gt;G24.2;Dyskinetic cerebral palsy;Idiopathic familial dystonia;Hallervorden-Spatz disease;Lesch-Nyhan syndrome;Idiopathic nonfamilial dystonia;G80.3;G24.1;G23.0;E79.1;G24.2
    </Condition>
    <Intervention>Group 1: With the aid of the registry data of patients with a childhood-onset dyskinetic movement disorder who received DBS before the age of 18 years should be systematically collected encompassing information on medical history of the patients, disease etiology, evolution of symptoms, pharmacotherapy, supportive therapy, technical details of DBS implantation, stimulation parameters and complications.
    </Intervention>
    <Primary_outcome>Change of Burke-Fahn-Marsden Dystonia Rating Scale after Deep Brain Stimulation
    </Primary_outcome>
    <Secondary_outcome>Deep Brain Stimulation effect on - dystonia - dyskinesia - pain - memory - affect - quality of life - spasticity - motor function - cognition - attention - speech
    </Secondary_outcome>
    <Source_Support>Univerität zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/10/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00006778#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12926031
    </Internal_Number>
    <TrialID>NTR4881
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease&#x0D;
comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treatment Deep Brain&#x0D;
Stimulation;
    </Public_title>
    <Scientific_title>Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease&#x0D;
comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treatment Deep Brain&#x0D;
Stimulation;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Academic Medical Center, University of Amsterdam
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141103
    </Date_registration3>
    <Date_registration>2014-11-03
    </Date_registration>
    <Source_Register>NTR
    </Source_Register>
    <web_address>https://www.onderzoekmetmensen.nl/en/trial/21505
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2014-12-01
    </Date_enrollement>
    <Target_size>66
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Active, Parallel
    </Study_design>
    <Phase/>
    <Contact_Firstname>J.M.
    </Contact_Firstname>
    <Contact_Lastname>Dijk
    </Contact_Lastname>
    <Contact_Address/>
    <Contact_Email>j.m.dijk@amc.uva.nl
    </Contact_Email>
    <Contact_Tel>020-5669111
    </Contact_Tel>
    <Contact_Affiliation>Academisch Medisch Centrum &lt;br&gt;&#x0D;
Afdeling Neurologie &lt;br&gt;&#x0D;
Postbus 22660
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor,&#x0D;&lt;br&gt;rigidity, and asymmetry; &lt;br /&gt;&#x0D;&lt;br&gt;- Despite optimal pharmacological treatment, at least one of the following symptoms: severe response&#x0D;&lt;br&gt;fluctuations, dyskinesias, painful dystonia or bradykinesia;&lt;br /&gt;&#x0D;&lt;br&gt;- A life expectancy of at least two years.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Age below 18 years&lt;br /&gt;&#x0D;&lt;br&gt;- Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);&lt;br /&gt;&#x0D;&lt;br&gt;- Previous CLI (through a PEG-tube or Nasal Jejuna| tube);&lt;br /&gt;&#x0D;&lt;br&gt;- Hoehn and Yahr stage 5 at the best moment during the day;&lt;br /&gt;&#x0D;&lt;br&gt;- A Montreal Cognitive Assessment score of 25 or less (MOCA; http://www.mocatest.org);&lt;br /&gt;&#x0D;&lt;br&gt;- Psychosis;&lt;br /&gt;&#x0D;&lt;br&gt;- Current depression;&lt;br /&gt;&#x0D;&lt;br&gt;- Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;&lt;br /&gt;&#x0D;&lt;br&gt;- Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for&#x0D;&lt;br&gt;Duodopa;&lt;br /&gt;&#x0D;&lt;br&gt;- Pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception;&lt;br /&gt;&#x0D;&lt;br&gt;- No informed consent;&lt;br /&gt;&#x0D;&lt;br&gt;- Legally incompetent adults.
    </Exclusion_Criteria>
    <Condition>advanced Parkinson's disease, gevorderde ziekte van Parkinson
    </Condition>
    <Intervention>Continuous Intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS).
    </Intervention>
    <Primary_outcome>The costs per unit on the PDQ-39 and the costs per QALY for the cost-effectiveness and cost-utility analyses respectively. The EQ-5D will be applied as the utility measure.
    </Primary_outcome>
    <Secondary_outcome>Secondary clinical outcomes are quality of life (PDQ-39 at baseline, 9 and 12 months), PD motor symptoms (MDS-UPDRS-score at baseline and 12 months), dyskinesias (CDRS at baseline and 12 months), 3-day motor symptom diary (at baseline and 12 months), non-motor symptoms such as autonomic functions and sleep (Non Motor Symptom Checklist, Rotterdam Symptom Checklist at baseline and 12 months), adverse effects and complications (at every visit), treatment failure (at every visit), stopping treatment, starting with the alternative than initially started treatment, PD-medication (at every visit), disability (Hoehn and Yahr stage at baseline and 12 months), functional health status (ALDS at baseline and 12 months), patient and physician preferences, patient satisfaction, caregiver burden, neuropsychological and psychiatric assessment at baseline and 12 months, and medical and non-medical care costs (iMCQ and iPCQ at every visit).
    </Secondary_outcome>
    <Secondary_ID>NL4753;NTR4881;NL51240.018.14 : 2014-004501-32
    </Secondary_ID>
    <Source_Support>ZonMw (Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie)&#x0D;
MedTronic
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/11/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/08/2017
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>5823318
    </Internal_Number>
    <TrialID>NCT02253498
    </TrialID>
    <Last_Refreshed_on>24 October 2016
    </Last_Refreshed_on>
    <Public_title>The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
    </Public_title>
    <Scientific_title>The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beijing Pins Medical Co., Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140929
    </Date_registration3>
    <Date_registration>29/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02253498
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2016
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 0
    </Phase>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Li Luming, PhD;Jia Fumin, PhD;Li Luming, PhD;Jia Fumin, PhD
    </Contact_Lastname>
    <Contact_Email>;pins_medical@163.com;;pins_medical@163.com
    </Contact_Email>
    <Contact_Tel>;010-59361265;;010-59361265
    </Contact_Tel>
    <Contact_Affiliation>Tsinghua University;;Tsinghua University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is aged 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient Group with Tourette's syndrome, Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Major Depressive Episode within the previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Schizophrenia or other psychotic disorder.Participate in other clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Has a life expectancy of &lt; 1 year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The investigator and/or enrollment review committee, would preclude participation in&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is aged 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient Group with Tourette's syndrome, Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Major Depressive Episode within the previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Schizophrenia or other psychotic disorder.Participate in other clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Has a life expectancy of &lt; 1 year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The investigator and/or enrollment review committee, would preclude participation in&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome;Tourette Syndrome
    </Condition>
    <Intervention>Device: deep brain stimulation (DBS);Device: deep brain stimulation (DBS)
    </Intervention>
    <Primary_outcome>Modified Rush Video Rating Scale (mRVRS);Modified Rush Video Rating Scale (mRVRS)
    </Primary_outcome>
    <Secondary_outcome>Tourette Syndrome Symptom List (TSSL);SF-36;Tourette Syndrome Symptom List (TSSL);SF-36
    </Secondary_outcome>
    <Secondary_ID>PINS-009;PINS-009
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Beijing Tiantan Hospital;Beijing Tiantan Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13637379
    </Internal_Number>
    <TrialID>DRKS00006257
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neuronal osciallations in basal-ganglia-loops and their therapeutic modulation in patients with idiopathic Parkinson syndrome.
    </Public_title>
    <Scientific_title>Neuronal osciallations in basal-ganglia-loops and their therapeutic modulation in patients with idiopathic Parkinson syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Uniklinik Köln, NeurologieArbeitsgruppe für Bewegungsstörungen und Tiefe Hirnstimulation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140708
    </Date_registration3>
    <Date_registration>08/07/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00006257
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/08/2014
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: Other; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Elfriede
    </Contact_Firstname>
    <Contact_Lastname>Stubbs
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>elfriede.stubbs@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-98842
    </Contact_Tel>
    <Contact_Affiliation>Klinik und Poliklinik für NeurologieArbeitsgruppe Bewegungsstörungen und Tiefe HirnstimulationStudienbüro
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy subjects:&lt;br&gt;• Male and female participants between 30 and 80 years of age&lt;br&gt;• Right handed persons&lt;br&gt;• Capability of signing an informed consent&lt;br&gt;&lt;br&gt;Parkinson’s patients:&lt;br&gt;• Male and female patients with the diagnosis of an IPS according to the guidelines of the DGN&lt;br&gt;• Right handed patients&lt;br&gt;• Patients with the indication for receiving deep brain stimulation (target areas: STN, GPi, Vim) with uncontrollable motor symptomes due to strong dyskinesia and/ or ON/OFF fluctuations &lt;br&gt;• positive motor response to L-Dopa or Apomorphine;&lt;br&gt;• Patients between 30 and 80 (in order to exclude genetic variants of the disease);&lt;br&gt;• time period of the symptomes longer than 4 years (differential diagnosis);&lt;br&gt;•  patients have to be able to sign an informed consent;&lt;br&gt;• Ability to cooperate during the measurements&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Healthy subjects:&lt;br&gt;• non- "sui juris" patients, underaged persons as well as subjects which are judically sent to an institution&lt;br&gt;• diagnosis of an idiopathic parkinson syndrom or any other neurological disease&lt;br&gt;• participants that take drugs regularly which influence the nervous system and which can not be stopped the evening before the experiment&lt;br&gt;• severe internal comorbidities&lt;br&gt;• presence of psychiatric diseases&lt;br&gt;•impaired vision or hearing defect that may hinder the testing&lt;br&gt;• pregnant or breast feeding mothers&lt;br&gt;&lt;br&gt;Parkinson’s patients:&lt;br&gt;• non- "sui juris" patients, underaged persons as well as subjects which are judically sent to an institution&lt;br&gt;• patients that suffer from another neurological disease apart from Parkinsons like Epilepsy, Alzheimers or Dystonia&lt;br&gt;• patients with severe frontal executive disturbances&lt;br&gt;• presence of a Parkinson-Plus-Syndrom like corticobasal degeneration, progressive supranuclear palsy or multisystem atrophy&lt;br&gt;• other hypokinetic movement disorders like MPTP- or manganese intoxication, chorea Huntington, subcortical arteriosclerotic encephalopathy or psychogenic movement disorder&lt;br&gt;• clinically relevant abnormalities in preoperative MR-Images like ischemia, or cerebral athropy&lt;br&gt;• previous surgeries in the ZNS due to, for example, brain tumors, epilepsy or vascular reasons&lt;br&gt;• severe internal comorbidities&lt;br&gt;• presence of psychiatric diseases&lt;br&gt;• impaired vision or hearing defect that may hinder the testing&lt;br&gt;• pregnant or breast feeding mothers
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: healthy volunteers, age-matched&lt;br&gt;(EEG recording with a 128-channel-system from the head surface and synchronous measurment of the EMG from the right forearm during the conduction of simple movments)&lt;br&gt;Group 2: Parkinsons-Patients&lt;br&gt;(pre- and posteroperatively EEG-recording with a 128 channel system from the head surface, synchronous recording of the EMG from the right forearm during the conduction of simple movements; intraoperatively: the above mentioned electrophysiological measurements will be accompanied by the recording of local field potentials as well as single cell activity from the target structures of deep brain stimulation using microelectrodes; perioperatively, in addition to EEG and EMG, local field potentials will be recorded by the use of externalized electrodes)
    </Intervention>
    <Primary_outcome>Pathological, oscillatory coupling between EEG and EMG in the beta range (13-30 Hz) on different measurement days without treatment
    </Primary_outcome>
    <Secondary_outcome>Comparision of pathological, electrophysiological acitivity for two Parkinsons-Subtypes (tremor-dominant versus akinetic rigid)
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/05/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00006257#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13637143
    </Internal_Number>
    <TrialID>DRKS00005797
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effect of Deep Brain Stimulation in the Globus Pallidus internus on quality of life in young patients with dyston-dyskinetic Cerebral Palsy
    </Public_title>
    <Scientific_title>Effect of Deep Brain Stimulation in the Globus Pallidus internus on quality of life in young patients with dyston-dyskinetic Cerebral Palsy - STIM-CP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140404
    </Date_registration3>
    <Date_registration>04/04/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00005797
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>28/02/2014
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Anne
    </Contact_Firstname>
    <Contact_Lastname>Koy
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>anne.koy@uk.koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 87353
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • The treating physician has chosen GPi-DBS for the treatment of the secondary dystonia caused by cere-bral palsy in this patient &lt;br&gt;• Patient and/or legal representative, if the patient is un-deraged or not capable to give consent himself, have chosen GPi-DBS as treatment&lt;br&gt;• The consent to participate in the trial of the underaged patient, if he is capable to understand the study re-quirements, is required&lt;br&gt;• Age at enrolment 7-18 years&lt;br&gt;• Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury&lt;br&gt;• Anti-dystonic pharmacotherapy insufficient (e.g. Jankovic J. Medical treatment of dystonia. Movement disorders, Vol. 28, No. 7, 2013) 67&lt;br&gt;• Stable anti-dystonic medication over the last 30 days&lt;br&gt;• Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible)&lt;br&gt;• No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention&lt;br&gt;• Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study&lt;br&gt;• Informed consent to take part in the study from patient and/or legal representative if the patient is underaged or not capable to give consent himself&lt;br&gt;• Patient and/or legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: • Patients with known primary (e.g. DYT1) or idiopathic dystonia&lt;br&gt;• Severe axial hypotonia with total loss of head control (e.g. absence of control at “upper thoracic level” in the SATCo score) (medication effect excluded)&lt;br&gt;• Fixed hemi-dystonia&lt;br&gt;• Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale &gt;3)&lt;br&gt;• Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention&lt;br&gt;• Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.)&lt;br&gt;• Condition likely to require use of MRI in the future&lt;br&gt;• Any intracranial abnormality or medical condition that would contraindicate DBS surgery&lt;br&gt;• Any findings in neuropsychological screening assessments that would contraindicate DBS surgery&lt;br&gt;• Any current drug and / or alcohol abuse&lt;br&gt;• Any history of frequent grand-mal seizures without response to anticonvulsive treatment&lt;br&gt;• Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device.&lt;br&gt;• Any previous brain surgery that would interfere with the placement of the leads or the functioning of the device.&lt;br&gt;• A history of neurostimulation intolerance in any area of the body.&lt;br&gt;• Currently on any anticoagulant medications that cannot be discontinued during perioperative period.&lt;br&gt;• Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival &lt;12 months.&lt;br&gt;• Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator.&lt;br&gt;• A female that is breastfeeding or of child bearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception („antibaby-pill“, hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G80.3;Dyskinetic cerebral palsy;G80.3
    </Condition>
    <Intervention>Group 1: In this single-arm, non-interventional trial qualitiy of life as well as motor skills, speech, pain perception, cognition, mood, memory and attention will be systematically assessed before and 6 and 12 months after Deep Brain Stimulation.
    </Intervention>
    <Primary_outcome>Difference in CPCHILD before and 12 months on DBS (response=improvement &gt; 10%)
    </Primary_outcome>
    <Secondary_outcome>Assensment of effect of bilateral GPi-DBS on&lt;br&gt;Dystonia&lt;br&gt;Spasticity&lt;br&gt;Dyskinesia&lt;br&gt;Motor function/disability&lt;br&gt;Pain&lt;br&gt;Cognition &lt;br&gt;Memory&lt;br&gt;Affection&lt;br&gt;Speech
    </Secondary_outcome>
    <Secondary_ID>NCT02097693
    </Secondary_ID>
    <Source_Support>Boston Scientific Corporation Neuromodulation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/01/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00005797#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13133043
    </Internal_Number>
    <TrialID>NCT02056873
    </TrialID>
    <Last_Refreshed_on>26 June 2023
    </Last_Refreshed_on>
    <Public_title>Tourette Syndrome Deep Brain Stimulation
    </Public_title>
    <Scientific_title>The Human Thalamocortical Network in Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140203
    </Date_registration3>
    <Date_registration>03/02/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02056873
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2014
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be 21+ years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Tourette Syndrome (TS) in accordance to the Diagnostic and Statistical&#x0D;&lt;br&gt;             Manual of Mental DIsorders (DSM-V) criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Yale Global Tic Severity Scale (YGTSS) must be =35/50 for at least 12 months; Motor&#x0D;&lt;br&gt;             Tic subscore must be =15&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TS must be causing incapacitation with severe distress, self-injurious behavior,&#x0D;&lt;br&gt;             and/or quality of life disruption&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TS must be medication refractory. Criteria to determine if medication refractory is&#x0D;&lt;br&gt;             the exact criteria stated by Mink et. al TSA DBS Guidelines published in 2006:&#x0D;&lt;br&gt;             Subjects must have been treated by a psychiatrist or neurologist experienced in TS&#x0D;&lt;br&gt;             with therapeutic doses of either 1-4 mg/day of haloperidol or 2-8 mg/day of pimozide,&#x0D;&lt;br&gt;             risperidone (1-3 mg/day), and aripiprazole (2.5-5 mg/day). Must be at minimum a single&#x0D;&lt;br&gt;             trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically relevant depression must be pharmacologically treated and deemed stable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have been stabilized for 1 month on TS medication without a dose change prior to&#x0D;&lt;br&gt;             surgical intervention. If medication trials resulted in discontinuation of TS&#x0D;&lt;br&gt;             medications, the subject must be stabilized for 3 months off TS medicines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be willing to keep TS related medications stable and unchanged throughout the&#x0D;&lt;br&gt;             trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have been offered habit reversal therapy/cognitive behavioral intervention&#x0D;&lt;br&gt;             therapy (HRT) if subject did not have it prior to enrollment. (Subjects not required&#x0D;&lt;br&gt;             to participate in HRT but it will be highly encouraged, and must be completed prior to&#x0D;&lt;br&gt;             start of this study's protocol. Those who improve significantly will be excluded from&#x0D;&lt;br&gt;             receiving DBS surgery)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If tic is focal or addressable by botulinum toxin treatment, the study neurologist&#x0D;&lt;br&gt;             will offer to administer a trial of botulinum toxin prior to consideration of surgical&#x0D;&lt;br&gt;             therapy. (If the subject chooses not to have the treatment, they cannot participate in&#x0D;&lt;br&gt;             the study. If the patient responds satisfactorily and their quality of life&#x0D;&lt;br&gt;             significantly improves, they will be excluded)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any previous neurological intervention including DBS or ablative brain lesions, any&#x0D;&lt;br&gt;             metal in the head, and any type of implanted stimulator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I&#x0D;&lt;br&gt;             psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of psychotic features&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant psychosocial factors that can cause increased risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of only simple motor tics, a movement disorder other than TS, or&#x0D;&lt;br&gt;             medication related movement disorders from TS medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney&#x0D;&lt;br&gt;             disease, chronic neurological disease, hematological disease, or frailty that impacts&#x0D;&lt;br&gt;             tolerability of the surgery as judged by the screening physicians&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy,&#x0D;&lt;br&gt;             hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious&#x0D;&lt;br&gt;             lesions that would potentially confound the outcome or safety of the surgery as judged&#x0D;&lt;br&gt;             by the study neurosurgeon&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia or cognitive dysfunction that will place the subject at risk for worsening&#x0D;&lt;br&gt;             cognition, and/or may impact the ability to cooperate with tasks involved in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any attempt or intent of suicide in the last 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant substance abuse or dependence within the last 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Multiple failed medication treatments of inadequate dose or duration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of noncompliance with previous medical and psychosocial treatment efforts&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe head banging tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of child-bearing potential who are pregnant or planning pregnancy (urine&#x0D;&lt;br&gt;             pregnancy test required)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive urine drug screen for illicit substances (urine drug screen required)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of multiple surgical procedures with poor outcomes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unexplained gaps in medical history&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pending lawsuits or other legal action&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: DBS System;Device: DBS System (RBS Setting)
    </Intervention>
    <Primary_outcome>Reduction in total tics on the Yale Global Tic Severity Scale (YGTSS) after 6 months as an effect of centromedian (CM) continuous DBS stimulation;Correlation between increase in gamma oscillations and improvement in TS symptomatology;Responsive brain stimulation (RBS) as an effective alternative to continuous DBS stimulation;Reduction in total tics on the YGTSS after 24 months as an effect of centromedian (CM) continuous DBS stimulation
    </Primary_outcome>
    <Secondary_ID>KL2TR001429;1553482;OCR20343;IRB201300850 -A-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;National Institutes of Health (NIH);National Science Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13636570
    </Internal_Number>
    <TrialID>DRKS00004770
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Impairments of Parkinson's disease patients with deep brain stimulation: Development and validation of a self-report and proxy-rated questionnaire
    </Public_title>
    <Scientific_title>Impairments of Parkinson's disease patients with deep brain stimulation: Development and validation of a self-report and proxy-rated questionnaire - DBS-IS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Deutsche Parkinson Vereinigung (dPV)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131126
    </Date_registration3>
    <Date_registration>26/11/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00004770
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/10/2012
    </Date_enrollement>
    <Target_size>1500
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Catharine
    </Contact_Firstname>
    <Contact_Lastname>Lewis
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>catharine.lewis@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 97435
    </Contact_Tel>
    <Contact_Affiliation>Klinik und Poliklinik für Neurologie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with Parkinson's disease and a respective caregiver
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients without Parkinson's disease and caregivers of patients without Parkinson's disease
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Parkinson's disease patients (with and without DBS), survey with questionnaires&lt;br&gt;Group 2: caregivers of Parkinson's disease patients (with and without DBS), survey with questionnaires
    </Intervention>
    <Primary_outcome>Development and validation of a self-report and proxy-rated questionnaire
    </Primary_outcome>
    <Source_Support>Deutsche Parkinson Vereinigung (dPV)
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/06/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00004770#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13636898
    </Internal_Number>
    <TrialID>DRKS00005316
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neurocognitive Specification of Dysfunctions within Basal Ganglia-Cortex Loops and their Therapeutic Modulation by Deep Brain Stimulation in Patients with Obsessive Compulsive Disorders and Tourette Syndrome
    </Public_title>
    <Scientific_title>Neurocognitive Specification of Dysfunctions within Basal Ganglia-Cortex Loops and their Therapeutic Modulation by Deep Brain Stimulation in Patients with Obsessive Compulsive Disorders and Tourette Syndrome - KFO219 TP7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131002
    </Date_registration3>
    <Date_registration>02/10/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00005316
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/10/2009
    </Date_enrollement>
    <Target_size>35
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: Other; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Daniel
    </Contact_Firstname>
    <Contact_Lastname>Huys
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>daniel.huys@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 86211
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: For OCD and Tourette patients:&lt;br&gt;- chronic course&lt;br&gt;- serious expression with subjective distress and significant impairment of psychosocial functioning levels&lt;br&gt;- The patient agrees after detailed education about DBS and gives his written informed consent&lt;br&gt;- The patient agrees to a detailed evaluation&lt;br&gt;&lt;br&gt;For OCD patients:&lt;br&gt;-  OCD (ICD-10: F42) is the main psychiatric diagnosis&lt;br&gt;- strong symptom severity as measured by the YBOCS score&lt;br&gt;- At least one documented fully implemented cognitive-behavioral psychotherapy without sufficient success&lt;br&gt;- at least two unsuccessful drug therapies with SSRIs or clomipramine for 10 weeks in adequate doses&lt;br&gt;- At least one unsuccessful drug augmentation carried out for 10 weeks with one of the following medications: lithium, buspirone or neuroleptics&lt;br&gt;&lt;br&gt;For Tourette patients:&lt;br&gt;- Tourette Syndrome (ICD-10: F95.2) is the main psychiatric diagnosis&lt;br&gt;- strong symptom severity as measured by the score YGTSS&lt;br&gt;- Inadequate symptom relief through drug treatment strategies, as a minimum pre-treatment with preparations from all three pharmacological groups listed (neuroleptics, benzodiazepines, alpha-agonists). This should be documented with adequate doses of at least 3-month treatment periods.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Acute suicidality&lt;br&gt;- Simultaneously or previously existing schizophrenia according to DSM-IV criteria&lt;br&gt;- Abuse of or dependence on drugs or alcohol in the last six months&lt;br&gt;- Craniocerebral trauma in the anamnesis&lt;br&gt;- Clinically relevant internal or neurological diseases&lt;br&gt;- Pregnancy or breastfeeding&lt;br&gt;- Participation in a clinical trial within the last 30 days before the start of the study&lt;br&gt;- Intellectual deficit
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2 &lt;br&gt;F42;Combined vocal and multiple motor tic disorder [de la Tourette];Obsessive-compulsive disorder;F95.2
    </Condition>
    <Intervention>Group 1: Tourette patients treated with thalamic DBS are examined preoperative as well as 6 and 12 month after operation in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.&lt;br&gt;Group 2: Patients with obsessive compulsive disorder treated with DBS of the Nucleus accumbens are examined preoperative as well as 6 and 12 month after operation in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.&lt;br&gt;Group 3: 15 healthy controll subjects are examined in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.
    </Intervention>
    <Primary_outcome>Changes in Obsessive compulsive symptoms should be measured 12 month after Operation using the YBOCS (Yale-Brown Obsessive Compulsive Scale).&lt;br&gt;&lt;br&gt;Changes in Tic symptoms in Tourette patients should be measured 12 month after operation using the YGTSS (Yale Global Tic Severerity Scale).
    </Primary_outcome>
    <Secondary_outcome>Psychopathology: STAI, HZI, IKP, SKID, GAF, DAPP-BQ, BDI, GAF, SCL-90&lt;br&gt;Neuropsychology: ToL, CPT, FWIT, Stroop-Test, Go/NoGo-Test, Inhibiton of Return, PPI&lt;br&gt;All examinations are executed preoperative as well as 6 and 12 month after operation
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/10/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00005316#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13385653
    </Internal_Number>
    <TrialID>NCT01922388
    </TrialID>
    <Last_Refreshed_on>9 October 2023
    </Last_Refreshed_on>
    <Public_title>Early Versus Late Application of STN DBS to PD Patients With Motor Complications
    </Public_title>
    <Scientific_title>Early Versus Late Application of Subthalamic Deep Brain Stimulation to Parkinson's Disease Patients With Motor Complications: a Multicentre, Prospective and Observational Study
    </Scientific_title>
    <Acronym>ELASS
    </Acronym>
    <Primary_sponsor>Chen Ling
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130808
    </Date_registration3>
    <Date_registration>08/08/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT01922388
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2013
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ling Chen, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>First Affiliated Hospital, Sun Yat-Sen University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's Disease with good response to levodopa(i.e. more than 30%&#x0D;&lt;br&gt;             improvement in the MDS-UPDRS Part III score after an acute levodopa challenge)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of fluctuations and/or dyskinesias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age ranging from 18 to 75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal brain MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of dementia (Mini Mental State Examination = 26)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of severe psychiatric diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe metabolic diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe cardiac/respiratory/renal/hepatic diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Secondary parkinsonism or multiple system atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Illiteracy or insufficient language skills to complete the questionnaires&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poor compliance and unreasonable expectation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are pregnant or breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Simultaneous participation in another clinical trial&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Bilateral deep brain stimulation of the subthalamic nucleus
    </Intervention>
    <Primary_outcome>Changes in 39-item Parkinson's disease questionnaire (PDQ-39) scores
    </Primary_outcome>
    <Secondary_outcome>Changes in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores;Changes in time spent in the "on" state without troubling dyskinesia based on Parkinson's disease home diary;Changes in MDS-UPDRS patient questionnaire (Part I B and Part II) scores;Severe adverse effects
    </Secondary_outcome>
    <Secondary_ID>[2013]19
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Prince of Wales Hospital, Shatin, Hong Kong;Shenzhen Second People's Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13071483
    </Internal_Number>
    <TrialID>NCT01817517
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome
    </Public_title>
    <Scientific_title>Phase 1 Study of Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130318
    </Date_registration3>
    <Date_registration>18/03/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01817517
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2014
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Shannon L Dean, MD, PhD;Shannon L Dean, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;sdean1@jh.edu
    </Contact_Email>
    <Contact_Tel>;4439234100
    </Contact_Tel>
    <Contact_Affiliation>The Johns Hopkins University School of Medicine, Kennedy Krieger Institute;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Males and females who are &gt;=15 years of age. There is no strict age cutoff at the&#x0D;&lt;br&gt;             upper limit of inclusion, however subjects may meet the exclusion criteria based on&#x0D;&lt;br&gt;             medical contraindications to deep brain stimulation surgery (Points 3. and 6. under&#x0D;&lt;br&gt;             the Exclusion Criteria). For subjects in the age range of 15-24 years, an additional&#x0D;&lt;br&gt;             Ethics Committee consultation will be obtained prior to offering the subject the&#x0D;&lt;br&gt;             required screening visit. This is based on the revised screening criteria now proposed&#x0D;&lt;br&gt;             by Shrock, Mink, et al. on studies investigating DBS in TS. Additionally, for subjects&#x0D;&lt;br&gt;             in the age range of 15-20, a caregiver will be required to be present for all study&#x0D;&lt;br&gt;             visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has a diagnosis of TS as determined by a review of medical records, discussion&#x0D;&lt;br&gt;             with referring psychiatrist as well as the DSM-IV criteria and videotaped assessment.&#x0D;&lt;br&gt;             This will include an assessment to determine the presence of psychogenic tics,&#x0D;&lt;br&gt;             embellishment, factitious symptoms, personality disorders and malingering.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject determined to be treatment-resistant for at least one year prior to the&#x0D;&lt;br&gt;             Screening Visit as demonstrated by clinical evidence (determined by review of medical&#x0D;&lt;br&gt;             records and discussion with referring psychiatrist or neurologist) of persistent&#x0D;&lt;br&gt;             functionally impairing tics that have not responded to treatment with a minimum of&#x0D;&lt;br&gt;             three adequate regimens of medication including two failed trials of at least one&#x0D;&lt;br&gt;             typical neuroleptic and one atypical neuroleptic medication, along with one failed&#x0D;&lt;br&gt;             trial of a first tier medication as defined as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Adequate trials of one non-neuroleptic medication including drugs from the&#x0D;&lt;br&gt;                  following (first tier) list: clonidine, guanfacine, topiramate, baclofen,&#x0D;&lt;br&gt;                  levetiracetam, and clonazepam. Trial failure is defined as demonstrated lack of&#x0D;&lt;br&gt;                  efficacy or severe side effects.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Two adequate trials of at least one typical neuroleptic medication (pimozide,&#x0D;&lt;br&gt;                  fluphenazine, haloperidol) and at least one atypical neuroleptic (risperidone,&#x0D;&lt;br&gt;                  aripiprazole, ziprasidone, olanzapine, quetiapine). Trial failure is defined as&#x0D;&lt;br&gt;                  demonstrated lack of efficacy or severe side effects.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. A mandatory trial of behavioral interventions in an attempt to reduce the severity of&#x0D;&lt;br&gt;             the tics or comorbid symptoms must also be completed by the subject before offering&#x0D;&lt;br&gt;             participation in this trial. This may include habit reversal therapies, stress&#x0D;&lt;br&gt;             reduction therapies, or other behavioral therapies under investigation for tic&#x0D;&lt;br&gt;             suppression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has both significant vocal and motor tics with a tic subscale score of at&#x0D;&lt;br&gt;             least 35 on the YGTSS (Yale Global Tic Severity Scale) at all three Baseline Visits&#x0D;&lt;br&gt;             prior to undergoing surgery. For subjects with predominantly vocal tics (and minimal&#x0D;&lt;br&gt;             motor) causing significant problems this score requirement will be reduced to 18,&#x0D;&lt;br&gt;             similarly for subjects with predominantly motor tics (and minimal vocal) causing&#x0D;&lt;br&gt;             significant problems the required score will be 18. A portion of the study team,&#x0D;&lt;br&gt;             including the surgeon and two neurologists, will determine by consensus which category&#x0D;&lt;br&gt;             the subject falls into and whether the tics are a significant problem.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. All other aspects of the subject's care must be optimized during the preceding 6&#x0D;&lt;br&gt;             months before admission to the study. This includes treatment for comorbid medical,&#x0D;&lt;br&gt;             neurological, and psychiatric disorders. Additionally, it includes psychological&#x0D;&lt;br&gt;             interventions for any ongoing psychosocial problems the subject may have during the&#x0D;&lt;br&gt;             preceding 6 months before study admission.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject must be ambulatory.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Females who are postmenopausal, physically incapable of childbearing, or practicing an&#x0D;&lt;br&gt;             acceptable method of birth control. Acceptable methods of birth control include&#x0D;&lt;br&gt;             surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or&#x0D;&lt;br&gt;             diaphragm with a spermicidal agent or intrauterine device [IUD]). If practicing an&#x0D;&lt;br&gt;             acceptable method of birth control, a negative urine pregnancy test result has been&#x0D;&lt;br&gt;             obtained at baseline Visits 1 and 3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject is determined by an independent psychiatrist with expertise in capacity&#x0D;&lt;br&gt;             assessments to have decision-making capacity to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject is able to read English, understand and cooperate with study procedures, and&#x0D;&lt;br&gt;             has signed a written informed consent form prior to any study procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has a positive urine drug screen at any of the three Baseline Visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject had major surgery within three months prior to Baseline Visit 1 or has other&#x0D;&lt;br&gt;             surgery planned during the proposed study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is determined by medical consultant to have medical contraindications to&#x0D;&lt;br&gt;             undergoing surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is pregnant or breast-feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has a history of alcohol or drug abuse within the past 6 months and/or&#x0D;&lt;br&gt;             dependence within the past year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subject has a medical illness/condition, and/or abnormal diagnostic finding that would&#x0D;&lt;br&gt;             interfere with the completion of the study, confound the results of the study, or pose&#x0D;&lt;br&gt;             risk to the patient.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject has an untreated or uncontrolled Axis I disorder or other major psychiatric&#x0D;&lt;br&gt;             disorder including major depression, bipolar disorder, or schizophrenia as determined&#x0D;&lt;br&gt;             by the screening psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject has either a current or past history of suicidal plan and/or intent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject has a tic disorder or other movement disorder attributable to another medical,&#x0D;&lt;br&gt;             neurological, or psychiatric disorder other than Tourette Syndrome.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject has a drug-induced tic disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Subject has significant psychosocial factors that might increase the risk of the DBS&#x0D;&lt;br&gt;             procedure or complicate recovery and outcome assessments. (Examples include - history&#x0D;&lt;br&gt;             of noncompliance with previous medical and psychosocial treatments, multiple failed&#x0D;&lt;br&gt;             medication treatments of inadequate dose or duration, a history of multiple other&#x0D;&lt;br&gt;             surgical procedures with poor outcome, unexplained medical history gaps, or pending&#x0D;&lt;br&gt;             lawsuits or other legal action.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Subject has metal in the head or any other type of implanted stimulator (i.e. cardiac&#x0D;&lt;br&gt;             pacemaker, deep brain stimulator for a different disease, spinal cord stimulator,&#x0D;&lt;br&gt;             cochlear implant, vagus nerve stimulator, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subject has participated in another investigational drug trial or therapeutic trial&#x0D;&lt;br&gt;             within 30 days of Baseline Visit 1.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Subject has a diagnosis of intellectual disability with documented IQ&lt;70.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Medtronic Activa Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Change from baseline in the Yale Global Tic Severity Scale (YGTSS);Incidence of adverse device effects (ADEs).
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in the Yale-Brown Obsessive Compulsive Scale;Change from baseline in the WHO Adult ADHD Self-Report Scale (ASRS)
    </Secondary_outcome>
    <Secondary_ID>NA_00073086
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13443389
    </Internal_Number>
    <TrialID>JPRN-UMIN000009229
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Juntendo Early Deep Brain Stimulation Trial (JuST)
    </Public_title>
    <Scientific_title>Juntendo Early Deep Brain Stimulation Trial (JuST) - JuST trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Department of Research and Therapeutics for Movement Disorders, Juntendo University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20121101
    </Date_registration3>
    <Date_registration>01/11/2012
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010634
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>75years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2012/10/22
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Atsushi
    </Contact_Firstname>
    <Contact_Lastname>Umemura
    </Contact_Lastname>
    <Contact_Address>2-1-1 Hongo, Bunkyo, Tokyo
    </Contact_Address>
    <Contact_Email>g_oyama@juntendo.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-3-3813-3111
    </Contact_Tel>
    <Contact_Affiliation>Juntendo University Department of Research and Therapeutics for Movement Disorders
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy  2. Patients who cannot understand informed consent.  3. Patients who are participating other clinical trial.  4. Patients who are considered not appropriate for the study by investigator.
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Combination of deep brain stimulation and best medical treatment&lt;br&gt;Best medical treatment
    </Intervention>
    <Primary_outcome>The Parkinson&amp;#39;s Disease Questionnaire (PDQ-39)
    </Primary_outcome>
    <Secondary_outcome>Unified Parkinoson&amp;#39;s Disease Rating Scale (UPDRS) part I-IV, Modified Hoehn &amp;amp; Yahr stage, Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAMD), Montgomery-Asberg Depression Scale (MADRS), Zung Self-rating Depression Scale (SDS), Apathy scale (AS), Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), Japanese version of Montreal Cognitive Assessment (MoCA-J), Keio version Wisconsin card sorting test (KWCST), other adverse events (impulse control disorder, dopamine disregulation syndrome, dopamine agonist withdrawal syndrome, e.t.c.)
    </Secondary_outcome>
    <Source_Support>Department of Research and Therapeutics for Movement Disorders, Juntendo University
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>22/10/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>g_oyama@juntendo.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Juntendo University Faculty of Medicine
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0338133111
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>g_oyama@juntendo.ac.jp
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>06/11/2019
    </results_date_posted>
    <results_date_completed>31/03/2016
    </results_date_completed>
    <results_url_link>NA
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12925226
    </Internal_Number>
    <TrialID>NTR3655
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation.
    </Public_title>
    <Scientific_title>Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation.&#x0D;
 First Acute-in-Man Evaluation of Steering Brain Stimulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Sapiens Steering Brain Stimulation B.V.&#x0D;
H.C.F. Martens, PhD&#x0D;
Director of Clinical Science&#x0D;
High Tech Campus 48&#x0D;
5656 AE Eindhoven&#x0D;
The Netherlands&#x0D;
Tel: +31 40 800 2104&#x0D;

    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121008
    </Date_registration3>
    <Date_registration>2012-10-08
    </Date_registration>
    <Source_Register>NTR
    </Source_Register>
    <web_address>https://www.onderzoekmetmensen.nl/en/trial/20700
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2012-10-22
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>N/A: single arm study, Open (masking not used), N/A , unknown, Parallel
    </Study_design>
    <Phase/>
    <Contact_Firstname>P.R.
    </Contact_Firstname>
    <Contact_Lastname>Schuurman
    </Contact_Lastname>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email>p.r.schuurman@amc.nl
    </Contact_Email>
    <Contact_Tel>+31 (0)20 5669111
    </Contact_Tel>
    <Contact_Affiliation>Academic Medical Center (AMC), department of Neurosurgery,&#x0D;
P.O. Box 22660
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosis of idiopathic Parkinson's disease;&lt;br /&gt;&#x0D;&lt;br&gt;2. Clinical indication for STN DBS with MER;&lt;br /&gt;&#x0D;&lt;br&gt;3. Age &gt; 18 years;&lt;br /&gt;&#x0D;&lt;br&gt;4. Subject is a male or non-pregnant female;&lt;br /&gt;&#x0D;&lt;br&gt;5. Ability to comply with the study assignments;&lt;br /&gt;&#x0D;&lt;br&gt;6. Ability to give informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Parkinson's disease graded according to Hoehn and Yahr stage 5;&lt;br /&gt;&#x0D;&lt;br&gt;2. Score on MATTIS dementia rating scale &lt;120;&lt;br /&gt;&#x0D;&lt;br&gt;3. Psychiatric contraindications to STN DBS;&lt;br /&gt;&#x0D;&lt;br&gt;4. General contraindications for stereotactic surgery and general anaesthesia (e.g.  severe hypertension, blood coagulation disorder);&lt;br /&gt;&#x0D;&lt;br&gt;5. Subject has factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use or history of hemorrhagic stroke, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding;&lt;br /&gt;&#x0D;&lt;br&gt;6. Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing;&lt;br /&gt;&#x0D;&lt;br&gt;7. Subject has a history of a seizure disorder;&lt;br /&gt;&#x0D;&lt;br&gt;8. Subject requires short surgery time due to general health issues, as determined by the investigator;&lt;br /&gt;&#x0D;&lt;br&gt;9. Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.
    </Exclusion_Criteria>
    <Condition>Parkinson's disease, Deep Brain Stimulation&#x0D;
Ziekte van Parkinson, Diepe Hersenstimulatie
    </Condition>
    <Intervention>Sapiens Deep brain stimulation lead.
    </Intervention>
    <Primary_outcome>1. Description of and threshold for effects obtained by stimulation through Sapiens lead in standard mode;&lt;br /&gt;&lt;br&gt;2. Analysis of safety of stimulation with the Sapiens lead compared to control data.
    </Primary_outcome>
    <Secondary_outcome>1. Description of and threshold for effects obtained by stimulation through Sapiens lead in different modes;&lt;br /&gt;&#x0D;&lt;br&gt;2. Determination and comparison of "therapeutic window", obtained by stimulation through Sapiens lead in different modes.
    </Secondary_outcome>
    <Secondary_ID>NL3475;NTR3655;CCMO : S-12-0076 / NL40206.018.12;;ISRCTN wordt niet meer aangevraagd.
    </Secondary_ID>
    <Source_Support>Sapiens Steering Brain Stimulation B.V.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/10/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>22/12/2013
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13636015
    </Internal_Number>
    <TrialID>DRKS00003530
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The impact of deep brain stimulation on intrinsic frontal lobe organization
    </Public_title>
    <Scientific_title>The impact of deep brain stimulation on intrinsic frontal lobe organization                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Neurologische Universitätsklinik Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120210
    </Date_registration3>
    <Date_registration>10/02/2012
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00003530
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>04/06/2013
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Lena
    </Contact_Firstname>
    <Contact_Lastname>Köstering
    </Contact_Lastname>
    <Contact_Address>Breisacher Strasse 64
    </Contact_Address>
    <Contact_Email>lena.koestering@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>0761 270 54795
    </Contact_Tel>
    <Contact_Affiliation>Neurologische Universitätsklinik Freiburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: healthy test persons;  Parkinson's Disease patients with implanted deep brain stimulation system
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: brain trauma with brain damage (contusion)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: The deep brain stimulation system will be deactivated after the information of the patient and the signing of the consent, followed by the application of the optodes above the frontal cortex. After a defined period of 2 h, necessary for reaching a steady state, we will measure the metabolism in the frontal cortex, using near-infrared spectroscopy (NIRS) for 8 minutes. Afterwards the stimulator will be turned on, while measuring for another 24 minutes. So the overall recording will take 32 minutes. &lt;br&gt;Group 2: Healthy control subjects: The metabolism of the frontal cortex will be recorded for 32 minutes, using near-infrared spectroscopy (NIRS).
    </Intervention>
    <Primary_outcome>The comparison of the frontal organization in  Parkinson's Disease patients with that of a control collective, using fNIRS (near-infrared spectroscopy).
    </Primary_outcome>
    <Secondary_outcome>The comparison of the frontal organization in PD patients with activated vs. deactivated DBS, using fNIRS.
    </Secondary_outcome>
    <Secondary_ID>U1111-1127-6717
    </Secondary_ID>
    <Source_Support>Neurologische Universitätsklinik Freiburg
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/01/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_date_completed>24/11/2015
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00003530#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10216355
    </Internal_Number>
    <TrialID>NCT01485276
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Combined Deep Brain Stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Pilot Study of Bilateral Pedunculo-Pontine Nucleus (PPN) Deep Brain Stimulation for Patients With Parkinson Disease (PD) Who Have Persistent Gait Disturbance, Despite Bilateral Subthalamic Nucleus (STN) Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20111202
    </Date_registration3>
    <Date_registration>02/12/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01485276
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 8, 2011
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mark Hallett, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>National Institute of Neurological Disorders and Stroke (NINDS)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        i. Greater than 22 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        ii. Successful bilateral STN DBS implants for at least 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iii. At least 30% improvement in the motor UPDRS following STN therapy, by history and&#x0D;&lt;br&gt;        record review&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iv. Improved UPDRS and self assessment questionnaire following STN DBS by at least 20%, by&#x0D;&lt;br&gt;        history and record review.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        v. Good STN DBS placement assessed with imaging (CT scan, MRI or fused CT-MRI imaging)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vii. Persistent gait disturbance as ascertained by abnormal performance on the&#x0D;&lt;br&gt;        time-up-and-go test compared to age-matched controls as well as preoperative evaluation&#x0D;&lt;br&gt;        with posturography and quantitative gait assessment (values compared to normal age-matched&#x0D;&lt;br&gt;        controls) at least 30% difference from age-matched controls on either measure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vii. Persistent speech and swallowing problems as measured by a minimum score of I in items&#x0D;&lt;br&gt;        5 and 7 of the UPDRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        viii. Evaluation by an independent movement disorders specialist who will confirm gait&#x0D;&lt;br&gt;        disturbance in the presence of STN stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        i. Pregnant or nursing women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        ii. Cognitively impaired subjects as determined by pre-operative neuropsychology&#x0D;&lt;br&gt;        evaluation, including Mattis Dementia Rating Scale (DRS). Patients scoring below 70 on the&#x0D;&lt;br&gt;        Mattis DRS will be excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iii. Depressed subjects as determined by the neuropsychology screen, including Beck&#x0D;&lt;br&gt;        Depression Inventory. Patients scoring above 20 on the Beck inventory will be excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iv. Patients with uncontrolled co-existing medical conditions: uncontrolled systemic&#x0D;&lt;br&gt;        hypertension with values above 170/100; heart disease needing intervention; respiratory&#x0D;&lt;br&gt;        disease needing intervention; uncorrected coagulation abnormalities or need for therapeutic&#x0D;&lt;br&gt;        anticoagulation which cannot be interrupted; any condition that would render the patient&#x0D;&lt;br&gt;        unable to safely cooperate with the study tests as judged by the screening physician.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        v. Patients with metal objects in their body that are not MRI compatible, excluding the&#x0D;&lt;br&gt;        previous STN DBS hardware&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vi. Patients who have a history of seizures, require repeated magnetic resonance imaging&#x0D;&lt;br&gt;        (MRI) scans or have had a cranial neurosurgical procedure since receiving an STN implant.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: DBS Surgery
    </Intervention>
    <Primary_outcome>Change in the amount of time needed to complete a standardized timed up and go (TUG) study at 6 months post-surgery on stimulation
    </Primary_outcome>
    <Secondary_outcome>TUG study at 1, 3 and 12 months post-surgery.;UPDRS III score and UPDRS III points 27-30 at 1, 3, 6 and 12 months;PDQ 31 questionnaire at 6 months;Swallowing function at 6 moths;Static and dynamic posturography parameters at 1, 3, 6 and 12 months on stimulation.
    </Secondary_outcome>
    <Secondary_ID>12-N-0012;120012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13440108
    </Internal_Number>
    <TrialID>JPRN-UMIN000005941
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>usefulness of neuro mate for stereotactic functional surgery for Parkinson disease
    </Public_title>
    <Scientific_title>usefulness of neuro mate for stereotactic functional surgery for Parkinson disease - usefulness of neuro mate for stereotactic functional surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Nagoya University hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110901
    </Date_registration3>
    <Date_registration>01/09/2011
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007022
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2011/09/01
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Shimizu Shinobu
    </Contact_Lastname>
    <Contact_Address>65 Tsurumai Shouwa Nagoya
    </Contact_Address>
    <Contact_Email>s-shimizu@med.nagoya-u.ac.jp
    </Contact_Email>
    <Contact_Tel>052-744-2942
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University hospital center for clinical study and
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: patients with severe physical and mental disorder
    </Exclusion_Criteria>
    <Condition>Parkinson disease
    </Condition>
    <Intervention>deep brain stimulation
    </Intervention>
    <Primary_outcome>Accuracy of electrode implantation  Unified Parkinson disease rating scale
    </Primary_outcome>
    <Secondary_outcome>Yahr grade, Mini Mental Scale Examination
    </Secondary_outcome>
    <Source_Support>Nagoya University hospital
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/10/2014
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13439777
    </Internal_Number>
    <TrialID>JPRN-UMIN000005610
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Clinical study for efficacy of the deep brain stimulation for the Tourette Syndrome with severe involuntary movement
    </Public_title>
    <Scientific_title>Clinical study for efficacy of the deep brain stimulation for the Tourette Syndrome with severe involuntary movement - The deep brain stimulation for the Tourette Syndrome with severe involuntary movement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Nagoya University, Postgraduate School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110520
    </Date_registration3>
    <Date_registration>20/05/2011
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006608
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2011/07/01
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Yasukazu Kajita
    </Contact_Lastname>
    <Contact_Address>65 Tsurumai Syouwa, Nagoya
    </Contact_Address>
    <Contact_Email>ykajita@med.nagoya-u.ac.jp
    </Contact_Email>
    <Contact_Tel>052-744-2353
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University, Postgraduate School of Medicine Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The patients with severe cardiac disease, Respiratory failure, epilepsy, severe head injury, cerebral vascular accident, autism, schizophrenia, manic-deprresive psychosis, gravida
    </Exclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Deep Brain Stimulation group&lt;br&gt;Sham Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_outcome>modified Rush video-based protocol and rating scale (mRVRS), Short-Form 36-Item Health Survey (SF-36), WAIS-III, WMS-R, BDI-II, MMPI
    </Secondary_outcome>
    <Source_Support>Nagoya University, Postgraduate School of Medicine
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>5389763
    </Internal_Number>
    <TrialID>NCT01495897
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study
    </Public_title>
    <Scientific_title>Adaptation Sensorimotrice, Cervelet et Mouvements Anormaux: Projet d'étude Oculomotrice
    </Scientific_title>
    <Acronym>MOUVADOC
    </Acronym>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110518
    </Date_registration3>
    <Date_registration>18/05/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01495897
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2011
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Emmanuel Flamand-Roze, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut National de la Santé Et de la Recherche Médicale, France
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age =18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  -normal cognitive functions (&gt;24y)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal clinical examination of ocular mobility, visualization of the target&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No drug potentially able to modify and to influence the data: anti-depressants,&#x0D;&lt;br&gt;             neuroleptics, anti-emetics, amphetamines, anti myoclonic/dystonic drugs, alcohol,&#x0D;&lt;br&gt;             dopaminergic drug, antiepileptic.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia or essential tremor or Parkinson: diagnostic made by a neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For DYT11: mutation in SGCE gene.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For dystonia: No secondary dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For Parkinson : UPDRS&lt;28&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No other neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For the patient having deep brain stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of stimulation&gt; 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cerebral imagery post operation made&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stimulation parameter stable since 3 months at least.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Usual stop of the stimulation during the night&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrollable medical problems not related to M-D&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current active psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intake during the last 3 days of drugs potentially able to modify and to influence&#x0D;&lt;br&gt;             the data: anti-depressants, neuroleptics, anti-emetics, amphetamines, anti&#x0D;&lt;br&gt;             myoclonic/dystonic drugs, alcohol, dopaminergic drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects legally protected.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are not enrolled at social security.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Healthy;Dystonia;Parkinson Disease
    </Condition>
    <Intervention>Device: Tracking eye movement;Device: Tracking eye movement under deep brain stimulation
    </Intervention>
    <Primary_outcome>Saccadic adaptation;Characteristics of the saccade
    </Primary_outcome>
    <Secondary_ID>2010-A00740-39;C10-18
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>5810272
    </Internal_Number>
    <TrialID>ISRCTN16511360
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>Deep brain stimulation of the pedunculopontine nucleus for Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep brain stimulation of the pedunculopontine nucleus for Parkinson's Disease: a single centre randomised interventional treatment trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>North Bristol NHS Trust (UK)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100528
    </Date_registration3>
    <Date_registration>28/05/2010
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN16511360
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>22/10/2007
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single centre randomised interventional treatment trial (Treatment)
    </Study_design>
    <Phase>Phase II
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosis of advanced idiopathic Parkinson's disease poorly controlled on optimum medication with significant functional disability and predominant symptoms of postural instability and gait dysfunction in both the on and off medication states&lt;br&gt;2. They will have a Unified Parkinson's Disease Rating Scale (UPDRS) motor score of 30 or greater in their practically defined off condition at an initial evaluation. They will each show at least a 30% improvement in the UPDRS motor score from that of the practically defined off condition following a morning levodopa challenge.&lt;br&gt;3. At two preoperative evaluations the practically defined off UPDRS motor score should differ no more than +/- 15%&lt;br&gt;4. Subjects will be under the age of 70 years, either sex&lt;br&gt;5. Appropriate surgical candidate with no medical conditions that would interfere with long-term implantation of device and follow up&lt;br&gt;6. Patient must give signed informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known current or past diabetes&lt;br&gt;2. Evidence of dementia, head trauma or medical conditions that may alter cerebral functioning&lt;br&gt;3. Past or present history of alcohol or substance abuse&lt;br&gt;4. Mini-mental state examination (MMSE) scores below 27 or above 30&lt;br&gt;5. Evidence of past or current serious psychopathology likely to affect the patients ability to benefit from surgery
    </Exclusion_Criteria>
    <Condition>Topic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Parkinson?s Disease; Disease: Parkinson's disease &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson's Disease
    </Condition>
    <Intervention>Following fully informed consent and surgical implantation of DBS electrodes to both the PPN and subthalamic region bilaterally, patients will enter into an initial 6 week period over which the Subthalamic region and PPN electrodes will be programmed individually and in combination in order to define the optimal settings for symptom control. At the end of the first 6 week period patients will be randomised into receiving deep brain stimulation at the predetermined optimal setting at either the Subthalamic region or the both the PPN and Subthalamic region simultaneously. This will occur for a further 6 - 12 week period at the end of which the primary and secondary outcome measures will be assessed. Following assessment of the outcome measures, patients will crossover to the other stimulator setting for a further 6 - 12 weeks. With two possible combinations of stimulator settings and an initial period used to define optimal stimulator settings the total duration of the trial will be 18 - 30 weeks.
    </Intervention>
    <Primary_outcome>Change in frequency of gait freezing, measured for 3 days in each condition and averaged.
    </Primary_outcome>
    <Secondary_outcome>1. Quality of life questionnaires (39-item Parkinson's Disease Questionnaire [PDQ-39] and 36-item Short Form Health Survey [SF-36])&lt;br&gt;2. The Unified Parkinson's Disease Rating Scale (UPDRS)&lt;br&gt;3. Change in concomitant antiparkinsonian medications&lt;br&gt;4. Neuropsychological assessment&lt;br&gt;5. Parkinson's Disease Non-Motor Symptoms Questionnaire&lt;br&gt;6. Timed walk, upper and lower limb movements and Purdue Pegboard&lt;br&gt;7. Tinetti balance and gait assessment tool&lt;br&gt;&lt;br&gt;Measured pre-operatively and after each of the two randomisation settings (which could be at 12 - 18 weeks, or 18 - 30 weeks depending on how long the patient needs to be on each &lt;br&gt;stimulation setting in order to reach a stable clinical state on each of the stimulation settings.
    </Secondary_outcome>
    <Secondary_ID>4455
    </Secondary_ID>
    <Source_Support>Medtronic PLC
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>8756063
    </Internal_Number>
    <TrialID>ACTRN12610000385044
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Cerebral Palsy
    </Public_title>
    <Scientific_title>A randomized, placebo controlled, double blinded trial of pallidal Deep Brain Stimulation for dystonic or dyskinetic Cerebral Palsy to improve Quality of Life                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Martin Krause
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100513
    </Date_registration3>
    <Date_registration>13/05/2010
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12610000385044.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/04/2010
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Randomised controlled trial;
    </Study_design>
    <Phase/>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Dystonic or dyskinetic Cerebral Palsy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Dementia&#x0D;&lt;br&gt;Predominant Spasticity
    </Exclusion_Criteria>
    <Condition>Cerebral Palsy; &lt;br&gt;Cerebral Palsy;Neurological - Other neurological disorders
    </Condition>
    <Intervention>All patients will have deep brain stimulator implanted in the globus pallidus internus, which is part of the basal ganglia network in the brain. The implantation of deep brain stimulators takes approximately 3 to 6 hours. Deep brain stimulators are similar to cardiac pacemakers and the battery is placed - like in pacemakers - under the collar bone. However the electrodes are not in the heart but end in the brain where they stimulate certain areas of the brain - in our study the pallidum or globus pallidus internus. This part of the brain is involved in involuntary movements. We believe that continuous high frequency stimulation of this part of the brain can block involuntary movements and improve dystonia. The treatment group will receive effective continuous stimulation through their implanted deep brain stimulators for three months; The standard setting of the stimulator are pulse width of 90µs, 130 Hz and the highest possible amplitude , that does not cause side effects. The sham group will receive ineffective stimulation through their implanted deep brain stimulators which will mean the stimulator is switched on with the same settings but amplitude of 0 Volt.
    </Intervention>
    <Primary_outcome>Quality of life will be assessed by the Quality of Life Instrument for People with Developmental Disabilities (Rosenbaum, P.L., et al., Quality of life and health-related quality of life of adolescents with cerebral palsy. Dev Med Child Neurol, 2007. 49(7): p. 516-21.) with the domains of Being, Belonging, and Becoming. This scale is validated in Cerebral Palsy (CP).  The health-related quality of life will be assessed with the Short Form General-Health-Survey (SF-36), which evaluates both physical and mental components of functioning (Ware, J.E., Jr. and C.D. Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 1992. 30(6): p. 473-83).[The primary outcome parameter will be measured within 2 months before the intervention. Within 48 hours after implantation of the deep brain stimulator patients will be randomised and either allocated to sham or active treatment. Three months after the randomisation and therefore three months after having had continuous effective deep brain stimulation or sham stimulation the primary endpoint will be assed again. Than all deep brain stimulators will be activated and the third assessment of the primary endpoint will be 6 months after the initial randomisation.]
    </Primary_outcome>
    <Secondary_outcome>Movement and disability will be assessed by the Burke-Fahn-Marsden-Dystonia Rating Scale (BFMDRS) (Burke, R.E., et al., Validity and reliability of a rating scale for the primary torsion dystonias. Neurology, 1985. 35(1): p. 73-7.), which comprises of a disability score ranging from 0 to 30 and motor score ranging from 0 to 120. Further more the motor function will be video taped according to the previous applied video protocol. &#x0D;&lt;br&gt;The Gross Motor Function Classification System for children with Cerebral Palsy (GMFCS) [Palisano, R., et al., Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 1997. 39(4): p. 214-23.] will be applied as a standard classification tool for children with CP, which rates the severity of the disease in 5 levels with regard to their motor function.[The secondary outcome parameter will be measured within 2 months before the intervention. Within 48 hours after implantation of the deep brain stimulator patients will be randomised and either allocated to sham or active treatment. Three months after the randomisation and therefore three months after having had continuous effective deep brain stimulation or sham stimulation the secondary endpoint will be assed again. Than all deep brain stimulators will be activated and the third assessment of the secondary endpoint will be 6 months after the initial randomisation.]
    </Secondary_outcome>
    <Secondary_ID>None
    </Secondary_ID>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>13437016
    </Internal_Number>
    <TrialID>JPRN-UMIN000002849
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Multicentric double-blinded crossover randomized clinical trial of deep brain stimulation for intractable Tourette syndrome
    </Public_title>
    <Scientific_title>Multicentric double-blinded crossover randomized clinical trial of deep brain stimulation for intractable Tourette syndrome - Crossover and randomization design of intractable Tourette syndrome after surgery (CARITAS) trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Department of Neurosurgery, National Center Hospital of Neurology and Psychiatry
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20091205
    </Date_registration3>
    <Date_registration>05/12/2009
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003478
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2010/12/01
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Phase III
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takanobu Kaido
    </Contact_Lastname>
    <Contact_Address>Ogawahigashicho 4-1-1, Kodaira, Tokyo, 187-8551, Japan
    </Contact_Address>
    <Contact_Email>kaido@ncnp.go.jp
    </Contact_Email>
    <Contact_Tel>+81-42-341-2711
    </Contact_Tel>
    <Contact_Affiliation>National Center Hospital of Neurology and Psychiatry Department of Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria are a significant untreated structural brain lesion, a tic disorder due to other medical causes, no severe medical, neurological, psychiatric, or cognitive disorders that inordinately increase the risk (e.g., severe cardiovascular, pulmonary, or hematological disorders, epilepsy, a history of head injury, stroke, neurodegenerative disease, autism, schizophrenia, bipolar disorder, recent substance dependence, current pregnancy, and a recent history of suicide attempts).
    </Exclusion_Criteria>
    <Condition>Intractable Tourette syndrome
    </Condition>
    <Intervention>A stereotactic operation is performed aided by functional software and computed tomography (CT) or magnetic resonance imaging (MRI). Two permanent quadripolar leads (model 3387, Medtronic) are implanted bilaterally under general anesthesia.  The pulse generators (Soletra, Medtronic) are also implanted bilaterally and attached to lead extensions at the same time.  The pulse generator is activated and neuroelectrical parameters were changed by an investigator.  Patients are randomized 1 month after DBS, and stimulation &amp;#39;on&amp;#39; or &amp;#39;off&amp;#39; is started in a double-blinded fashion 1 month more later.    Group A: &amp;#39;On&amp;#39; for 3 months and &amp;#39;off&amp;#39; for 3 months, then open-labeled &amp;#39;on&amp;#39; for 6 months.&lt;br&gt;Group B: &amp;#39;Off&amp;#39; for 3 months and &amp;#39;on&amp;#39; for 3 months, then open-labeled &amp;#39;on&amp;#39; for 6 months.
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS) tic score
    </Primary_outcome>
    <Secondary_outcome>modified Rush Video-Based Rating Scale (mRVRS)  YGTSS social impairment score  Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score  Short Form-36 (SF-36)  Gilles de la Tourette syndrome-specific health-related -QOL scale (GTS-QOL)
    </Secondary_outcome>
    <Source_Support>Ministry of Health, Labour and Welfare, Japan
    </Source_Support>
    <Secondary_Sponsor>Kyoto Univ.  Kinki Univ.  Natl Ctr of Neurol and Psychiat  Univ. of Tokyo  Tokyo Metropolitan Neurological Hosp.  Tohoku Univ.  Nagoya Univ.  Nara Med. Univ.  Nihon Univ.  Hamamatsu Univ. School of Med.  Yamaguchi Univ.
    </Secondary_Sponsor>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/03/2012
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>4652329
    </Internal_Number>
    <TrialID>NCT00821743
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Pedunculo-Pontin Nucleus (PPN) - Deep Brain Stimulation (DBS) in Gait and Balance Disturbance in Parkinson's Disease (PPN-GAB-PARK Study)
    </Public_title>
    <Scientific_title>Study of Deep Brain Stimulation of the Pedunculo-pontin Nucleus (PPN) for the Treatment of Gait and Balance Disturbances in Patients With Parkinson's Disease (PPN-GAB-PARK Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090112
    </Date_registration3>
    <Date_registration>12/01/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00821743
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2010
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Denys FONTAINE, PhD;Denys FONTAINE, PhD;Denys Fontaine, PhD
    </Contact_Lastname>
    <Contact_Email>;fontaine.d@chu-nice.fr;fontaine.d@chu-nice.fr
    </Contact_Email>
    <Contact_Tel>;04 92 03 84 50;04 92 03 84 50
    </Contact_Tel>
    <Contact_Affiliation>Department of neurosurgery, CHU de Nice;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe idiopathic Parkinson's disease (stage of Hoehn and Yahr = 3).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease duration = 5 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Predominant axial motor signs (gait and balance disturbance as freezing of gait,&#x0D;&lt;br&gt;             postural instability, falls) with disability in daily life, defined by a score UPDRS&#x0D;&lt;br&gt;             II  2 of item  13 or  3 of item 14 or 15.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Axial motor signs resistant to optimal drug and non-drug treatment, including&#x0D;&lt;br&gt;             physical therapy and eventually STN-DBS (if STN-DBS is ongoing for at least 1 year&#x0D;&lt;br&gt;             and has shown no efficacy on axial motor signs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No significant abnormality on brain MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Non-inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with non-axial, dopa-responsive motor signs and indication of first line&#x0D;&lt;br&gt;             STN-DBS. In case of absence of efficacy of STN-DBS on axial motor signs after one&#x0D;&lt;br&gt;             year of stimulation, PPN-DBS may be proposed to these patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with major cognitive disturbances defined by a score Mattis DRS 130 (of 144).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding woman.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with contraindication for general anaesthesia, a contraindication for surgery&#x0D;&lt;br&gt;             (including disorders of haemostasis, or necessity of anticoagulant and antiaggregant&#x0D;&lt;br&gt;             drug), or a contraindication for MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient presenting major depression, psychosis or addiction in six months preceding&#x0D;&lt;br&gt;             inclusion.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation electrode
    </Intervention>
    <Primary_outcome>Primary endpoint will be the optimal parameters of PPN-DBS, defined as those leading to the best improvement of posture, balance and gait disturbance
    </Primary_outcome>
    <Secondary_outcome>Efficacy of PPN-DBS on disturbance of posture, balance and gait;Long term tolerance will be assessed by general and neurological examination, neuro-psychological tests (MMS, Mattis-DRS, Score fontal, BREF, MADRS) and by assessment of adverse events;;the components of gait that are most improved by PPN-DBS will be determined using computer-based systems (GAITRite and VICON);;evaluation of unilateral versus bilateral stimulation will be done during the double-blind assessment of all efficacy criteria;;effects of PPN-DBS on other PD symptom will be assessed using UPDRS and Hoehn and Yahr's staging;;the impact of PPN-DBS on quality of life and activities of daily living will be assessed by UPDRS II, SF36 and PDQ39 questionnaires and by a global satisfaction scale.
    </Secondary_outcome>
    <Secondary_ID>PPN-GAB-PARK study
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>10203600
    </Internal_Number>
    <TrialID>NCT00552474
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
    </Public_title>
    <Scientific_title>A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20071031
    </Date_registration3>
    <Date_registration>31/10/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00552474
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2005
    </Date_enrollement>
    <Target_size>136
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>DeLea Peichel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>ANS/St Jude Medical
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is 18 to 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has been diagnosed with Parkinson's disease for at lease five (5) years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person experiences at least six (6) hours or more daily "off-time" or moderate to&#x0D;&lt;br&gt;             severe dyskinesias during waking hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of improvement of Parkinson's symptoms with l-dopa (levodopa)&#x0D;&lt;br&gt;             therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person must be willing to maintain a constant dose of anti-Parkinson's disease&#x0D;&lt;br&gt;             medication for at least one month prior to study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person must be available for appropriate follow-up times for the length of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has any major illness or medical condition that would interfere with&#x0D;&lt;br&gt;             participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person currently suffers from untreated, major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has an electrical or electromagnetic implant (e.g. cochlear prosthesis or&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has had a prior surgery for the treatment of PD symptoms, including previous&#x0D;&lt;br&gt;             DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of seizures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Movement Disorders
    </Condition>
    <Intervention>Device: Libra Deep Brain Stimulation System;Device: Libra Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Increase the duration of "on time" without dyskinesias or with non-bothersome dyskinesias
    </Primary_outcome>
    <Secondary_outcome>Changes in the following over time: Incidence of AEs; UPDRS motor scores; Activities of Daily Living; Quality of Life, Quality Sleep Index, Hoehn and Yahr Staging, Global Outcome evaluation and Patient Satisfaction
    </Secondary_outcome>
    <Secondary_ID>C-04-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>5810383
    </Internal_Number>
    <TrialID>ISRCTN45455499
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>Pilot randomised controlled trial of deep brain stimulation in Tourette syndrome
    </Public_title>
    <Scientific_title>Pilot randomised controlled trial of deep brain stimulation in Tourette syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>University Hospital Birmingham NHS Foundation Trust (UK)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070706
    </Date_registration3>
    <Date_registration>06/07/2007
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN45455499
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/04/2008
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised placebo-controlled crossover study (Treatment)
    </Study_design>
    <Phase/>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Adults with medically intractable Tourette syndrome for whom surgery and post-operative care is not contraindicated.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Tics for other neurological reasons&lt;br&gt;2. High risk for surgery or post-op care
    </Exclusion_Criteria>
    <Condition>Tourette syndrome &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Somatoform disorders
    </Condition>
    <Intervention>Current interventions as of 05/12/2007:&lt;br&gt;Group 1:&lt;br&gt;Group 1 will have deep brain stimulation electrodes placed in the globus palludus internum. After 6 weeks, the electrodes will be switched on and adjusted maximally. After 3 months, electrodes will be switched off and the patient followed up after a further 3 months. &lt;br&gt; &lt;br&gt;Group 2:&lt;br&gt;Group 2 will have deep brain stimulation electrodes placed in the globus pallidus internum. After 6 weeks, the participant will have a "sham" switching on of electrodes. After 3 months, the electrodes will be switched on and adjusted maximally. The patient will be followed up and assessed after a further 3 months.&lt;br&gt;&lt;br&gt;Previous interventions:&lt;br&gt;Intervention group:&lt;br&gt;Intervention group will have deep brain stimulation electrodes placed in globus pallidus externum. After 6 weeks, the electrodes will be switched on and further adjusted at 12 and 18 weeks. Follow-up assessments will then happen at 6 months, 9 months and 12 months. &lt;br&gt;&lt;br&gt;Control group:&lt;br&gt;Control group will also have severe Tourette syndrome. They will also have electrodes implanted in the same way as the patients. After 6 weeks they will have a "sham switch on" proceedure. Follow-ups will be done in the same way as the intervention group.&lt;br&gt; &lt;br&gt;After one year of treatment, the code will be broken and data analysed. Participants in the intervention and control group will then be invited to participate in a further year of open-label extension study with all stimulators switched on. Data will then be gathered at 18 and 24 months.
    </Intervention>
    <Primary_outcome>Yale Global Tic severity scale.
    </Primary_outcome>
    <Secondary_outcome>1. Yale-Brown Obsessive Compulsive Scale&lt;br&gt;2. Hospital Anxiety and Depression Scale&lt;br&gt;3. Total Subjective Quality Of Life (TS-QOL)
    </Secondary_outcome>
    <Secondary_ID>NCT01647269;V 1.0
    </Secondary_ID>
    <Source_Support>Tourette Syndrome Association (UK) - applied for funding
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>6609239
    </Internal_Number>
    <TrialID>NCT00478842
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Pallidal Stimulation and Gilles de la Tourette Syndrome
    </Public_title>
    <Scientific_title>Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS
    </Scientific_title>
    <Acronym>STIC
    </Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070524
    </Date_registration3>
    <Date_registration>24/05/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00478842
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2007
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>France;France;France;France;France
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome
    </Condition>
    <Intervention>Device: Deep brain stimulation;Device: Deep brain stimulation;Device: Deep brain stimulation;Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.;To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.;To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.
    </Primary_outcome>
    <Secondary_outcome>To evaluate time necessary to obtaining the maximum effect and its evolution after this one (maintenance or not of the effect in the course of time);To study the effects of the stimulation of GPI in its former part, on the driving tics simple and complex, vocal, the self-mutilations, and the psychopathology of which time, emotions and impulsiveness;To evaluate the repercussion of this technique on the sociological-professional handicap, operation and the adaptation;To seek determinants before intervention of the effectiveness of stimulation (determining neurological, psychiatric, neuropsychological, functional);To establish correlations between the localization of the studs of stimulation (retiming atlas/IRM) and the symptoms;To determine the modifications of cerebral activation induced by the bilateral stimulation of GPI at the time of the improvement of the neurological symptoms (study in Mtoe).
    </Secondary_outcome>
    <Secondary_ID>P051050
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>6484735
    </Internal_Number>
    <TrialID>NCT00360009
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease
    </Public_title>
    <Scientific_title>Cognition and Mood in Parkinson's Disease (PD) in Subthalamic Nucleus (STN) Versus Globus Pallidus Interna (GPi) Deep Brain Stimulation (DBS)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060802
    </Date_registration3>
    <Date_registration>02/08/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00360009
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2004
    </Date_enrollement>
    <Target_size>62
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>United States;United States;United States;United States
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinson Disease
    </Condition>
    <Intervention>Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI
    </Intervention>
    <Primary_outcome>Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State;Change in Visual Analogue Mood Scales (VAMS) Afraid State;Change in Visual Analogue Mood Scales (VAMS) Confused State;Change in Visual Analogue Mood Scales (VAMS) Energetic State;Change in Visual Analogue Mood Scales (VAMS) Happy State;Change in Visual Analogue Mood Scales (VAMS) Sad State;Change in Visual Analogue Mood Scales (VAMS) Tense State;Change in Visual Analogue Mood Scales (VAMS) Tired State;Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State;Change in Visual Analogue Mood Scales (VAMS) Afraid State;Change in Visual Analogue Mood Scales (VAMS) Confused State;Change in Visual Analogue Mood Scales (VAMS) Energetic State;Change in Visual Analogue Mood Scales (VAMS) Happy State;Change in Visual Analogue Mood Scales (VAMS) Sad State;Change in Visual Analogue Mood Scales (VAMS) Tense State;Change in Visual Analogue Mood Scales (VAMS) Tired State
    </Primary_outcome>
    <Secondary_outcome>Change in Spielberger State-Trait Anxiety Inventory (STAI);Change in Beck Depression Inventory (BDI);Change in Letter Fluency Tasks (LFT)
    </Secondary_outcome>
    <Secondary_ID>K23NS044997;303-2002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>02/02/2010
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00360009
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>4617321
    </Internal_Number>
    <TrialID>NCT00358189
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation and Motor Function in Parkinson's Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Department of Veterans Affairs
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20060728
    </Date_registration3>
    <Date_registration>28/07/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00358189
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2006
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jay L Alberts, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Investigator
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a) Patients must have had the Deep Brain Stimulator implanted for at least six months&#x0D;&lt;br&gt;             prior to enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage III or worse when off stimulation and medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling motor fluctuations, dyskinesias or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal cognition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Demonstrated good response to levodopa.  In order to exclude patients with&#x0D;&lt;br&gt;             Parkinson's plus (i.e. progressive supranuclear palsy, multiple system atrophy,&#x0D;&lt;br&gt;             striato-nigral degeneration, etc) all patients included in this study must have&#x0D;&lt;br&gt;             demonstrated a good response to levodopa, defined as demonstrating at least 30%&#x0D;&lt;br&gt;             improvement in parkinsonian motor signs, based on UPDRS motor examination subscore&#x0D;&lt;br&gt;             following the administration of levodopa during their screening neurological exam.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management A stable and optimal&#x0D;&lt;br&gt;             medical regimen of antiparkinsonian drug therapy for at least three months prior to&#x0D;&lt;br&gt;             or after surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g. significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of CVA's, exposure to toxins, neuroleptics or encephalitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze&#x0D;&lt;br&gt;             palsy or significant orthostatic hypertension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of DBS for psychiatric disorder (obsessive compulsive or depression)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Secondary_ID>B4061I
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>12267331
    </Internal_Number>
    <TrialID>NCT00311909
    </TrialID>
    <Last_Refreshed_on>16 May 2022
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Tourette Syndrome
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospitals Cleveland Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060405
    </Date_registration3>
    <Date_registration>05/04/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00311909
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2005
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double. 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Robert J Maciunas, MD MPH FACS
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospitals Cleveland Medical Center
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tic frequency at least one per minute at screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prior failure of at least two dopamine receptor or presynaptic blockers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  negative impact on quality of life&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant structural brain lesion (on imaging studies)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe head trauma preceding onset of tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  use of dopamine receptor blockers prior to recognition of tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prior implanted electrical device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  electroconvulsive therapy (ECT) within 24 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suicide attempt within 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant sociopathic personality&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current or planned pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Thalamic deep brain stimulation
    </Intervention>
    <Primary_outcome>modified Rush Video Rating Scale (mRVRS)
    </Primary_outcome>
    <Secondary_outcome>tic counts (on video recording);Yale Global Tourette Severity Scale (YGTSS);Tourette Syndrome Symptom List (TSSL);Quality of Life Visual Analog Scale (VAS);SF-36;Neuropsychological battery
    </Secondary_outcome>
    <Secondary_ID>UHC DBS TS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:25:45</Export_date>
    <Internal_Number>4607130
    </Internal_Number>
    <TrialID>NCT00221793
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Study of Ponderal Load in Parkinsonian Patients After Deep Brain Stimulation of the Subthalamic Nucleus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050913
    </Date_registration3>
    <Date_registration>13/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00221793
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2002
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>François TISON, Pr;Jacques DEMOTES-MAINARD, Pr
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Service de neurologie Hôpital Haut-Lévêque Pessac;CIC Inserm-CHU de Bordeaux Pessac
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 35 and 70; male or female; parkinson disease, with levo dopa response (at&#x0D;&lt;br&gt;             least 30%); severe but stable incapacity; no dementia, no psychosis, no depression;&#x0D;&lt;br&gt;             normal brain scanner done during the last 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diabetes thyroid disease pacemaker coagulation troubles previous drug abuse&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Measurement of energy expenditure with indirect calorimetry in open chamber: at rest in the morning, without 24h-dopaminergic treatment, and after dopaminergic treatment intake; and post prandial thermogenesis after a test meal.
    </Primary_outcome>
    <Secondary_outcome>Weight gain;increase of energy intake;leptin, glucose, insulin blood levels;cognitive and psychological assessments;UDPRS scale
    </Secondary_outcome>
    <Secondary_ID>9212-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>